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ABSTRACT 
 
Bactericidal/permeability-increasing protein fold-containing family member A1 (BPIFA1) 
is abundantly secreted protein of the upper airways that plays a pleiotropic role in airway 
defence, including antimicrobial and bacteriostatic functions. The mechanisms by which 
BPIFA1 exhibits these diverse functions is not fully resolved.  
I investigated the regions of BPIFA1 predicted to be functionally important by using 
BPIFA1-tagged proteins to visualise their ability to bind to bacteria. The ability of mouse 
and human BPIFA1 to bind to bacteria were compared. I also used in vitro differentiated 
mouse tracheal epithelial cells (mTECs) from wild-type (WT) and Bpifa1-/- mouse 
tracheas to investigate if BPIFA1 plays a role in host response to nontypeable 
Haemophilus influenzae (NTHi).  
Human full-length and disulphide-bond mutant BPIFA1 proteins bound to both Gram-
negative and Gram-positive bacteria. However, human BPIFA1 lacking residues 22-42 
was not able to bind to bacteria, implying that this region may be important for BPIFA1’s 
binding. Mouse BPIFA1 also bound to both Gram-negative and Gram-positive bacteria. 
No apparent differences in the bacterial binding of human and mouse BPIFA1 proteins 
were observed. In vitro studies with WT and Bpifa1-/- mTECs showed the trend towards 
an increased NTHi colonisation in Bpifa1-/- mTEC cultures compared to WT. NTHi 
caused patchy infection of mTECs, suggesting that they exhibit resistance to NTHi. No 
clear differential infection between WT and Bpifa1-/- cells was detected. NTHi was 
capable of associating with the multiple cell types of tracheal epithelium, but not with 
BPIFA1-positive cells. NTHi infection disrupted cellular tight-junctions, suggesting that 
epithelial barrier function was impaired. This, in turn, allowed NTHi to cross through the 
mTECs. Differences in the BPIFA1 secretion by NTHi-exposed WT mTECs was 
observed compared to WT MOCK-exposed mTECs but no clear difference between WT 
and Bpifa1-/- mTECs inflammatory responses was detected.  
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Overall, the data from this study suggest that human and mouse BPIFA1 proteins play a 
role in airway defence by binding to Gram-negative and Gram-positive bacteria. The S18 
region (G22-L42) of human BPIFA1, but not the disulphide bond, appears to be 
important for the binding activity of protein but further research is required to determine 
the true biological functions of this region. Mouse BPIFA1 binds to NTHi and appears to 
initially protect BPIFA1-positive cells from NTHi invasion, however BPIFA1 deficiency 
does not lead to significantly increased NTHi infection in mTECs. These findings imply 
that BPIFA1 is mucosal defence molecule that functions to modulate bacterial infection 
of the airways.  
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The airway epithelium plays an essential role in innate host defence as it forms a barrier 
between the host and environmental hazards. Maintenance of normal airway epithelial 
function is crucial as airway mucosa is the first line of host defence against respiratory 
pathogens and irritants (Akira et al., 2006, Tam et al., 2011). Upon the recognition of 
pathogens, airway epithelial cells secrete various mediators into the airways, which 
immediately act against invading foreign particles. These mediators include cytokines, 
mucins, antimicrobial peptides such as defensins and cathelicidins, and antimicrobial 
proteins such as lysozyme and Bactericidal/Permeability-Increasing Fold-containing 
protein (BPIF) A1 (BPIFA1) (Bals and Hiemstra, 2004, Guaní-Guerra et al., 2010, 
Steinstraesser et al., 2011). BPIFA1 is an abundantly secreted protein found in epithelial 
lining fluids and much data supports its role in airway defence (Britto et al., 2013, Gakhar 
et al., 2010, Jiang et al., 2013b, Leeming et al., 2015, Liu et al., 2013b, Sayeed et al., 
2013). A better understanding of the contribution of BPIFA1 to airway defence may 
enable the development of drug targets for the treatment of respiratory diseases and 
bacterial infections (Ahmad et al., 2016, Garland et al., 2013, Walton et al., 2016). 
 
1.1 Respiratory tract infections 
 
Infections of the respiratory tract affect people worldwide and are mainly caused by 
bacterial and viral pathogens. Infectious airway diseases are divided into upper and 
lower respiratory tract infections. Epiglottitis, rhinosinusitis, and pharyngitis are examples 
of upper respiratory tract infectious diseases (Jain et al., 2001, Melio and Berge, 2014), 
whereas pneumonia and acute bronchitis are examples of lower respiratory tract 
infections (Finegold and Johnson, 1985, Priftis et al., 2013, Worrall, 2008). These 
infections are associated with bacterial pathogens such as Staphylococcus aureus, 
Streptococcus pneumoniae, and NTHi. These are also frequently linked to the 
exacerbations of pre-existing lung diseases such as chronic obstructive pulmonary 
disease (COPD) (Qureshi et al., 2014, Sethi, 2010), cystic fibrosis (CF) (Ciofu et al., 
2013, Lyczak et al., 2002), asthma (Toews, 2005), and bronchiectasis (Goeminne et al., 
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2014, Whitters and Stockley, 2012). However, S. aureus, S. pneumoniae, and NTHi are 
also often defined as commensal bacteria of the upper respiratory tract, which together 
with other types of commensal microorganisms form the airway microbiome. In a 
balanced state, these microorganisms colonise the upper respiratory tract without 
causing any infections, but imbalances caused by environmental insults can lead to the 
spread of these microbes from their normal environmental niche into sites of the 
respiratory tract where they cause invasive infections (Bosch et al., 2013, Pettigrew et 
al., 2008, Siegel and Weiser, 2015, de Steenhuijsen Piters et al., 2015). 
 
1.1.1 Staphylococcus aureus and respiratory tract 
 
Staphylococcus aureus is a Gram-positive coccus which can exist aerobically and 
anaerobically. The ability of S. aureus to tolerate anaerobic conditions allows the 
bacterium to invade host cells and cause tissue infection. In the balanced state, S. 
aureus is commensal microbe of the nasopharynx, but under environmental insults it 
may switch into a pathogen causing an invasive infection (Feng et al., 2008, Parker and 
Prince, 2012). This switch of S. aureus to a pathogenic state is triggered after a 
movement from the normal environmental niche to a different environment within the 
lower airways where the bacterium encounters more potent host defence mechanisms. 
The ability of S. aureus to bind the nasal epithelium is mediated through expression of 
clumping factor B which enables a binding to cytokeratins on the surface of epithelial 
cells. After a successful adherence to epithelial tissue, S. aureus multiples and initiates 
colonisation (Liu, 2009, Parker and Prince, 2012). Additionally, S. aureus must persist in 
the face of the host defence system and become a successful coloniser and to do so it 
uses microbial surface components recognising adhesive matrix molecules 
(MSCRAMM). MSCRAMMs (e.g. surface proteins and secreted toxins) also enable the 
bacterium to invade host cells. Expression of surface proteins and secreted toxins is 
controlled by the accessory gene regulator (agr), which plays an important role in the 
invasive airway infection. For example, one of the secreted toxins α-hemolysin 
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contributes to development of tissue infection through induction of pro-inflammatory 
responses, impairs ciliary function, calcium fluxes, and increases permeability of the 
airway epithelium (Liu, 2009, Parker and Prince, 2012). Moreover, S. aureus has evolved 
to persist in the lower respiratory tract during infection by avoiding host bacterial 
clearance mechanisms. Expression of factors such as the bacterial capsule, protein A, 
clumping factor A, and complement inhibitors, preventing S. aureus from being 
phagocytosed by specialised host immune cells such as macrophages and neutrophils 
(Lin and Peterson, 2010, Parker and Prince, 2012). It is also evident that S. aureus can 
survive within macrophages and is less resistant to neutrophil killing (Liu, 2009, Parker 
and Prince, 2012). Consequently, S. aureus secretes a number of molecules such as 
Panton-Valentine leukocidin and chemotaxis inhibitory protein to escape from neutrophil 
killing (Guerra et al., 2017, Liu, 2009, Parker and Prince, 2012, Waness, 2010). 
S. aureus infections are associated with pre-existing respiratory diseases such as CF 
and linked to the worsening of symptoms (Ahlgren et al., 2015, Chmiel et al., 2014, 
Sanders et al., 2010). S. aureus infection in CF lungs causes damage to the epithelial 
surfaces, leading to the adherence of other bacterial pathogens such as Pseudomonas 
aeruginosa, which is highly associated with mortality of patients (Goss and Muhlebach, 
2011, Lyczak et al., 2002). Respiratory infections caused by S. aureus are usually 
treated with antibiotics, but the emergence of antibiotic resistant strains (e.g. penicillin-, 
oxacillin-, and methicillin-resistant strains) has complicated treatment (Foster, 2017). For 
example, only a limited number of antibiotics work against methicillin-resistant S. aureus 
(MRSA) infection and there is a significant concern of the bacteria becoming resistant 
even to last resort antibiotics. The ability of MRSA to colonise healthy individuals 
possesses additional threats as these individuals usually become asymptomatic carriers 
of the bacterium and increase its spread (Goss and Muhlebach, 2011, Parker and 
Prince, 2012, Waness, 2010). Therefore, there is an urgent need for developing new 
antimicrobials to treat respiratory infections caused by S. aureus. 
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1.1.2 Streptococcus pneumoniae and respiratory tract 
 
Streptococcus pneumoniae is extracellular Gram-positive spherical bacterium. The 
peptidoglycan structure of S. pneumoniae is unique as it contains a ribitol phosphate 
backbone and phosphorylcholine, meaning that the bacterium requires choline uptake 
(Henriques-Normark and Tuomanen, 2013). S. pneumoniae is commonly described as a 
commensal organism of the upper respiratory tract where it is usually found within nasal 
passages. Children under 5 years of age are the main asymptomatic carriers of S. 
pneumoniae with less than 10% of adults being carriers (Henriques-Normark and 
Tuomanen, 2013). S. pneumoniae is also a common cause of invasive airway infection. 
S. pneumoniae exists in two states: transparent and opaque colony types, with 
transparent colonies being dominant colonisers of the nasopharynx and opaque colonies 
being dominant in causing pulmonary infection (Bogaert et al., 2004, Henriques-Normark 
and Tuomanen, 2013). Adherence of S. pneumoniae to the surface of epithelial cells 
within nasal passages is mediated through the number of different bacterial proteins 
such as choline-binding protein A, pneumococcal surface adhesin A, neuraminidase, IgA 
protease and pilus proteins (Bogaert et al., 2004, Henriques-Normark and Tuomanen, 
2013). After successful attachment to the epithelial cells, S. pneumoniae initiates 
multiplication and colonisation of the tissue. Colonisation of nasal passages with S. 
pneumoniae does not induce disease and is usually asymptomatic. However, S. 
pneumoniae transforms into a pathogenic bacterium after environmental insult and 
causes invasive tissue infection (Bogaert et al., 2004, Henriques-Normark and 
Tuomanen, 2013). After translocation into the lower respiratory tract, S. pneumoniae 
enhances expression of its virulence factors to escape from the hosts’ defence 
mechanisms. Increased expression of neuraminidase enables the bacterium to cross 
through the mucus avoiding mucosal defence mechanisms and loosely adhere to the 
epithelial surfaces. Firm attachment to the cells is achieved through enhanced 
production of surface proteins and the release of pneumolysin, which impairs ciliary 
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function, induces release of pro-inflammatory cytokines, and increases epithelial 
permeability by disrupting cellular tight-junctions (Bogaert et al., 2004, Henriques-
Normark and Tuomanen, 2013). After epithelial insult, S. pneumoniae replicates and 
causes further damage to the alveolar epithelium which leads to the development of 
pneumonia. S. pneumoniae also employs its polysaccharide capsule and pneumolysin to 
escape from host defence mechanisms. The polysaccharide capsule exhibits 
antiphagocytic activity which prevents the bacterium from being phagocytosed by 
immune cells and pneumolysin is known for impairing the function of immune cells and 
inducing apoptosis (Henriques-Normark and Tuomanen, 2013, Kadioglu et al., 2002, 
Zysk et al., 2000). If pulmonary infection with S. pneumoniae is not treated in time, it can 
progress into bacteremia and cause sepsis (Henriques-Normark and Tuomanen, 2013). 
Airway infections caused by S. pneumoniae are also associated with pre-existing 
respiratory diseases such as COPD (Qureshi et al., 2014, Sethi, 2010) and asthma 
(Toews, 2005). S. pneumoniae infection in the lungs of COPD and asthmatic patients 
causes exacerbations of disease and significant mortality. The treatment of patients with 
S. pneumoniae infection is usually based on antibiotics. However, the emergence of 
antibiotic resistant S. pneumoniae strains complicates treatment of infection because 
these bacterial strains exhibit resistance to most antibiotics. Vancomycin is the last resort 
antibiotic which still can successfully eliminate S. pneumoniae infection (Henriques-
Normark and Tuomanen, 2013). The ability of S. pneumoniae to exhibit resistance to the 
most antibiotics creates a need for development of new antimicrobial therapies to fight 
the infection. 
 
1.1.3 Nontypeable Haemophilus influenzae and respiratory tract 
 
NTHi is a Gram-negative coccobacillus lacking a polysaccharide capsule. It can grow 
aerobically and anaerobically. However, the aerobic growth of NTHi requires hemin and 
nicotinamide adenine dinucleotide (NAD) (King, 2012, Van Eldere et al., 2014). NTHi is 
recognised as a part of the normal nasopharyngeal microbiome of healthy individuals, 
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but it can also spread down to the lower airways and cause inflammation and disease. 
NTHi is an extracellular microorganism, but some published studies observed this 
bacterium within or between airway epithelial cells (Clementi and Murphy, 2011). NTHi is 
able to adhere to cell secretions to initiate colonisation and infection of tissue. Fimbriated 
NTHi strains bind the mucus more efficiently than non-fimbriated NTHi strains. It 
multiples in the mucus and then binds to the airway epithelium which is structurally 
damaged and lacks functioning cilia (Read et al., 1991). Binding of NTHi to the injured 
but not healthy epithelium may depend on the specific receptors expressed by damaged 
epithelial cells. Expression of these receptors on the surface of cells may lead to the 
interactions of bacterial adhesins with epithelial cells. This may be a strategy used by 
NTHi to attach to the areas of damaged epithelium (Ahearn et al., 2017, Read et al., 
1991). The first-line of host defence against bacterial airway infection is mucociliary 
clearance which enables the removal of pathogens from the respiratory tract. The 
function of mucociliary clearance is usually impaired in the lungs of patients with chronic 
respiratory disease (Livraghi and Randell, 2007, McIlwaine et al., 2017). This impairment 
of mucociliary apparatus may enable NTHi remain bound to the mucus longer, allowing 
bacterium to multiple and firmly adhere to the injured epithelial cells (Read et al., 1991). 
Furthermore, NTHi has evolved a range of strategies to disrupt the function of 
mucociliary apparatus (King, 2012). For example, lipooligosaccharide (LOS) present in 
the wall of NTHi acts as a ciliostatic substance and affects the function of ciliated cells 
(Denny, 1974, King and Sharma, 2015). 
NTHi is associated with a variety of respiratory diseases such as CF, COPD, and 
pneumonia (King, 2012, King and Sharma, 2015). The ability of NTHi to colonise and 
infect the lower respiratory tract tissue is dependent on the presence of the underlying 
airway disease (Foxwell et al., 1998). NTHi is prevalent in the lungs of CF patients and 
its presence predisposes patients to the development of pneumonia (King and Sharma, 
2015). NTHi may also induce the inflammatory responses which allow colonisation of CF 
lungs with P. aeruginosa, which is also well known for causing pneumonia (Van Eldere et 
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al., 2014). NTHi is a dominant cause of bacterial infection in the lungs of COPD patients 
and its prevalence is associated with exacerbations of the disease (King and Sharma, 
2015, Van Eldere et al., 2014). Pulmonary infections caused by NTHi are usually treated 
with standard antibiotics and full recovery of the patients is often observed. However, 
treatment of NTHi-infected patients with pre-existing respiratory disease is more 
complicated as NTHi usually establishes a niche within the airways which protects it from 
antibiotics. In such case, antibiotic treatment only partially clears bacteria from the lungs. 
Consequently, re-occurrence of NTHi infections is common among the patients with pre-
existing respiratory disease (King, 2012, Van Eldere et al., 2014).  
 
1.2 Airway epithelium and its importance in host defence 
 
1.2.1 Structure of respiratory tract and airway epithelium  
 
The respiratory tract is divided in the conducting airways (also known as conditioning 
zone) and respiratory region (Figure 1.1). The conditioning zone comprises of the nasal 
cavity, pharynx, larynx, trachea, bronchi, and up to terminal bronchioles. The respiratory 
portion of airways consists of respiratory bronchioles, alveolar ducts and alveoli. The 
conducting airways are responsible for transporting cleaned and moistened air to the 
distal portion of the airways, whereas the function of respiratory zone is to carry out  gas 
exchange (Soleas et al., 2012).  
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The human respiratory tract is divided into the conditioning zone and the respiratory zone. 
Conditioning zone includes the nasal cavity, pharynx, larynx, trachea, bronchi, and up to terminal 
bronchioles. The respiratory zone comprises of respiratory bronchioles, alveolar ducts and alveoli. 
 
The interior of the respiratory tract is lined with a layer of epithelium, which is 
pseudostratified in the large airways and simple cuboidal in the small airways (Figure 
1.2). Simple cuboidal epithelium changes to simple squamous epithelium in the alveolar 
ducts and alveoli (Crystal et al., 2008, Soleas et al., 2012). The major types of airway 
Figure 1.1: Human respiratory tract. 
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epithelial cells include: ciliated, undifferentiated columnar, secretory (goblet, serous, and 
club cells) and basal cells. All major types of airway epithelial cells are found in the 
pseudostratified epithelium. The number of ciliated, goblet, and basal cells is reduced, 
and number of club cells is increased in the simple cuboidal epithelium. The squamous 
epithelium which lines the alveolar ducts and alveoli consists of specialised type 1 and 
type 2 alveolar cells (Crystal et al., 2008, Soleas et al., 2012). 
 
Large airways are lined with pseudostratified epithelium, which later changes in to columnar-
cuboidal epithelium in the small airways. Alveoli are lined with simple squamous epithelium.  
  
1.2.2 Functions of airway epithelial cells 
 
Major cell types of airway epithelial cells are ciliated, secretory and basal cells. Each cell 
plays a different role in the respiratory tract.  
 
1.2.2.1 Ciliated cells 
 
Ciliated cells possess motile cilia on their apical surfaces and one ciliated cell can have 
up to 300 cilia. The cilia have motor proteins which enable them to beat in coordinated 
waves, allowing the transport of mucus from the lungs. Removal of the mucus from the 
lungs through mucociliary apparatus is important as foreign particles and 
Figure 1.2: Airway epithelium and major types of epithelial cells. 
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microorganisms get trapped within mucus after invading respiratory tract. Impairment in 
ciliary function may result in the build-up of mucus, foreign particles, and potentially 
pathogenic microorganisms within the respiratory tract, which eventually may contribute 
to the development of respiratory disease (Knight and Holgate, 2003, Soleas et al., 
2012).  
 
1.2.2.2 Secretory cells 
 
There are three types of secretory cells present within airway epithelium: goblet, serous, 
and club cells. Goblet cells also known as mucous cells, secrete mucus into the airway 
lumen which moistens the inhaled air. Balanced secretion and viscoelasticity of mucus 
are important as mucus traps harmful respiratory pathogens and particles which are 
removed from the respiratory tract through mucociliary apparatus (Knight and Holgate, 
2003, Soleas et al., 2012). Serous cells morphologically resemble goblet cells and 
provide a host defence for airway mucosa by secreting bactericidal compounds such as 
lysozyme, lactoferrin, and peroxidase. In addition, serous cells play a role in the renewal 
of airway epithelium as they are able to convert into goblet cells (Crystal et al., 2008, 
Basbaum et al., 1990, Widdicombe and Wine, 2015). Functions of club cells involve 
production of bronchial surfactants and secretion of antimicrobial peptides. Club cells 
also play an important role as progenitor cells in the repopulation of goblet and ciliated 
cells in the smaller airways (Knight and Holgate, 2003, Soleas et al., 2012). 
  
1.2.2.3 Basal cells 
 
Basal cells are abundant in the epithelium of the conducting airways, but their numbers 
are significantly reduced, or they are absent in the respiratory zone (Ganesan et al., 
2013, Knight and Holgate, 2003, Rackley and Stripp, 2012). Basal cells play an 
important role in tissue renewal after airway injury as they give a rise to secretory and 
ciliated cells and maintain homeostasis of normal epithelium. In addition, they express 
hemidesmosomes which enable them to firmly attach to the basement membrane. Basal 
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cells also play a role in the attachment of columnar cells (i.e. ciliated and secretory cells) 
to the basement membrane, as they are able to form desmosomal attachments with 
adjacent columnar cells (Knight and Holgate, 2003, Soleas et al., 2012).  
 
1.2.3 Airway epithelium as the first-line host defence barrier  
 
The airway epithelium forms a physical barrier between the body and environmental 
hazards. The main component of this barrier are the airway epithelial cells, which attach 
to each other by cell-cell junctions. These junctions include tight junctions, adherens 
junctions, gap junctions, and desmosomes. Cell-cell junctions form a barrier to 
respiratory pathogen entry and spreading into the airway submucosa (Vareille et al., 
2011).  
The mucus layer lining the airway epithelium protects the airway mucosa as mucus 
forms a semipermeable barrier. This barrier allows the exchange of gases, water, and 
nutrients but it is impermeable to most lung pathogens and irritants (Vareille et al., 2011). 
Airborne particles and respiratory pathogens are trapped within the mucus layer, where 
they are inactivated by the innate mucosal defence system and removed from the 
respiratory tract through the mucociliary apparatus (Joo et al., 2004). Mucus is 
continuously secreted by epithelial goblet cells and mucous cells of the submucosal 
glands. The main components of mucus include mucins, antimicrobial substances, 
cytokines, and antioxidant proteins. Balanced secretion of mucus is important as an 
increased secretion of mucus in lung infection causes airway obstruction which leads to 
impaired respiratory function. Mucus hypersecretion is associated with the pathogenesis 
of severe airway obstruction in infection-induced exacerbations of CF, COPD, and 
asthma (Vareille et al., 2011).  
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1.2.4 Antimicrobial products of the airway epithelium  
 
Airway epithelial cells produce antimicrobial products which play a host defence role in 
the airway mucosa. Production of many of these is induced upon recognition of airborne 
particles, including pathogens (Bals, 2000, Parker and Prince, 2011). Major antimicrobial 
products of airway epithelium include β-defensins, cathelicidin LL37, C-C motif 
chemokine ligand 20 (CCL20, also known as MIP-3α), lactoferrin, and lysozyme.  
 
1.2.4.1 β-defensins 
 
There are six different β-defensin peptides found in the human body, but only β-
defensins 1-4 are expressed in the airway epithelium (Parker and Prince, 2011). β-
defensins have a great range of activity against enveloped viruses, fungi, and as well as 
bacteria (Bals, 2000). For example, β-defensin-1 and -2 exhibit bactericidal activity 
against Escherichia coli and P. aeruginosa (Harder et al., 2000, Singh et al., 1998). β-
defensins are normally not found in healthy bronchoalveolar lavage fluid (BAL), but their 
levels are increased in airway fluid from the patients with respiratory disease (Singh et 
al., 1998). 
 
1.2.4.2 Cathelicidin (LL37) 
 
LL37 is a cationic peptide that has a broad-spectrum of antimicrobial activity (Bals, 2000, 
Parker and Prince, 2011). LL37 possesses bactericidal activity and has been shown to 
kill Gram-negative bacteria in vitro (Singh et al., 2000). In addition to its killing ability, 
LL37 exhibits anti-inflammatory functions. LL37 was shown to play a role in the blocking 
of Gram-negative bacterial signalling pathways through toll-like receptor 4 (TLR4) 
(Kahlenberg and Kaplan, 2013) and reduce levels of pro-inflammatory cytokines in the 
airways of influenza virus-infected mice (Barlow et al., 2011).  
 
1.2.4.3 Motif chemokine ligand 20 (CCL20) 
 
CCL20 is another airway protein that exhibits antimicrobial and chemotactic functions. 
Production and secretion of CCL20 is induced by a variety of microorganisms (Parker 
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and Prince, 2011). It was shown to be secreted in response to Brucella abortus infection 
and pro-inflammatory cytokines produced by B. abortus-infected monocytes. It does not 
exhibit direct antimicrobial properties and acts by stimulating the recruitment of adaptive 
immune cells to the site of infection (Hielpos et al., 2015). Interaction of CCL20 with C-C 
chemokine receptor type 6 (CCR6) was shown to induce migration of immune cells such 
as immature dendritic cells and T-cells to the site of infection (Starner et al., 2003).  
 
1.2.4.4 Lactoferrin 
 
Lactoferrin is an iron-binding protein found in the serum and mucosal secretions. It can 
produce an iron deficient environment which limits the growth of microorganisms. 
Lactoferrin is directly bactericidal to microorganisms and can increase the activity of 
immunoglobulin A (Actor et al., 2009, Ellison et al., 1988, Lee et al., 2016, Orsi, 2004). 
Lactoferrin causes release of lipopolysaccharide (LPS) from the outer membrane of E. 
coli and Salmonella typhimurium (Ellison et al., 1988). This results in increased 
permeability of the bacterial outer membrane, making bacteria more susceptible to other 
host defence mechanisms. It has also been demonstrated that the bactericidal activity of 
lactoferrin against Gram-negative and Gram-positive bacteria increased synergistically 
when in combination with lysozyme (André et al., 2015, Singh et al., 2000).  
 
1.2.4.5 Lysozyme 
 
Lysozyme is secreted by epithelial cells and submucosal glands of the respiratory tract 
(Dajani et al., 2005). Levels of lysozyme in the lungs are directly associated with the 
ability of airways to clear bacterial infection (Dajani et al., 2005). In addition, lysozyme in 
combination with human secretory leukocyte peptidase inhibitor (SLPI) was shown to 
have an increased bacterial killing activity, meaning that these proteins functioned 
synergistically (Singh et al., 2000). It has been suggested that lysozyme cannot easily 
penetrate the outer membrane of Gram-negative bacteria, suggesting that it performs a 
secondary function in host defence against these microorganisms (Liu et al., 2015, 
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Martinez and Carroll, 1980, Ragland and Criss, 2017, Ragland et al., 2018). In contrast, 
Gram-positive bacterial strains are highly sensitive to lysozyme activity as it can degrade 
β-(1→4)-glycosidic linkage of the N-acetylglucosaminyl-N-acetylmuramic acid polymer in 
the bacterial peptidoglycan (Liu et al., 2015, Ragland and Criss, 2017, Wadström and 
Hisatsune, 1970).  
 
1.2.4.6 Antimicrobial products of airway epithelium for the treatment of 
pulmonary infections 
 
Interest in the role of airway epithelium derived peptides and proteins in host defence 
has become of more significance with the emergence of antibiotic resistant bacterial 
strains. Respiratory epithelium derived products have the potential to become new 
antimicrobial agents as they can kill a wide range of microorganisms and are largely  
non-immunogenic (Hancock and Lehrer, 1998). Understanding the mechanisms 
employed by antimicrobial peptides and proteins in the killing of microbes may contribute 
to the development of novel treatment for microbial infections (Bals, 2000, Czaplewski et 
al., 2016, Prat and Lacoma, 2016, Hancock and Lehrer, 1998). BPIFA1, as a 
multifunctional, antimicrobial protein of the respiratory tract, is a potential candidate 
which could be used as antimicrobial agent for the treatment of respiratory tract 
infections in the future. However, the mechanisms by which BPIFA1 performs its 
biological functions are not fully determined and require further investigations. 
Consequently, the main focus of this thesis is to gain a better understanding of the 
mechanisms used by BPIFA1 to perform its antimicrobial functions and the role of 
BPIFA1 in host defence against respiratory bacterial pathogens. 
 
1.3 PLUNC/BPIF protein family 
 
The Palate Lung and Nasal Epithelium Clone (PLUNC) proteins belong to, and form a 
separate branch of, the BPI/LBP protein superfamily, and consequently, were recently 
renamed as BPIF proteins (Bingle and Craven, 2002, Bingle et al., 2011b). BPIF proteins 
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share sequence and structure similarity with four other members of BPI/LBP protein 
superfamily, namely: bactericidal/permeability-increasing protein (BPI), 
lipopolysaccharide (LPS)-binding protein (LBP), phospholipid transfer protein (PLTP), 
and cholesteryl ester-transfer protein (CETP) (Bingle and Craven, 2002). BPI proteins 
are composed of C-terminal and N-terminal domains. The cationic, antibacterial and 
endotoxin-neutralising functions of BPI is conferred by its N-terminal region, whereas 
anionic/hydrophobic and opsonic functions of BPI is conferred by its C-terminal region 
(Levy, 2000). BPI has anti-inflammatory activity as it inhibits LPS signalling and prevents 
LPS transfer to Cluster of differentiation-14 (CD14) (Elsbach and Weiss, 1998, Levy, 
2000, Tobias et al., 1997). This, in turn, stops activation of toll-like receptors (TLRs) and 
production of pro-inflammatory cytokines. In comparison to BPI, LBP has a pro-
inflammatory activity as it binds to LPS to transfer it to CD14 (Elsbach and Weiss, 1998). 
BPIF family proteins share between 13% to 22% pairwise amino acid identity with 
proteins of the wider BPI/LBP family (Bingle and Craven, 2002). The structural similarity 
of BPIF proteins to LBP and BPI initially led to the suggestion that BPIF proteins may 
have a role in host defence against bacteria (Bingle and Craven, 2002, Bingle et al., 
2004). This hypothesis is further supported by the rapid evolution of BPIF proteins and 
their low levels of sequence identity (Bingle and Craven, 2002, Bingle et al., 2011a). The 
BPIF family is subdivided into two groups: BPIFA (previously short PLUNC (SPLUNC)) 
proteins, and BPIFB (previously long PLUNC (LPLUNC)) proteins (Bingle and Craven, 
2002, Bingle et al., 2011b). This subdivision is based on the size of BPIF proteins and 
the two-domain structure of the BPI fold. BPIFA proteins contain one domain structurally 
similar to N-terminal domain of BPI, whereas BPIFB proteins contain two domains 
structurally similar to both N-terminal and C-terminal domains of BPI (Bingle and Craven, 
2002, Bingle et al., 2004). Human BPIFA proteins (BPIFA1, BPIFA2, and BPIFA3) 
consist of approximately 250 amino acids whereas human BPIFB proteins (BPIFB1, 
BPIFB2, BPIFB3, BPIFB4 and BPIFB6) consist of approximately 450 amino acids 
(Bingle and Craven, 2002, Bingle et al., 2011a). BPIF proteins are encoded by genes 
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found in a single locus on human chromosome 20 and on mouse chromosome 2 (Figure 
1.3) (Bingle and Craven, 2002, Bingle et al., 2011a). Fourteen Bpif genes (of which one 
Bpifa2f-ps is a pseudogene) have been identified in the mouse locus, whereas eleven 
BPIF genes (of which three BPIFA4P, BPIFB5P, and BPIFB9P are pseudogenes) have 
been identified in the human locus (Bingle et al., 2011a). It is important to note that the 
number of BPIF genes present varies across mammalian species and that the full 
repertoire of BPIF genes are only found in mammals (Bingle et al., 2004, Bingle et al., 
2011a). 
 
Human BPIF genes are located on the chromosome 20 and mouse BPIF genes are located on 
the chromosome 2. Orthologs of individual genes are demonstrated by arrows. Chromosomal 
positions of human and mouse BPIF genes on the chromosomes are indicated by arrowheads. 
Grey boxes represent BPIFA genes, white boxes – BPIFB genes, and shaded boxes – BPIF 
pseudogenes. SPA4L and CDK5RAP1 are unrelated genes flanking the loci of mouse and human 
BPIF genes. BPIFA1 is highlighted in red rectangle. Scale bar: 200kb. Image re-used with 
permission from (Bingle et al., 2011a), copyright 2011 Portland Press. 
 
 
 
1.4 Expression and distribution of BPIFA1 
 
1.4.1 Mouse BPIFA1 
 
BPIFA1 was first described in 1999. The gene was localised to the epithelium of nasal 
structures of the embryonic mouse. BPIFA1 was also detected in the epithelium of the 
trachea and upper bronchi of adult mice (Weston et al., 1999). Following this, a study 
from our laboratory confirmed that nasal passages and upper respiratory tract of mice 
Figure 1.3: Chromosomal positions of human and mouse BPIF genes. 
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are the main sites of Bpifa1 expression (Musa et al., 2012). Further analysis of mouse 
BPIFA1 localisation sites revealed that BPIFA1 is also found in Bowman’s glands of the 
nasal passages and serous glands in the posterior region of tongue (Musa et al., 2012). 
The presence of BPIFA1 was also confirmed in Bowman’s gland ducts. In addition, 
epithelium of larynx at the opening of trachea was shown to be positive for BPIFA1. It 
was also reported that BPIFA1 is localised within non-ciliated epithelial cells of 
respiratory tract (Musa et al., 2012). Recently, mouse BPIFA1 has also been shown to 
be present in the epithelium of middle ear (Mulay et al., 2016). 
 
1.4.2 Human BPIFA1 
 
Expression of BPIFA1 is also found in the major airways of humans (Campos et al., 
2004, Bingle and Bingle, 2000, Bingle et al., 2005). BPIFA1 has been localised to the 
serous cells of submucosal ducts and glands and non-ciliated cells of the surface 
bronchial epithelium have been shown to be positive for BPIFA1 expression. In the distal 
airways, BPIFA1 has been detected in luminal secretions and along the ciliary border of 
the epithelium (Campos et al., 2004, Bingle et al., 2005). Furthermore, Bingle et al. 
showed that BPIFA1 is present in the minor glands of the nasal cavity, sinuses and the 
posterior part of the tongue (Bingle et al., 2005). The presence of BPIFA1 in nasal 
lavage fluid has been reported (Ghafouri et al., 2004). BPIFA1 has been localised to the 
normal submandibular gland of human, where it is found within the ducts and the 
mucous cells of acini (Vargas et al., 2008). The highest expression of BPIFA1 is found in 
the trachea and lungs (Figure 1.4). More recently, expression of BPIFA1 was also shown 
within the epithelium of middle ear (Hadzhiev et al., 2017). BPIFA1 is not found in the 
normal epithelium of the smaller airways (peripheral lung). However, the levels of 
BPIFA1 are highly increased in the smaller airways in respiratory diseases such as CF, 
where BPIFA1 is seen in the inflammatory plugs within the airway lumen, suggesting that 
it is secreted (Bingle et al., 2007).   
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Human tissue microarray data, showing a restricted expression of BPIFA1. The highest 
expression found in trachea and lungs. Data was recovered from BioGPS portal and is based on 
the study by Su et al. (Su et al., 2004). 
 
 
 
1.5 Structure of BPIFA1  
 
The structures of human and mouse BPIFA1 proteins have been recently defined. 
Availability of BPIFA1 secondary structures may facilitate determination of the 
mechanisms used by BPIFA1 to perform its biological functions.  
 
Figure 1.4: BPIFA1 is expressed in limited tissues. 
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1.5.1 Human BPIFA1 
 
Bingle et al. were first to predict the secondary structure of BPIFA1 and suggest its 
similarity to the secondary structure of BPI proteins (Bingle and Craven, 2002). BPIFA1 
was also determined as glycine-leucine-rich protein that may confer BPIFA1 with a high 
degree of conformational flexibility. Furthermore, the glycine-leucine-rich region was 
suggested to be associated with a hydrophobic core of protein, potentially allowing it to 
bind to hydrophobic lipids (Bingle and Craven, 2002). More recently the crystal structure 
of BPIFA1 has been determined (Figure 1.5). Two studies defined similar structures, with 
exception of two helices and a short helix fragment (located in the region between 
residues 193 and 203), which were absent in one study (Garland et al., 2013, Ning et al., 
2014). BPIFA1 was described as a monomer comprising of six antiparallel β-sheets 
orientated centrally within the structure and flanked by six α-helices (Garland et al., 
2013). The S18 region (G22-A39) of BPIFA1 was not present in the crystal structure, 
with the first residue identified being amino acid 43 (Garland et al., 2013). Residue 43 
was shown to be located in the close proximity to a cluster of charged residues (D112, 
K138, R152 and D193), forming the salt bridge within the structure. This was reported to 
be associated with pH-dependant functioning of protein and its removal was shown to 
render BPIFA1 activity pH-insensitive (Garland et al., 2013). The cluster of charged 
residues and S18 region of human BPIFA1 were shown to differ from mouse and rat 
BPIFA1 proteins, suggesting that function and pH-sensitivity may vary among species 
(Garland et al., 2013). Moreover, Ning et al. reported that α3 helix and β5 sheet of 
BPIFA1 are connected by disulphide bridge, which provides the whole protein structure 
with stability (Ning et al., 2014). However, the disulphide bridge was later determined to 
be present between α5 helix and β5 sheet (Walton et al., 2016). These discrepancies 
were associated with the different methods of protein crystallisation used in the studies, 
because Ning et al. reported that BPIFA1 consists of 4 helices (Ning et al., 2014) 
whereas it actually consists of 6 helices. Position of α3-helix determined by Ning et al. 
 21 | P a g e  
 
was actually a position of α5-helix as shown in other studies (Ahmad et al., 2016, 
Garland et al., 2013, Walton et al., 2016). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The protein consists of six α-helices and six β-sheets. Residues 43, 77, 89, and 254 are labelled 
for clarity. Image re-used with permission from (Garland et al., 2013), copyright PNAS. 
 
 
 
1.5.2 Mouse BPIFA1 
 
Differences between mouse and human BPIFA1 were first identified by Bingle et al. 
(Bingle and Bingle, 2000). Weston et al. demonstrated that extreme N-terminal region of 
mouse BPIFA1 contains a PLPL repeat region, which was later shown to be missing 
from the sequence of human BPIFA1 (Bingle and Bingle, 2000, Weston et al., 1999). 
This region exhibits high variability among different species (Bingle and Bingle, 2000, 
Garland et al., 2013). Mouse BPIFA1 consists of 278 amino acids, while human BPIFA1 
consists of 256 amino acids, meaning that mouse BPIFA1 (28.6kDa) is a slightly larger 
protein compared to human BPIFA1 (26.6kDa). Human and mouse BPIFA1 proteins 
share 66% sequence identity, suggesting that some mechanisms by which these both 
BPIFA1 proteins perform biological functions may differ (Britto and Cohn, 2015, Little and 
Redinbo, 2018). For example, it was reported that proline-rich region of mouse BPIFA1 
is longer compared to human BPIFA1 and a salt bridge present in the structure of human 
BPIFA1 is missing from mouse BPIFA1 (Little and Redinbo, 2018). The salt bridge of 
Figure 1.5: Structure of human BPIFA1. 
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human BPIFA1 (charged residues D112, K138, R152 and D193) is not conserved in 
mouse BPIFA1, meaning that electrostatic charge of human and mouse BPIFA1 proteins 
are different. Human BPIFA1 exhibits a positive surface electrostatic charge within this 
region of protein (Garland et al., 2013), whereas mouse BPIFA1 shows a negative 
charge in this region (Little and Redinbo, 2018). The overall fold of mouse BPIFA1 was 
determined to be similar to the fold of human BPIFA1, with the greatest structural 
variability detected within the regions of the connecting loops: β3-β4, β4-β5, β6-α5 (Little 
and Redinbo, 2018). In addition, α4-helices were shown to differ between human and 
mouse BPIFA1 proteins (Figure 1.6). The α4-helix of mouse BPIFA1 folds in two distinct 
helices (α-4a and α-4b), whereas in human BPIFA1 α4 is present as single helix (Little 
and Redinbo, 2018). 
 
 
Structure of mouse BPIFA1, revealing residues 66-277 and lacking residues 108-113. Mouse 
BPIFA1 consists of six β-sheets orientated centrally within the structure and flanked by six α-
helices (α4-helix folds in two distinct helices: α-4a and α-4b. Residues 66, 107, 114 and 277 are 
labelled for clarity (A). Superposition of mouse and human BPIFA1 proteins, showing structure 
similarity between two proteins (B). Images re-used with permission from (Little and Redinbo, 
2018), copyright International Union of Crystallography. 
 
1.6 Biological functions of BPIFA1 
 
Studies have shown that BPIFA1 exhibits a variety of functions, including: antimicrobial, 
immunodulatory, chemotactic, and surfactant. BPIFA1 was also reported to be involved 
in the mucociliary clearance and regulation of airway surface liquid (ASL).  
 
Figure 1.6: Structure of mouse BPIFA1. 
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1.6.1 Antibacterial properties of BPIFA1    
 
The structural similarity of BPIFA1 to BPI/LBP protein superfamily led to the prediction of 
an involvement in host defence (Bingle and Craven, 2002). Many different studies have 
been published on the antimicrobial activity of human and mouse BPIFA1 proteins 
against bacterial pathogens with the main focus on Gram-negative bacteria.  
 
1.6.1.1 Antibacterial functions of human BPIFA1 
 
In vitro studies with recombinant human BPIFA1 showed that the protein exhibits 
bacteriostatic activity against P. aeruginosa, Mycoplasma pneumoniae, and Klebsiella 
pneumoniae. The ability of human BPIFA1 to inhibit the growth of bacterium was 
determined to be dose-dependent (Chu et al., 2010, Sayeed et al., 2013, Zhou et al., 
2008). It was also reported that BPIFA1 maintained its bacteriostatic activity against 
Gram-negative bacteria for 24hrs (Sayeed et al., 2013). Activity of BPIFA1 against P. 
aeruginosa was shown to be associated with its ability to form small pores in the 
bacterial outer membrane, suggesting that BPIFA1 increases permeability of the 
bacterial cell wall (Sayeed et al., 2013). The antibacterial role of BPIFA1 was studied in 
M. pneumoniae infection model in vivo using human BPIFA1 transgenic mice. Bacterial 
load was three-fold lower and bacterial clearance was increased in the lungs of BPIFA1 
transgenic mice compared to controls. Bacteriostatic activity of BPIFA1 against M. 
pneumoniae was linked to its ability to inhibit P1 adhesin expression, which plays an 
important role in the adherence process of M. pneumoniae to the host epithelial cells 
(Gally et al., 2011). Human BPIFA1 is also capable of interfering with formation of Gram-
negative bacterial biofilm in vitro (Gakhar et al., 2010). These studies demonstrated the 
antibacterial properties of human BPIFA1 but neither the regions of protein important for 
these functions nor mechanisms by which BPIFA1 performs its biological activity were 
fully defined. Recently Walton et al. and Ahmad et al. undertook studies to determine the 
regions of human BPIFA1 important for protein’s antibacterial functions. In these studies, 
it was further confirmed that human BPIFA1 acts as bacteriostatic and anti-biofilm agent 
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against Gram-negative bacteria, including P. aeruginosa and Burkholderia cepacia 
(Ahmad et al., 2016, Walton et al., 2016). The antibacterial activity of human BPIFA1 
was strain dependent for B. cepacia strains (Ahmad et al., 2016). Both studies reported 
that antimicrobial activity of human BPIFA1 against Gram-negative pathogens was 
dependent on the α4-helix (76-105 residues) and that deletion of this region resulted in 
the loss of antibacterial properties (Ahmad et al., 2016, Walton et al., 2016).  
BPIFA1 does not exhibit anti-growth and anti-biofilm properties against S. aureus, 
suggesting that BPIFA1 exerts antibacterial activity only against Gram-negative bacteria 
(Ahmad et al., 2016, Walton et al., 2016). However human BPIFA1 was able to inhibit 
the formation of S. aureus biofilm after the electrostatic charge of GL-rich region between 
residues 58 and 88 was altered (Walton et al., 2016). This suggests that the neutral 
electrostatic charge of human BPIFA1 surface within GL-rich region may be linked to 
BPIFA1’s inability to exhibit anti-biofilm activity against Gram-positive bacteria (Walton et 
al., 2016). However, it is important to mention that this study analysed anti-biofilm activity 
of human BPIFA1 against only one Gram-positive bacterium, S. aureus. Therefore, 
antibacterial activity of BPIFA1 against Gram-positive bacteria requires further 
investigations to enable a full determination of its role against Gram-positive pathogens. 
 
1.6.1.2 Antibacterial functions of mouse BPIFA1 
 
Antibacterial properties of mouse BPIFA1 have also been studied and it has been shown 
that it is also able to act as bacteriostatic and anti-biofilm agent. The role of mouse 
BPIFA1 was investigated in respiratory bacterial infection models with NTHi, P. 
aeruginosa, M. pneumoniae, K. pneumoniae, and S. aureus. In vivo studies with WT and 
Bpifa1-/- mice intranasally challenged with P. aeruginosa and intratracheally challenged 
with K. pneumoniae showed that bacterial load was significantly higher in Bpifa1-/- mice 
compared to control littermate mice. It was also demonstrated that mouse BPIFA1 was 
able to inhibit the formation of P. aeruginosa and K. pneumoniae biofilms in vitro and that 
bacterial biofilm biomass was reduced in the dose-dependent pattern (Liu et al., 2013a, 
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Liu et al., 2013b). Deficiency of BPIFA1 was also shown to be associated with increased 
bacterial burden and inflammation in the lungs of Bpifa1-/- mice challenged with NTHi and 
M. pneumoniae (Gally et al., 2011, Jiang et al., 2013b). In addition, recombinant mouse 
BPIFA1 was shown to exhibit bacteriostatic activity against M. pneumoniae in a dose-
dependent manner (Chu et al., 2007). Therefore, existing data shows anti-growth and 
anti-biofilm functions of mouse BPIFA1 against Gram-negative bacteria, but there is no 
data available on the direct antibacterial activity of mouse BPIFA1 against Gram-positive 
bacteria. Mouse BPIFA1 has been shown to be able to bind S. aureus in vivo (Ventura et 
al., 2008) but no other antibacterial properties of protein against this Gram-positive 
pathogen have been investigated. 
Overall, ability of the mouse protein to act as a bacteriostatic and anti-biofilm agent in the 
host defence against Gram-negative bacteria is currently well reported. However, none 
of the studies investigated the mechanisms by which mouse BPIFA1 performs its 
antibacterial activity. The regions of protein important for antibacterial functions of mouse 
BPIFA1 also remain to be determined. 
 
1.6.2 Antiviral activity of BPIFA1 
 
Antimicrobial activity of BPIFA1 is not unique for bacterial pathogens as BPIFA1 also 
plays a role in the host defence against viral infections. Antiviral activity of BPIFA1 was 
first reported in the study by Zhou et al., which showed that addition of BPIFA1 to the 
primary cultures of peripheral blood lymphocytes (PBLs) infected with Epstein-Barr virus 
(EBV) increased apoptosis of virus-infected PBLs and reduced the expression of EBV 
latent membrane protein 1 (LMP1). These findings suggested a role for BPIFA1 in host 
defence against EBV-induced nasopharyngeal carcinoma (Zhou et al., 2008). 
Subsequently, it was revealed that BPIFA1 exhibits antiviral activity against respiratory 
syncytial virus (RSV), human rhinovirus (HRV) and influenza A virus (IAV) (Akram et al., 
2018, Fornander et al., 2011, Wu et al., 2014). Decreased levels of BPIFA1 were shown 
to be associated with worse outcome of RSV-infected infants, suggesting that lower 
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levels of BPIFA1 are linked to the development of severe pneumonia (Fornander et al., 
2011). Furthermore, BPIFA1 deficient mice were shown to have increased IAV and HRV 
viral replication and cell death compared to their littermate controls (Akram et al., 2018, 
Wu et al., 2014). 
Overall, the findings suggest an important role of BPIFA1 in host defence against viral 
infections and reduced levels or loss of BPIFA1 may be a contributing factor to the 
increase of viral replication and worsening of infection.   
 
1.6.3 Chemotactic properties of BPIFA1 
 
Chemotactic properties of BPIFA1 were examined in the presence of bacterial infections 
caused by P. aeruginosa, M. pneumoniae, and K. pneumoniae. In vivo and in vitro 
studies were used to determine the effect of mouse and human BPIFA1 on migratory 
immune cells. Results from in vitro cell migration assay showed that recombinant human 
BPIFA1 stimulates migration of neutrophils and macrophages, suggesting that human 
BPIFA1 acts as a chemotactic agent (Sayeed et al., 2013). In agreement with these 
findings it was also shown that migration of neutrophils and macrophages was induced 
after human BPIFA1 transgenic mice were challenged with P. aeruginosa (Lukinskiene 
et al., 2011). This study also reported that human BPIFA1 transgenic mice demonstrated 
a reduced recruitment of neutrophils compared to control WT mice, suggesting that over-
expression of BPIFA1 may reduce tissue inflammation (Lukinskiene et al., 2011). The 
ability of BPIFA1 to act as anti-inflammatory factor was also shown by Chu et al., 
demonstrating that in vivo blockade of BPIFA1 in mice before intranasal challenge with 
M. pneumoniae resulted in increased neutrophil recruitment into the lungs. The number 
of neutrophils detected in the BAL fluid from anti-BPIFA1 pre-treated mice after bacterial 
exposure was significantly higher compared to WT mice (Chu et al., 2007). These 
findings are similar to those of Lukinskiene et al. and suggest that up-regulation of Bpifa1 
in respiratory bacterial infection may reduce tissue inflammation and enhance bacterial 
clearance (Chu et al., 2007, Lukinskiene et al., 2011). Other studies also demonstrated 
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significantly increased neutrophil counts in the BAL fluid from Bpifa1-/- mice after 
bacterial exposure compared to WT mice (Gally et al., 2011, Liu et al., 2013a, Liu et al., 
2013b). Despite increased neutrophil numbers in the lungs of Bpifa1-/- mice, it was 
reported that the activity of neutrophil elastase was significantly diminished compared to 
WT mice. These findings suggested that reduced neutrophil elastase activity may 
contribute to the impairment of host defence against bacterial infection in Bpifa1-/- mice 
(Gally et al., 2011). It was also shown that macrophage infiltration to the lungs of WT 
mice challenged with P. aeruginosa was greater compared to Bpifa1-/- mice, suggesting 
that the killing of bacteria in WT mice is more efficient (Liu et al., 2013b). 
Overall, these studies suggest that BPIFA1 may act as anti-inflammatory agent and its 
loss in the case of respiratory bacterial infection may be linked to the increased severity 
of tissue inflammation due to the recruitment of elevated numbers of inflammatory cells 
to the site of infection. 
 
1.6.4 Immunomodulatory properties of BPIFA1 
 
A number of studies have investigated the immunodulatory properties of BPIFA1 in the 
inflammation caused by bacterial infections. BPIFA1 appears to suppress the release of 
pro-inflammatory cytokines in the response to Gram-negative bacterial challenge. In vivo 
and in vitro studies showed that the release of pro-inflammatory cytokines such as IL-8, 
IL-6, TNF-α, IL-1α and IL-1β was significantly elevated in the absence of BPIFA1 (Chu et 
al., 2007, Liu et al., 2013a, Liu et al., 2013b, Lukinskiene et al., 2011). Considerably 
increased production of pro-inflammatory chemokines such as CXCL1, CXCL2, CCL3, 
CCL5 and CCL20 was also detected in the absence of BPIFA1 (Liu et al., 2013a, Liu et 
al., 2013b, Lukinskiene et al., 2011). Increased release of pro-inflammatory molecules in 
the absence of BPIFA1 is also directly linked to the elevated infiltration of inflammatory 
cells to the site of infection, and these both events are directly associated with increased 
severity of tissue inflammation. These studies also showed that the profile of pro-
inflammatory cytokines and chemokines generated by the host defence system in the 
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response to bacterial challenge was bacterial strain dependent. BPIFA1 may also control 
airway inflammation by influencing production of other antimicrobial molecules. It was 
reported that Bpifa1-/- mice show significantly decreased expression of LL37, Lysozyme, 
and Lactoferrin after bacterial challenge compared to WT mice (Liu et al., 2013b). 
Reduced expression of LL37, Lysozyme, and Lactoferrin could contribute to a decrease 
in bacterial clearance from the lungs of mice.  
An immunodulatory role of BPIFA1 was also investigated in an allergic airway 
inflammation study, where BPIFA1 deficiency caused an increased production of TH2 
cytokines and was associated with elevated numbers of eosinophils. This allergic host 
defence response was rescued by transgenic expression of Bpifa1 (Wright et al., 2010). 
In agreement with this this study, Thaikoottathil et al. showed that ovalbumin-challenge 
significantly increased levels of eotaxin-2 in the lungs of Bpifa1-/- mice compared to WT. 
Elevated levels of eotaxin-2 were directly associated with increased number of 
eosinophils in the lungs, causing allergic airway inflammation (Thaikoottathil et al., 2012).  
In contrast to the findings of above studies, Di et al. showed that BPIFA1 is capable of 
acting as both a pro-inflammatory and anti-inflammatory factor (Di et al., 2013). The 
immunodulatory role of BPIFA1 was investigated in a model of respiratory inflammation 
caused by inhalation of carbon nanotubules. Overexpression of human BPIFA1 in mice 
was associated with significantly increased leukocyte infiltration and release of pro-
inflammatory cytokines in the lungs during acute inflammation caused by inhalation of 
the nanotubules. These findings suggest that BPIFA1 functions as pro-inflammatory 
agent. However, an anti-inflammatory activity of BPIFA1 was observed during the 
chronic phase of inflammation. BPIFA1 was shown to reduce levels of TNF-α secretion 
and inhibit processes causing pulmonary fibrosis.  
 
1.6.5 Role of BPIFA1 in mucociliary clearance  
 
Another proposed function of BPIFA1 is its ability to influence mucociliary clearance. 
BPIFA1 loss in the airways of mice causes a reduction in the expression of major airway 
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mucin genes (Muc5ac and Muc5b) and the gene for Clara cell secretory protein (CCSP), 
which contribute to the formation of extracellular lining fluid and are involved in 
mucociliary clearance (Liu et al., 2013b). Ablation of BPIFA1 also decreased expression 
of Foxj1, a gene involved in ciliogenesis and a marker of ciliated cells. Consequently, it 
was suggested that BPIFA1 deficiency is associated with impaired mucociliary clearance 
and causes an increased bacterial burden in the lungs during the airway infection (Liu et 
al., 2013b). A study on chinchillas reported that BPIFA1 exhibits surfactant properties, 
which are essential for a normal function of Eustachian tube (ET) in NTHi-induced Otitis 
media (McGillivary and Bakaletz, 2010). Silencing expression of chinchilla Bpifa1 was 
shown to result in the impaired mucociliary clearance in the ET, which is associated with 
defective functioning of the tympanum. In contrast to this, Mulay et al. reported no 
phenotypic alterations and inflammation signs in the middle ear of NTHi-challenged 
BPIFA1 deficient mice, suggesting that the absence of BPIFA1 alone does not cause 
development of Otitis media (Mulay et al., 2018). Discrepancies in these results may be 
associated with the usage of different animal models, different techniques of BPIFA1 
deletion, size of NTHi inoculum and usage of different NTHi strains. 
 
1.6.6 Surfactant properties of BPIFA1 
 
The possibility that BPIFA1 may exhibit surfactant activity was predicted after BPIFA1 
and latherin were shown to share sequence similarity. Bingle et al. demonstrated that 
latherin, which is a known surfactant protein, shares sequence similarity with BPIFA1 
(Bingle et al., 2004). Afterwards, protein sequence similarity between BPIFA1 and 
latherin was reported in other two studies (Gakhar et al., 2010, McDonald et al., 2009), 
but Gakhar et al. was first to reveal surfactant properties of BPIFA1. It was shown that 
BPIFA1 reduced surface tension and inhibited P. aeruginosa biofilm formation at the air-
liquid interface in aqueous solutions (Gakhar et al., 2010). Following this, it was 
demonstrated that the ability of BPIFA1 to modulate surface tension reduced K. 
pneumoniae biofilm biomass and inhibited of P. aeruginosa biofilm formation on the 
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apical surface of mouse airway epithelial cells (Liu et al., 2013a, Liu et al., 2013b). In 
addition, BPIFA1 was reported to act as a surfactant in the middle ear and the loss of 
BPIFA1 was shown to be associated with impaired function of the ET. BPIFA1 deficiency 
may weaken the ability of the ET to block the entry of microorganisms into the middle ear 
and contribute to the development of Otitis media (McGillivary and Bakaletz, 2010). 
Recently, leucine residues present in the α4-helix of BPIFA1 were defined to be crucial 
for the surfactant properties (Walton et al., 2016). However, Ning et al. demonstrated the 
capacity of BPIFA1 to bind airway surfactant molecules such as 
dipalmitoylphosphatidylcholine (DPPC), suggesting that BPIFA1 does not function 
directly as surfactant itself but stimulates function of other surfactant molecules in the 
ASL (Ning et al., 2014). 
 
1.6.7 BPIFA1 regulates the height of ASL and ion transport  
 
The respiratory epithelium is covered by ASL, which prevents mucus from adhering to 
epithelial surfaces and enables efficient mucus clearance from the airways. Maintenance 
of normal ASL volume (~7μm) homeostasis in the airways is crucial for defence against 
respiratory pathogens. Airway epithelial ASL volume is influenced by the levels of 
sodium (Na+) and chloride (Cl-) ions and the precise balance of these ions is regulated by 
absorption of Na+ via epithelial sodium channel (ENaC) and secretion of Cl- via cystic 
fibrosis transmembrane conductance regulator (CFTR) (Gaillard et al., 2010, Tarran, 
2004). The activity of ENaC has been shown to be influenced by BPIFA1 in the ASL 
(Garcia-Caballero et al., 2009, Garland et al., 2013, Hobbs et al., 2013, Kim et al., 2018, 
Rollins et al., 2010). BPIFA1 binds to ENaC and protects it from proteolytic cleavage and 
activation (Garcia-Caballero et al., 2009). It was also demonstrated that BPIFA1 
deficiency in human bronchial epithelial cells (HBECs) caused an increase in ASL 
absorption and addition of BPIFA1 to HBECs rescued this effect and restored normal 
ASL height (Garcia-Caballero et al., 2009). It was also suggested that BPIFA1 regulates 
ENaC activity by reducing expression of ENaC molecules in the plasma membrane of 
 31 | P a g e  
 
the airway epithelial cells (Rollins et al., 2010). The protein specifically binds to the β-
subunit of ENaC but not α- and γ- subunits (Hobbs et al., 2013). This BPIFA1 binding 
was reported to be highly dependent on the glycosylation state of ENaC β-subunit. 
Furthermore, the S18 peptide consisting of 18 amino acids corresponding to residues 
G22-A39 of BPIFA1 was shown to control ENaC function in the similar manner to full-
length BPIFA1 and BPIFA1 lacking this region was demonstrated to have no effect on 
the ENaC activity. These findings suggested that the S18 region of BPIFA1 is important 
for inhibition of ENaC proteolytic cleavage and activation. The S18 peptide was also 
shown to retain its functionality in the presence of high proteolytic activity, which is 
common in CF airways (Hobbs et al., 2013). ASL height is not affected by the absence of 
BPIFA1 nor addition of recombinant BPIFA1 in CF airway cultures (Garland et al., 2013). 
However, addition of both BPIFA1 and bicarbonate to CF airway cultures restored a 
normal height of ASL, suggesting that the ability of BPIFA1 to control ENaC activity is 
pH-dependent. Consequently, it was suggested that an acidic pH of CF ASL causes an 
impairment in BPIFA1 function, that blocks binding to ENaC and blocks Na+ 
hyperabsorption. Subsequently, it was shown that the S18 peptide was able to control 
ENaC activity in pH-insensitive manner (Garland et al., 2013). More recently, Kim et al. 
determined the mechanism by which BPIFA1 regulates ENaC activity (Kim et al., 2018). 
It was shown that BPIFA1 acts as allosteric regulator of ENaC that causes dissociation 
of αβγ-ENaC, leading to the internalisation of αγ-ENaC and allowing the formation of 
BPIFA1 and β-ENaC complex within the plasma membrane of cells (Kim et al., 2018). 
Overall, it appears that BPIFA1 controls ENaC function. Maintenance of the ASL height 
homeostasis is crucial for healthy functioning of airways. In the case of respiratory 
disease such as CF, ASL height is reduced, mucus is thickened, and the function of 
BPIFA1 is impaired.  
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1.6.8 Other proposed functions of BPIFA1 
 
Two other proposed functions of BPIFA1 are the ability to maintain airway homeostasis 
and to regulate airway smooth muscle contractions. 
Existing literature suggests that BPIFA1 plays a role in the maintenance of airway 
mucosal homeostasis, but this function is impaired under epithelial insult. McGillivary et 
al. was first to propose that BPIFA1 functions as homeostatic factor (McGillivary and 
Bakaletz, 2010). BPIFA1 deficiency caused abnormal middle ear pressure and 
diminished mucociliary clearance by the ET, suggesting that loss of BPIFA1 impairs host 
defence against bacterial pathogens and contributes to the development of Otitis media 
(McGillivary and Bakaletz, 2010). A homeostatic function of BPIFA1 in the middle ear 
mucosa was later confirmed in another study which showed that BPIFA1 deficiency in a 
murine model of chronic Otitis media caused worsening of disease (Mulay et al., 2018). 
The ability of BPIFA1 to maintain mucosal homeostasis of upper respiratory tract was 
also proposed by Liu et al. and Chu et al., who showed that the absence of BPIFA1 was 
linked to diminished mucociliary clearance and increased bacterial burden (Chu et al., 
2007, Liu et al., 2013b). A homeostatic role of BPIFA1 has not been well studied yet, but 
existing evidence does support this function for BPIFA1.   
Recently, it was reported that BPIFA1 is also involved in the regulation of airway smooth 
muscle contractions by inhibiting activity of Ca2+ influx channel Orai1. The structural 
region responsible for this function was defined as α6-helix of BPIFA1. The absence of 
BPIFA1 was shown to be associated with the increased airway smooth muscle 
contractility which may contribute to the development of airway hyperresponsiveness 
(Wu et al., 2017). 
 
1.7 Regulation of BPIFA1 by respiratory pathogens and 
inflammation 
 
Expression and secretion of BPIFA1 by airway epithelial cells are influenced by 
respiratory pathogens and tissue inflammation.  
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Mice infected with viral pathogens such as IAV and gammaherpesvirus were shown to 
have considerably reduced BPIFA1 expression and secretion after 7 days post-infection 
compared to mock-infected controls but increased or not significantly different after 14 
days post-infection. These fluctuations in the expression and secretion of BPIFA1 during 
viral infections were suggested to indicate a role for  BPIFA1 in host defence against 
viral pathogens (Akram et al., 2018, Britto et al., 2013, Leeming et al., 2015, LeMessurier 
et al., 2016). Reduction in the levels of BPIFA1 during early infection may trigger an 
activation of more specific host defence mechanisms against viral pathogens and 
increased or normalised levels of BPIFA1 during later stages of infection may contribute 
towards to the recovery of airway epithelium and resolution of inflammation. 
Infections caused by bacteria have also been shown to influence the expression and 
secretion of BPIFA1. S. pneumoniae and P. aeruginosa significantly reduced BPIFA1 in 
the lungs of infected mice (Britto et al., 2013). In contrast, levels of BPIFA1 were 
reported to be significantly up-regulated upon infection with M. pneumoniae and K. 
pneumoniae (Chu et al., 2007, Chu et al., 2010, Liu et al., 2013a). These findings 
suggest that activation of innate immune responses by pathogen-associated molecular 
patterns (PAMPs) causes alterations in BPIFA1 levels and direction of change is 
bacterial strain dependent. Moreover, stimulation of cells with pro-inflammatory cytokines 
such as IFN-γ, IL-1α, IL-6, IL-17A, and TGF-β were shown to cause a significant 
reduction in BPIFA1 amounts (Wei et al., 2014), whereas stimulation with IL-1β and 
TNF-α did not cause a decrease of Bpifa1 (Bingle and Bingle, 2000). These results 
suggest that BPIFA1 is regulated by pro-inflammatory mediators and that such 
alterations are stimulus-specific.  
Allergic inflammation driven by TH2 cytokines was reported to modulate BPIFA1 levels. 
Airway epithelial cells stimulated with TH2 cytokines such as IL-13 and IL-4 were shown 
to significantly decrease expression and secretion of BPIFA1 (Chu et al., 2007, Wei et 
al., 2014). In contrast, Britto et al. showed that IL-13 stimulation of human and mouse 
airway epithelial cells caused an increase in BPIFA1 levels (Britto et al., 2013). However, 
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TH2 stimulation-induced allergic inflammation in mice was demonstrated to reduce 
amounts of BPIFA1 (Britto et al., 2013). Discrepancies seen in the in vitro data may be 
caused by differences in the cell culture techniques and treatment conditions. Although 
existing in vitro data is contradictory, it may be suggested that TH2 driven inflammation 
causes a down-regulation of BPIFA1.   
 
1.8 Role of BPIFA1 in pulmonary diseases  
 
Multiple studies have investigated BPIFA1 in respiratory diseases such as CF, COPD, 
asthma, and idiopathic pulmonary fibrosis (IPF). BPIFA1 is predominantly expressed and 
produced by upper airway epithelial cells, however its expression and production profiles 
are altered in the airways of patients with pulmonary disease. 
 
1.8.1 BPIFA1 and CF 
 
The role of BPIFA1 in CF lung disease is not clear, but it has been shown that levels of 
BPIFA1 mRNA and protein are increased in the respiratory tract of CF patients 
compared to non-CF subjects (Roxo-Rosa et al., 2006, Scheetz et al., 2004). BPIFA1 
staining was significantly increased in the epithelium of CF small airways compared to 
non-CF small airways (Bingle et al., 2007). Strong staining of BPIFA1 was also seen in 
the inflammatory plugs within the airway lumen of CF patients, suggesting secretion of 
BPIFA1. Increase in the levels of BPIFA1 within the epithelium of CF small airways is 
probably a consequence of phenotypic alterations of the airway epithelium (Bingle et al., 
2007). Subsequently, βENaC-transgenic mice, a model for CF-like lung disease, were 
shown to have increased levels of BPIFA1 in the peripheral lung compared to their 
littermate controls (Bingle et al., 2012). More recently, Saferali et al. reported that a 
single nucleotide polymorphism in the G allele of rs1078761 located in the exon 3 of the 
BPIFB1 gene is associated with the reduced mRNA and protein levels of BPIFA1 and 
BPIFB1 in the lungs of CF patients. Decreased levels of BPIFA1 and BPIFB1 in CF 
lungs were correlated with the greater severity of CF disease. This suggests that the G 
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allele of rs1078761 is a non-CFTR genetic factor influencing the severity of CF disease 
(Saferali et al., 2015). 
Dysregulation of ENaC is a factor contributing to the development of CF lung disease, as 
it is known to be associated with a significantly reduced volume of ASL and increased 
mucus dehydration (Garland et al., 2013). This impaired regulation of ENaC has been 
suggested to be the result of the reduced ASL pH and impaired function of BPIFA1 in the 
airways of CF patients (Garland et al., 2013). Since BPIFA1 is involved in the regulation 
of ENaC cleavage and activity, therapy directed towards raising the pH of CF airways 
may restore the function of BPIFA1. In addition, antibacterial properties of BPIFA1 were 
suggested to be hindered by decreased pH and elevated levels of neutrophil elastase in 
CF, resulting in the increased bacterial burden in the airways of CF patients (Garland et 
al., 2013, Jiang et al., 2013a, Jiang et al., 2013b, Nichols et al., 2015).  
 
1.8.2 BPIFA1 and COPD 
 
The main risk factor contributing to the development of COPD is tobacco smoking 
(Turato et al., 2001). Cigarette smoke has been shown to be associated with BPIFA1 
reduction in the airways. Diminished amounts of BPIFA1 protein were reported in the 
upper respiratory tract of smokers compared to never smokers (Steiling et al., 2009). 
Subsequently, levels of BPIFA1 in the BAL of COPD smokers and non-COPD smokers 
were shown to be significantly reduced compared to the healthy non-smokers (Jiang et 
al., 2013b). In vitro exposure of human airway epithelial cells to the electronic cigarette 
liquid with or without nicotine was also shown to inhibit BPIFA1 expression (Wu et al., 
2014). However, levels of BPIFA1 seem to be highly variable in the airways of smokers 
and COPD patients. Ghafouri et al. reported that amounts of BPIFA1 were considerably 
increased in the nasal lavage fluid from smokers compared to non-smokers (Ghafouri et 
al., 2002). In addition, Di et al. showed a significantly elevated BPIFA1 expression in the 
serous cells and ducts of submucosal gland, airway epithelial surface, and sputum of 
COPD patients compared to healthy controls (Di et al., 2003). It was suggested that this 
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was a consequence of the recurrent respiratory infections observed in COPD patients (Di 
et al., 2003). The reasons for these discrepancies are unclear, but it may be explained 
by the type of samples used for analysis, small number of samples, degrees of COPD 
severity, and smoking pack-years. More recently, De Smet et al. used the large number 
of samples to investigate the expression of BPIFA1 in COPD (De Smet et al., 2018). It 
was demonstrated that BPIFA1 expression was significantly increased in stage 3 and 4 
COPD patients compared to patients with stage 2 COPD and healthy controls. Moreover, 
COPD patients were shown to have significantly increased levels of BPIFA1 protein 
compared to control subjects and these elevated BPIFA1 levels were associated with 
worsening of COPD (De Smet et al., 2018). Although this study did not measure the 
levels of secreted BPIFA1 in the sputum and BAL fluid of COPD patients, the increased 
levels of secreted BPIFA1 were suggested based on the findings from the previous 
studies (Di et al., 2003, Ghafouri et al., 2002). It was also suggested that increased 
levels of BPIFA1 in COPD lungs are required to resolve inflammation and restore airway 
homeostasis (De Smet et al., 2018). However, the attempt of host defence system to 
resolve inflammation and restore airway homeostasis in COPD lungs by increasing 
expression and secretion of BPIFA1 seems to be not efficient and the reason for this 
might have been provided by Moore et al. (Moore et al., 2018). Exposure of BPIFA1 to 
the cigarette smoke triggered a disulphide bond modification, causing a significant 
alteration in the protein structure. This disulphide bond modification was shown to inhibit 
BPIFA1 ability to bind and control ENaC activity, resulting into ASL hyperabsorption and 
impaired airway homeostasis (Moore et al., 2018). 
 
1.8.3 BPIFA1 and IPF 
 
IPF is characterised by chronic inflammation and progressive lung tissue fibrosis, with 
approximate survival of patients for 2.5-5 years after disease diagnosis (Fujimoto et al., 
2015, Richeldi et al., 2017). The role of BPIFA1 in IPF airways has not been widely 
studied yet and remains unclear. In the study by Boon et al., levels of BPIFA1 were 
 37 | P a g e  
 
reported to differ between IPF patients and healthy controls. Approximately 9-fold 
increase in BPIFA1 mRNA was detected in the lungs of patients with rapidly progressive 
IPF compared to the patients with relatively stable IPF (Boon et al., 2009). In addition, 
investigation of BPIFA1 cellular distribution in the IPF and normal lung tissue showed 
BPIFA1 in the bronchial columnar cells, bronchial and bronchiolar epithelia, and mucus 
in IPF patients, whereas it was absent from these regions in the healthy subjects (Boon 
et al., 2009). The expression of another BPIF family member BPIFB1 was also shown to 
be increased in the lungs of IPF patients. This increase in BPIFB1 is greater than the 
increase in BPIFA1 expression (Bingle et al., 2013). Therefore, current findings suggest 
that alterations in BPIFA1 may play a role in IPF, but there is no data available on the 
association of BPIFA1 and IPF pathogenesis. 
 
1.8.4 BPIFA1 and asthma 
 
Asthma is an obstructive airway disease, causing the chronic airway inflammation which 
leads to the airway hyperresponsiveness and reversible airflow limitation in the most of 
asthmatic patients (Saetta and Turato, 2001). The most common clinical symptoms of 
asthma such as wheezing, chest tightness, breathlessness and coughing occur due to 
the airway hyperresponsiveness (Buist, 2003). Follettie et al. showed markedly reduced 
Bpifa1 mRNA in the lungs of mice with an asthmatic phenotype produced after antigen 
challenge (ovalbumin; OVA), either alone or treated with IL-13 antagonist compared to 
the mice challenged with PBS control buffer (Follettie et al., 2006). These findings were 
confirmed by Chu et al. by showing that Bpifa1 was significantly diminished in the lungs 
of mice with allergic airway inflammation after exposure to OVA (Chu et al., 2007). 
Intranasal administration of IL-13 and IL-4 neutralising antibodies caused an increase in 
Bpifa1 in the lungs of OVA challenged-mice, suggesting that IL-13 and IL-4 contribute to 
BPIFA1 reduction in the allergic situation (Chu et al., 2007). Subsequently, Thaikoottathil 
et al. showed that airway inflammation was significantly increased in the lungs of Bpifa1-/- 
mice after OVA-challenge compared to WT mice (Thaikoottathil et al., 2012). This 
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inflammation was characterised by elevated numbers of leukocytes and increased 
Muc5ac expression. It was also suggested that BPIFA1 deficiency promotes eotaxin-2 
production by alveolar macrophages which caused an increased eosinophil infiltration. 
These findings suggested that restoring levels of BPIFA1 in the lungs of patients with 
allergic airway inflammation may reduce eosinophilic inflammation and improve 
symptoms of disease (Thaikoottathil et al., 2012). More recently, Fang et al. and Wu et 
al. reported significantly reduced BPIFA1 levels in samples from asthmatic patients 
(Fang et al., 2017, Wu et al., 2017). Reduced BPIFA1 levels were also shown to be 
associated with increased airway smooth muscle contractility which causes airway 
hyperresponsiveness. Consequently, it was suggested that the therapy aiming to restore 
natural BPIFA1 levels in the lungs of asthmatic patients should help to treat this disease 
(Wu et al., 2017). 
 
In summary, the discovery of antimicrobial properties of BPIFA1 led to further 
investigations of BPIFA1’s role in host defence. Studies have demonstrated that the 
levels of BPIFA1 expression differ in the airways of CF, COPD, IPF, and asthmatic 
patients compared to healthy controls. Expression of BPIFA1 was shown to be increased 
in the airways of CF and COPD patients, whereas it was found to be decreased in the 
airways of asthmatic patients. Reduced levels of BPIFA1 in the lungs of asthmatic 
patients were reported to be associated with disease severity. In the case of IPF, 
BPIFA1 expression was shown to be significantly elevated in the patients with rapidly 
progressive IPF compared to the patients with relatively stable IPF. Currently, the 
reasons for BPIFA1 level differences in the diseased airways are not fully clear and 
require further investigations. Existing data also supports the role of BPIFA1 in airway 
defence but the exact mechanisms by which BPIFA1 performs its functions remain to be 
determined. Therefore, further studies are required to elucidate how BPIFA1 protects the 
airways from infections and injury. 
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1.9 Hypotheses and aims 
 
This project consists of two parts and hypotheses of this project are: 
 
1. BPIFA1 protein plays a role in the host defence by binding to respiratory 
pathogens. 
2. The loss of BPIFA1 results in the enhanced susceptibility of mouse airway 
epithelial cells to NTHi infection. 
 
This project consisted of three major aims: 
 
1. To determine the regions of human BPIFA1 enabling it to bind to respiratory 
pathogens: S. aureus, S. pneumoniae, and NTHi.  
2. To compare the bacterial binding abilities of mouse BPIFA1 with human BPIFA1.  
3. To determine whether the BPIFA1 loss in mTECs causes an enhanced 
susceptibility of the cells to NTHi infection. 
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CHAPTER 2: MATERIALS AND METHODS 
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General methods 
 
2.1 Cloning and transformation  
 
2.1.1 Cloning and ligation reactions 
 
VR1255 and pcDNA5/FRT/V5-His-TOPO (pcDNA5/FRT) were used for generation of 
BPIFA1-plasmid constructs. For BPIFA1 DNA cloning into pcDNA5/FRT (Invitrogen), 
DNA was diluted in relation to the amount of vector used and cloned into vector 
according to the established protocol. For ligation of digested BPIFA1 DNA into VR1255, 
DNA was diluted and T4 DNA ligase with ligase 10x buffer (Promega) was used in 
ligation reactions according to “T4 DNA Ligase, Blue/White Cloning Qualified” protocol. 
Ligation reactions were performed at 15ºC for 18 hours. 
 
2.1.2 Transformation of Escherichia coli 
 
TOP10 E. coli and One Shot® Mach1TM1 Phage-Resistant Chemically Competent E. 
coli (Invitrogen) were transformed with DNA of BPIFA1-plasmid constructs according to 
the Invitrogen protocols. Transformed E. coli cells were grown on LB-agar plates 
containing ampicillin (100µg/mL) or kanamycin (100µg/mL) overnight at 37ºC. Positive 
transformants were grown in LB-broth containing ampicillin (100µg/mL) or kanamycin 
(100µg/mL) overnight at 37ºC on the orbital shaker (200 RPM). 
 
2.2 Extraction of plasmid DNA and verification of DNA 
 
2.2.1 Minipreparation and maxipreparation  
 
Transformed E. coli cells were miniprepped or maxiprepped to extract and purify plasmid 
DNA. Minipreps were performed using Thermo Scientific GeneJET Plasmid Miniprep Kit 
and protocol. Maxipreps were performed using Qiagen Plasmid Maxiprep kit and 
protocol.  Concentration of minipreps and maxipreps was determined using NanoDrop 
ND-1000 (ThermoScientific). Quality of extracted DNA was verified by restriction 
digestion and Sanger sequencing.  
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2.2.2 Agarose gel electrophoresis of DNA  
 
DNA products were run alongside 1kb or 100bp DNA ladder (New England BioLabs Inc.) 
on 1% or 2% agarose gels containing ethidium bromide (Fisher Scientific) at 70V. Gels 
were prepared using 1g or 2g of agarose powder (Geneflow) in 100ml of 1x Tris Acetate 
EDTA (TAE) buffer and 0.5µg/ml of ethidium bromide (Fisher Scientific). Fragments of 
DNA were visualised using Biorad ChemiDocTM XRS+.  
 
2.2.3 DNA extraction from agarose gel  
 
DNA samples were run on an agarose gel and visualised using UV transilluminator. DNA 
fragments of interest were cut from the agarose gel and recovered using GeneJET Gel 
Extraction and DNA Cleanup Micro Kit (Thermo Scientific). Concentration of recovered 
DNA was determined using NanoDrop ND-1000 (Thermo Scientific). DNA was stored at     
-20ºC. 
 
2.2.4 Restriction digestion  
 
Plasmid DNA was digested with restriction endonucleases (Promega). In all cases, 1µL 
of restriction endonuclease, 1µL of 10x buffer (Promega) and 5µL of plasmid-DNA were 
used, and the total volume was made up to 10μl with nuclease free H2O. Digests were 
incubated overnight at 37ºC prior to analysis. HyPlus loading buffer green (1µl; Bioline) 
was added to digested plasmid DNA (10µl) and sample was run alongside 1kb or 100bp 
DNA ladder (New England BioLabs Inc.) on 1% or 2% agarose gels containing ethidium 
bromide. 
 
2.2.5 Sanger sequencing  
 
Verification of DNA was performed using Sanger sequencing. DNA (10µl) was 
sequenced to validate the orientation of insert and scan for any possible mutations. DNA 
sequencing was performed at the Core Genomics Facility, Faculty of Medicine, Dentistry 
and Health, University of Sheffield. Primers used for sequencing are provided in Table 
2.1: 
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Table 2.1: Primer pairs used in Sanger sequencing. 
Primer name Primer type Sequence (5’-3’) 
T7 Forward TAATACGACTCACTATAGGG 
BGH Reverse TAGAAGGCACAGTCGAGG 
pVR1255 
Forward 
Reverse 
AATAGCTGACAGACTAACAGACTG 
GAGTGAGCTGATACCGCTC 
GFP Reverse GCTGATCAGCGGGTTTAATTC 
 
2.3 Gene expression studies 
 
2.3.1 RNA extraction 
 
Cells were lysed in 250µl Trizol reagent (Sigma-Aldrich) and RNA was extracted 
according to the manufacturer’s protocol. Briefly, 50μl of chloroform (Fisher Scientific) 
was added to cell lysate, vortexed for approximately 30 seconds, and incubated for 15 
minutes at room temperature (RT). Samples were centrifuged at 13,000 RPM for 15 
minutes at 8˚C. Subsequently, the aqueous phase containing RNA was transferred to a 
new eppendorf tube and 125μl of isopropanol (Fisher Scientific), and 1μl of GlycoBlueTM 
dye (Ambion) were added. Samples were vortexed, incubated for 10 minutes at RT, and 
then centrifuged at 13,000 RPM for 10 minutes at 8˚C. The isopropanol was removed, 
and the RNA pellet was washed with 250μl of 75% ethanol (Fisher Scientific) and 
centrifuged as described previously. The ethanol was discarded, the RNA pellet was air-
dried, and resuspended in 20μl of nuclease free H2O. Concentration of RNA was 
measured using NanoDrop ND-1000 (Thermo Scientific). RNA samples were stored at    
-20ºC. 
 
2.3.2 Agarose gel electrophoresis of RNA 
 
RNA samples were prepared for analysis as follows: 2µl of total RNA was added into 4µl 
of RNA sample loading buffer containing ethidium bromide (Sigma) and gently mixed. 
Samples were heated at 65ºC to denature the RNA. Samples were loaded onto the 
denaturing formaldehyde (37-41% solution; Fisher Chemical) 1% agarose (Thermo 
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Scientific) gel and electrophoresed in 1X MOPS buffer (Fisher Scientific) at 70V to 
visualise RNA and determine its integrity. All equipment used in the assay was RNase 
free. Gel visualisation was performed using Biorad ChemiDocTM XRS+. 
 
2.3.3 DNase treatment 
 
DNase I treatment (Promega) was used to remove a residual genomic DNA 
contamination from 200ng of extracted RNA. Briefly, RQ1 RNase free 10x reaction buffer 
(1μl) and RQ1 RNase free DNase (1μl) were added to RNA sample, and the total volume 
was made up to 10μl with nuclease free H2O. The components were mixed, and the 
sample incubated for 30 minutes at 37ºC in the thermocycler (MJ Research PTC-200). 
Afterwards, 1μl of RQ1 DNase STOP solution was added and sample was incubated for 
10 minutes at 65ºC in the thermocycler to terminate DNase activity. DNase treated RNA 
was used in cDNA synthesis. 
 
2.3.4 Complementary DNA (cDNA) synthesis 
 
DNase treated RNA was reverse transcribed into cDNA using AMV Reverse 
Transcriptase kit (Promega). Briefly, 0.5μl of OligoDT (Sigma) was added to RNA 
solution and the total reaction volume was made up to 19μl with nuclease free H2O. The 
sample was heated at 70˚C for 5 minutes in the thermocycler. Afterwards, 6μl of reverse 
transcription master mix, consisting of AMV RT 5x buffer (5μl), AMV RT enzyme (0.25μl), 
RNasin ribonuclease inhibitor (0.25μl), and dNTPs (100μM) was added to the sample 
and cDNA was synthesised for 42˚C for 1 hour and denatured at 95˚C for 5 minutes. 
cDNA samples were stored at -20ºC. 
 
2.3.5 Polymerase Chain Reaction (PCR) 
 
Polymerase chain reaction was used to analyse genes of interest. All PCR reactions 
were performed using Maxima Hot Start Green PCR Master Mix (Thermo Scientific) 
according to the manufacturer’s protocol. Briefly, cDNA sample was diluted in the 
nuclease free water at the ratio of 1:4 and 1µl of it was added into the tube, containing 
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12.5µl of Maxima Hot Start Green PCR Master Mix, 4.5µl of nuclease free water, and 
1µM of forward and reverse primers. The list of primer pairs used in PCR reactions is 
provided in Table 2.2. PCR reaction samples were vortexed, and PCR was performed at 
the following cycling conditions in the thermocycler: 1) Initial denaturation/enzyme 
activation 95ºC for 4 minutes; 2) Denaturation at 95ºC for 1 minute; 3) Annealing at 60ºC 
for 1 minute; 4) Elongation at 72ºC for 1 minute; and 5) Final elongation at 72ºC for 7 
minutes. PCR reactions were run for 35 cycles for all genes (steps from 2 to 4 repeated), 
except for Bpifa1 for which 30 cycles were used. The endogenous control for all PCR 
reactions was Oaz1 gene. PCR products were run on the agarose gel and visualised 
using Biorad ChemiDocTM XRS+. 
 
Table 2.2: Primer pairs used in PCR reactions. 
Gene Primer type Sequence (5’-3’) 
Product size 
(bp) 
Oaz1 
Forward 
Reverse 
ACAGAGGAGCCGACGTCTAA 
CCAAGAAAGCTGAAGGTTC 
274 
Tekt1 
Forward 
Reverse 
CAGTGCGAAGTGGTAGACG 
TTCACCTGGATTTCCTCCTG 
373 
Ltf 
Forward 
Reverse 
TCTGTCCCTGTGTATTGGT 
GTTTCCGGGTGTCATCAAGG 
237 
Bpifa1 
Forward 
Reverse 
GGTGCACAACATTGCTGAAT 
CAAGAGGCAGGAGACTGAG 
127 
 
 
 
2.4 Cell line culture and transfections 
 
2.4.1 Cell line cultures 
 
Three cell lines were used for transfections: NCI-H292 (human mucoepidermoid 
pulmonary carcinoma 292), Flp-In-CHO (Chinese hamster ovary), and HEK293T (human 
embryonic kidney 293 SV40 large T antigen expressing). Growth medium was changed 
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twice a week for all cell lines. Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma-
Aldrich) growth medium was used for the maintenance of NCI-H292 and HEK293T cell 
lines. Roswell Park Memorial Institute-1640 growth medium (RPMI-1640; Sigma-Aldrich) 
was used for the maintenance of Flp-In-CHO cells. Both types of growth media were 
supplemented with foetal bovine serum (10%) (FBS; Sigma), penicillin (100U/ml), 
streptomycin (100mg/ml) (Sigma) and L-glutamine (2mM; Sigma). Cell line cultures were 
split upon reaching the confluence using 1x Trypsin-EDTA solution (Sigma). Cell line 
cultures were grown in the incubator at 37ºC, 5% CO2. 
 
2.4.2 Optimisation of G418 killing assay 
 
A killing assay was performed to determine the lowest concentration of G418 (Melford) 
required to kill 100% of NCI-H292 cells within 7 days from the start of selection. NCI-
H292 cells were seeded (8x104 cells/well) onto 24-well culture plate one day prior to 
introducing G418 antibiotic selection. The following day, DMEM growth medium (Sigma-
Aldrich) was removed and medium containing G418 was added to the cells. Different 
concentrations (μg/mL: 200, 400, 600, 800, and 1000) of antibiotic were used. G418 
untreated cells were used as the control. 
 
2.4.3 Transfections of cell lines  
 
Two types of transfection methods were used: stable transfections and transient 
transfections. NCI-H292 and Flp-In-CHO cells were used for stable transfections, 
whereas HEK293T cells were used for transient transfections. NCI-H292 cells were 
transfected using FuGENE® HD (Promega) according to “Promega FuGENE® HD 
Transfection Reagent” protocol. Flp-In-CHO cells were transfected using 
LipofectamineTM LTX transfection reagent (Invitrogen) according to “Flp-In System” 
protocol. After transfections, G418 (1000μg/mL) was used to select positively transfected 
NCI-H292 cells and establish a stable cell line expressing BPIFA1. Hygromycin B 
(450μg/ml; Invitrogen) was used for selection of positively transfected Flp-In-CHO cells 
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and establishment for a stable cell line expressing BPIFA1. Transient transfections of 
HEK293T cells were carried out using a standard calcium phosphate protocol. 
 
2.5 Immunoblotting 
 
2.5.1 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE)  
 
Samples prepared in 2x SDS lysis buffer were heated at 95ºC for 10 minutes to denature 
proteins. Afterwards, samples were loaded onto 10% or 12% SDS-PAGE gel and run 
alongside 10µl of marker (Geneflow wide range 10-245kDa ladder or New England 
BioLabs® Inc. broad range 11-245kDa standard) at 100V through the stacking gel, and 
at 150V through the resolving gel till the dye reached the bottom of the gel. 
Subsequently, the stacking gel was discarded, and the resolving gel was placed in 1x 
transfer buffer. Transfer of proteins from the resolving gel onto PVDF membrane 
(Milipore) was performed using semi-dry blotter system (Biorad Trans-bot turbo). 
Transfer of proteins was prepared in the following order from the anode to the cathode 
direction: three layers of Whatman paper, methanol activated PVDF membrane, 
resolving gel, and three layers of Whatman paper. All components were soaked in 1x 
transfer buffer before assembly and buffer excess was removed before the semi-dry 
transfer. Proteins were transferred onto PVDF membrane at 25V for 25 minutes. PVDF 
membranes were blocked in 5% milk in 1x Tris buffered saline-Tween (TBS-Tween) 
buffer for 1 hour on the orbital shaker. Membranes were washed for 5 minutes 1x TBS 
and probed with primary antibody (Table 2.3) overnight at 4ºC on a rolling platform. 
Primary antibodies were diluted in 5% milk in TBS-Tween buffer. The following day, 
membranes were washed three times for 10 minutes in 1x TBS-Tween. The primary 
antibody was detected using a secondary antibody (Table 2.3) diluted in 5% milk in TBS-
Tween. Membranes were incubated for 1 hour on the rolling platform at RT. Afterwards, 
membranes were washed three times in 1x TBS-Tween and enhanced 
chemiluminescence (ECL) detection solution (Biorad) was added onto the membranes 
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for detection of the secondary antibody. Membranes were placed in a plastic sleeve and 
1ml of ECL solution (0.5ml solution A (luminol) and 0.5ml solution B (H2O2)) was added 
onto the membrane. Excess ECL was removed and plastic sleeve with membrane was 
placed in a light-proof cassette. Two methods were used for visualisation: 
1. Photographic X-ray film (GE Healthcare) was exposed to membrane for an 
appropriate period of time in the dark room.  Subsequently, the film was developed, 
rinsed in water and fixed.  
2. The membranes were exposed for an appropriate period of time using Biorad 
ChemiDocTM XRS+ and the bands were developed. 
Please see Appendix I (Table I) for detailed preparation of all stock solutions used in 
SDS-PAGE. Densitometry was used for analysis of SDS-PAGE results. Quantification 
was performed using ImageJ-win32 program.  
 
Table 2.3: Primary and secondary antibodies used for SDS-PAGE. 
Primary antibodies 
Antibody Type Dilution Manufacturer 
Anti-GFP tag Mouse monoclonal 1:3000 ThermoFisher Scientific 
Anti-FLAG tag M2, Clone2 Mouse monoclonal 1:1000 Sigma -Aldrich 
Anti-human BPIFA1 Rabbit polyclonal 1:200 
Prepared in lab (De Smet et al., 
2018) 
Anti-mouse BPIFA1 Rabbit polyclonal 1:200 
Prepared in lab (Musa et al., 
2012) 
Secondary antibodies 
Antibody Type Dilution Manufacturer 
Anti-mouse HRP Goat polyclonal 1:2000 Dako 
Anti-rabbit HRP Goat polyclonal 1:2000 Dako 
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2.5.2 Dot blotting 
 
Samples of apical cell secretions (10µl) were dotted on the PVDF membrane (Milipore) 
and air-dried. The membrane was blocked in 5% milk in 1x TBS-Tween buffer for 1 hour 
on the orbital shaker. Subsequent steps were performed as per the SDS-PAGE method 
using polyclonal rabbit anti-mouse BPIFA1 primary and polyclonal goat anti-rabbit 
secondary antibodies (Table 2.3). Results were visualised using Biorad ChemiDocTM 
XRS+. Densitometry was used for analysis of results. Quantification was performed 
using ImageJ-win32 program. Data was analysed, and statistical tests were performed.  
 
2.6 Cell fixation and DAPI staining  
 
Cells, grown onto glass chamber slides, were fixed in 10% buffered formalin for 30 
minutes at RT. Subsequently, formalin was removed, and cells were washed with 1x 
PBS (Gibco). The frame of glass chamber slide was removed from the glass slide and a 
drop of Vectashield mounting medium for fluorescence with DAPI (Vector Laboratories, 
Inc.) was added. A coverslip was applied on the cell samples and DAPI excess was 
drained from the slide. The coverslip was sealed onto the glass slide with nail polish. 
Slides were stored in a light-proof box at -4ºC. 
 
Methods for the study of BPIFA1 interactions with bacterial 
pathogens 
 
2.7 Bioinformatic analysis of human and mouse BPIFA1 
 
2.7.1 Structure and sequence similarity of human BPIFA1 protein to 
BPI, LBP, PLTP, and CETP proteins 
 
Multiple sequences analysis of human BPIFA1, BPI, LBP, PLTP, and CETP proteins was 
performed using Kalign (EMBL-EBI, 2018) and BoxShade (Hofmann and Baron, 2018). 
Protein sequences of all proteins were gained from NCBI protein data base (NCBI, 
2017). Information about protein sequences is provided in the Table 2.4. Investigation of 
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structure similarity between BPIFA1 and BPI was performed using Protein 
Homology/analogY Recognition Engine V 2.0 (Phyre2) (Kelley et al., 2015). 3D models 
of proteins were built using Phyre2 and PyMOL was used for visualisation and 
construction of protein superpositions (Schrodinger, 2015). The aim was to highlight the 
position of cysteine residues which form the disulphide bond in BPIFA1 and BPI proteins 
and to show that disulphide bond is present at the same position in all proteins analysed. 
 
Table 2.4: Information about BPIFA1, BPI, LBP, PLTP, and CETP protein sequences. 
Protein (Homo sapiens) Sequence NCBI number 
BPIFA1 NP_001230122.1 
BPI CAD99178.1 
LBP NP_004130.2 
PLTP BAB79630.1 
CETP AAA51977.1 
 
 
2.7.2 Features of human and mouse BPIFA1 proteins  
 
Predict Protein Open Software was used to predict binding sites and residue composition 
of mouse and human BPIFA1 proteins (Yachdav et al., 2014). Conserved domains, sites 
and regions of BPIFA1 were predicted using ExPASy Prosite (Sigrist et al., 2013), 
EMBL-EBI InterPro (Finn et al., 2017), and Motif Scan-MyHits (Pagni et al., 2004). 
Multiple sequences alignment of BPIFA1 from a variety of species was constructed using 
Kalign (EMBL-EBI, 2018) and BoxShade (Hofmann and Baron, 2018). Protein 
sequences of all proteins were from NCBI protein data base (NCBI, 2017). Information 
about sequences is provided in the Table 2.5. 
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Table 2.5: Information about BPIFA1 protein sequences. 
 
 
2.8 Generation of GFP- and FLAG-tagged BPIFA1 constructs 
 
BPIFA1 proteins were fused either to GFP tag or FLAG tag to generate BPIFA1 
constructs for transfection assays. GFP-tagged human full-length (256aa), F/R1 (39aa), 
and F/R2 (58aa) BPIFA1 constructs were previously generated in the laboratory. FLAG-
tagged human full-length and cysteine mutant (cysteine 224 residue replaced by glycine 
residue) BPIFA1 constructs were previously generated in Prof J. Stewart’s group 
Species of BPIFA1 protein Sequence NCBI number 
Human (Homo sapiens) NP_001230122.1 
Mouse (Mus musculus) NP_035256.2 
Wood mouse (Apodemus sylvaticus) AEA07326.1 
Rat (Rattus norvegicus) NP_742028.1 
Hamster (Mesocricetus auratus) XP_012979514.1 
Chinchilla (Chinchilla lanigera) NP_001269294.1 
Kangaroo rat (Dipodomys ordii) XP_012866135.1 
Shrew (Elephantulus edwardii) XP_006881757.1 
Cow (Bos taurus) NP_776851.1 
Camel (Camelus dromedaries) XP_010982659.1 
Elephant (Loxodonta Africana) XP_003411552.1 
Pig (Sus scrofa) NP_001005727.1 
Sheep (Ovis aries) AIG92771.1 
Dolphin (Tursiops truncates) XP_004319467.1 
Whale (Delphinapterus leucas) XP_022448419.1 
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(University of Liverpool). FLAG-tagged human S18 mutant and mouse full-length BPIFA1 
constructs were generated during this study. 
 
2.8.1 Synthesis of human S18 mutant BPIFA1-FLAG gene  
 
Human S18 deletion BPIFA1-FLAG gene was synthesised by Invitrogen GeneArtTM 
Gene Synthesis service (ThermoFisher Scientific). DNA sequence of human BPIFA1-
FLAG gene missing 22-42 amino acids was synthesised and cloned into pMA-T vector 
(Appendix I: Figure I). DNA sequence of the gene can be found in Appendix I (Figure II). 
Plasmid DNA was purified from transformed bacteria and concentration was determined 
by UV spectroscopy. The final construct was verified by sequencing. Sequencing data of 
the construct can be found in Appendix I (Figure III). Lyophilised plasmid DNA (5µg) 
containing DNA of human S18 deletion BPIFA1-FLAG was provided. 
 
2.8.2 Generation of mouse full-length BPIFA1-FLAG construct 
 
RNA of mouse endogenous BPIFA1 was isolated from mTECs differentiated at the air 
liquid interface (ALI) conditions (section 2.14.4). Isolation of RNA was performed, and 
genomic DNA was removed by DNase treatment as described. DNase digested RNA 
was reverse transcribed into cDNA which was used in PCR using the primer pair shown 
in Figure 2.1. 
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Figure 2.1: Primer pair used to generate mouse BPIFA1-FLAG construct. 
DNA sequences highlighted in the red colour represent sequences of restriction endonucleases – 
sites which are necessary for cloning reactions in the linear VR1255 vector (digested with NotI 
and BamHI). DNA sequence highlighted in the yellow colour represents Kozak sequence which 
plays a role in the initiation of translation process. STOP codon is highlighted in the green colour 
and nucleotide sequence of FLAG tag in the cyan colour.  
 
2.9 Generation of BPIFA1-plasmid constructs 
 
DNA of human full-length (256aa), F/R1 (39aa), and F/R2 (58aa) BPIFA1-GFP were 
previously cloned in pcDNA3.1/CT-GFP-TOPO (pcDNA3.1) vector in the laboratory to 
prepare BPIFA1 constructs for transfection assays. In this study, all human BPIFA1-GFP 
constructs were re-cloned in pcDNA5/FRT plasmid. DNA of human full-length and 
cysteine mutant BPIFA1-FLAG were previously cloned in VR1255 expression system in 
Prof J. Stewart’s group (University of Liverpool). DNA of the human S18 deletion and 
mouse BPIFA1-FLAG were ligated to VR1255 vector DNA (kindly gifted to our group by 
Prof J. Stewart) during this study to generate BPIFA1 constructs for transfection assays. 
 
2.9.1 Preparation of BPIFA1-GFP constructs for cloning into 
pcDNA5/FRT 
 
TOP10 E. coli cells were transformed with DNA of human full-length, F/R1, and F/R2 
BPIFA1-pcDNA3.1 constructs. Ampicillin (100µg/mL) was used for selection of positive 
transformants. DNA minipreps were performed and DNA of pcDNA3.1 plasmids 
containing FL-, F/R1-, and F/R2-BPIFA1-GFP were digested with HindIII and BamHI in 
mA1 Not I Forward: 
 
5’-ATGCGGCCGCCGCCGCCACCATGTTTCTAGTTGGGAGCCT-3’ 
 
mA1 Stop Reverse: 
 
5’-GCGGATCCTTACTTGTCATCGTCGTCCTTGTAGTCAACTTTGATGACAAACTGTAG-3’ 
Not I 
BamH I Stop FLAG tag 
Kozak 
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10x buffer E. Miniprep samples (10µL) of all three constructs were sent for Sanger 
sequencing which was performed using T7 and BGH primers. The coding regions of 
human pcDNA3.1-BPIFA1-GFP constructs were amplified using PCR and primers 
(Sigma-Aldrich) flanking the CT-GFP-TOPO restriction sites (F: 5’-
GATCCACTAGTCCAGTGTGGT-3’; R: 5’-GCTGATCAGCGGGTTTAATTC-3’). The PCR 
reaction was run for 35 cycles. PCR products were run on 1% agarose gel to visualise 
DNA fragments. 
 
2.9.2 Cloning BPIFA1-GFP constructs into pcDNA5/FRT vector 
system 
 
PCR products of full-length, F/R1-, and F/R2-BPIFA1-GFP were diluted in relation to the 
amount of vector used (FL-BPIFA1-GFP - 1:15; F/R1-BPIFA1-GFP - 1:20; and F/R2-
BPIFA1-GFP - 1:5) and cloned into pcDNA5/FRT. After the cloning reaction, TOP10 E. 
coli cells were transformed with plasmid DNA and ampicillin (100µg/mL) was used for 
selection of positive transformants. Minipreps were performed and plasmid DNA was 
digested with NcoI in 10x buffer D. Restriction digests were run on agarose gel to 
visualise DNA fragments. Minipreps (10µl) of pcDNA5/FRT-BPIFA1-GFP constructs 
were sent for Sanger sequencing which was performed using T7 and BGH primers. 
 
2.9.3 Transformation of E. coli with pOG44 plasmid 
 
Empty pOG44 plasmid, which works in the Flp-In system, was required for co-
transfections of Flp-In-CHO cells. TOP10 E. coli cells were transformed with DNA of 
pOG44 plasmid and ampicillin (100µg/mL) was used for selection of positive 
transformants. Minipreps were digested with EcoRI in 10x buffer H to verify the quality of 
plasmid DNA.  
 
2.9.4 Preparation of VR1255 for ligation reactions with BPIFA1 DNA 
 
To verify a quality of VR1255, vector DNA was digested with BamHI and NotI in 10x 
buffer D. To generate a linear plasmid DNA for ligation reactions, VR1255 DNA (1267ng) 
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was digested with BamHI and NotI and the DNA fragment of interest (4761bp) was 
visualised using UV transilluminator, cut from the gel and recovered.  
 
2.9.5 Preparation of human S18 mutant BPIFA1-FLAG for ligation with 
VR1255 
 
Nuclease free water (50µl) was added to 5µg of lyophilised pMA-T plasmid DNA 
containing S18 mutant BPIFA1-FLAG and incubated for 1 hour at RT. Plasmid DNA was 
used to transform TOP10 E. coli cells and ampicillin (100µg/mL) was used for selection 
of positive transformants. Six transformed E. coli colonies were grown and miniprepped. 
DNA was digested with NotI and BglII in 10x buffer D. Restriction digests were run on 
1% agarose gel and the fragment (773bp) was recovered from the agarose gel. The 
quality of recovered DNA was verified using agarose gel electrophoresis. 
 
2.9.6 Preparation of mouse BPIFA1-FLAG for ligation with VR1255 
 
PCR product of mouse BPIFA1-FLAG was cloned into pCRII-TOPO vector (Invitrogen) 
according to the “TOPO TA Cloning® Kit” protocol. DNA minipreps were performed and 
DNA was digested with NotI and BamHI in 10x buffer D. Restriction digests were run on 
1% agarose gel and the DNA fragment (878bp size) was recovered from the agarose 
gel. 
 
2.9.7 Ligation of human S18 deletion and mouse BPIFA1-FLAG with 
VR1255 
 
Linear VR1255 vector DNA was ligated using T4 DNA ligase with S18 deletion BPIFA1-
FLAG DNA at the ratio of 1:6 and with mouse BPIFA1-FLAG DNA at the ratio of 1:1, 1:3, 
and 3:1. TOP10 E. coli cells were transformed with ligation products and kanamycin 
(100µg/mL) was used for selection. DNA minipreps were performed and DNA was 
digested as described: 
• VR1255 ligated with S18 deletion BPIFA1-FLAG: 
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1. EcoRV and KpnI in Multi-Core buffer; 
2. BamHI and XbaI in 10x buffer E. 
• VR1255 ligated with mouse BPIFA1-FLAG: 
1. EcoRV and KpnI in Multi-Core buffer; 
2. HindIII in 10x buffer E. 
Miniprep samples (10µL) were sequenced using pVR1255F and pVR1255R primers.  
 
2.9.8 Transformation of E. coli with human full-length and cysteine 
mutant BPIFA1-FLAG constructs 
 
TOP10 E. coli cells were transformed with DNA of FLAG-tagged human full-length and 
cysteine mutant BPIFA1-VR1255. Kanamycin (100µg/mL) was used for selection of 
positive transformants. Samples were miniprepped and DNA was digested with NotI and 
BamHI.  
 
2.10 Transfections 
 
Transfections were performed to obtain secreted BPIFA1 recombinant proteins for the 
functional analysis of BPIFA1. Three different techniques were used to transfect cells. All 
transfections were performed using maxiprep samples of BPIFA1 constructs. 
 
2.10.1 Preparation of BPIFA1 constructs and control vectors for 
transfections  
 
E. coli cells transformed with DNA of pOG44 vector and BPIFA1 expression constructs 
were used for DNA maxipreps. All DNAs were digested to confirm their identity (sections: 
2.9.3, 2.9.7, and 2.9.8). 
 
2.10.2 Stable transfections of NCI-H292 cells 
 
NCI-H292 cells were seeded (8x104 cells/well) onto 24-well plates and the next day were 
transfected with pcDNA3.1-BPIFA1-GFP. Empty EGFP-C3 served as a positive control 
for the transfection assay. Transfection was performed in the duplicates using FuGENE® 
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HD. Transfection was undertaken using 500ng of DNA and 1μL-2μL-3μL of FuGENE 
reagent per well at the ratio of transfection reagent to DNA of 1:1, 2:1 and 3:1, 
respectively. Transfection reagent and DNA was added into 100μL of OptiMEM reduced 
serum medium (Gibco® by Life technologies) and incubated for 15mins at RT. Growth 
medium was removed from the cell culture plate, cells were washed with OptiMEM 
medium, and fresh 400μL of OptiMEM was added to the cells. After 15 minutes, DNA-
transfection reagent mixture was added to the cells and the plate was returned to the 
incubator (37ºC/5% CO2) for 24 hours incubation. The following day, the transfection 
mixture was removed, cells were washed with OptiMEM medium, and DMEM growth 
medium was added into the cell culture plate. Transfection efficiency was determined 
using fluorescent microscopy. Two days after transfection, DMEM growth medium was 
removed and medium containing 1000μg/ml of G418 was added. Cells were fed every 
third day with fresh medium containing G418 (1000μg/ml) to establish a stable cell line 
expressing BPIFA1. Cells transfected with EGFP-C3 were also fed with medium 
containing G418 and used as the control. After selection for the positive cells, G418 was 
still used in the cell culture for the maintenance of selected cell line. Subsequently, serial 
dilution was used for isolation of BPIFA1-GFP positive cells. Cells were collected from 
24-well culture plates and seeded onto 96-well culture plates. Serial dilutions were 
performed to enable the isolation of single cell colonies expressing the protein of interest. 
BPIFA1-GFP positive single cell colonies were transferred back onto 24-well culture 
plate when cells reached the confluence. After cells were confluent in 24-well plate, they 
were moved onto 6-well plates. A sample of transfected cells was collected and lysed in 
2x SDS lysis buffer for western blotting analysis. Afterwards, transfected cells were 
grown in T75 flasks and once they were confluent, 6x106 of cells were taken for cell 
sorting by flow cytometry to isolate human BPIFA1-GFP positive cells from negative 
cells. Flow cytometry cell sorting was performed at the University of Sheffield core 
facility. Sorting of cells was done based on the GFP fluorescence associated with 
BPIFA1-GFP positive cells. NCI-H292 control cells were used as a negative control 
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sample. Highly fluorescent cells were selected as BPIFA1-GFP positive ones. Samples 
of BPIFA1-GFP positive and negative cells were collected. Both types of cells were 
seeded into different T75 flasks and returned to the incubator (37ºC/5% CO2). Next, 
positive and negative cells were seeded into T25 flasks in the serum supplemented and 
serum-free DMEM medium (2ml). The following day, conditioned medium and cell 
samples were collected. Cells were lysed in 2x SDS buffer as were conditioned medium 
samples. Samples were analysed for BPIFA1-GFP protein production and secretion 
using SDS-PAGE. 
 
2.10.3 Stable transfections of Flp-In-CHO cells 
 
CHO (pFRT/lacZ-Zeocin) cells were seeded (4x104 cells/well) onto 24-well plates the day 
before transfection. The next day, co-transfection of CHO cells was performed in the 
duplicates using LipofectamineTM LTX transfection reagent. Co-transfection components 
were mixed in the following order: 1) 2μL of Lipofectamine was added into 100µl of 
OptiMEM medium (Gibco® by Life technologies) (ratio of DNA to Lipofectamine: 1:2); 
and 2) 100ng of GFP-tagged BPIFA1-pcDNA5/FRT (i.e. full-length, F/R1, and F/R2-
BPIFA1-GFP) with 900ng of pOG44 were added into 100µl of OptiMEM medium (ratio of 
construct DNA to pOG44 – 1:9). The DNA mix and transfection reagent mix were 
combined and incubated for 30 minutes at RT. During the incubation time, RPMI-1640 
growth medium was removed from the cell culture plates, cells were washed with 
OptiMEM reduced serum medium and fresh 800µl of OptiMEM was added. The mixed 
DNA and transfection reagent was added to the cells and plates were returned to the 
incubator (37ºC/5% CO2) for 4 hours incubation. CHO cells were also co-transfected with 
empty EGFP-N1 and pOG44 as positive controls. After incubation, the transfection 
mixture was removed and 1ml of RPMI-1640 growth medium was added. The following 
day, RPMI-1640 growth medium was removed and RPMI-1640 growth medium 
containing hygromycin B (450μg/ml; Invitrogen) was added to the cells for selection of 
positively transfected cells. Cells were fed every third day with RPMI-160 growth medium 
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containing hygromycin B for two weeks until stable cell lines expressing BPIFA1 were 
established. Samples of stably transfected cells were taken for genomic DNA extraction 
to verify integration of GFP-tagged BPIFA1-pcDNA5/FRT DNA into the genome of CHO 
cells. DNeasy® Blood & Tissue Kit (Qiagen) was used according to the quick-start 
protocol. Genomic DNA from GFP-tagged full-length, F/R1, and F/R2-BPIFA1 cells was 
used for PCR. The coding regions of FL, F/R1-, and F/R2-BPIFA1 were amplified with 
primers flanking the TOPO cloning site (F: 5’-ACCCACTGCTTACTGGCTTA-3’; R: 5’-
GCAACTAGAAGGCACAGTCG-3’). Minipreps of construct DNA were used as positive 
controls. Samples of stably transfected cells and serum supplemented conditioned 
medium were collected for detection of BPIFA1-GFP protein. Cells were lysed in 2x SDS 
lysis buffer as were conditioned medium samples at the ratio of 1:1. Samples were 
processed for western blotting as described. 
 
2.10.4 Transient transfections of HEK293T cells 
 
Transient co-transfections of HEK293T cells with FLAG-tagged BPIFA1-VR1255 
constructs (i.e. human full-length, cysteine mutant, S18 deletion BPIFA1-FLAG and 
mouse BPIFA1-FLAG) were performed to generate BPIFA1 secreted proteins. Empty 
pEGFP-N1 was used as a control. The day before transfection, HEK293T cells were 
seeded onto 24-well plate (2.5x105 cells/well) for small-scale co-transfection to find out 
whether proteins of interest would be produced and secreted by transfected cells. Empty 
pEGFP-N1 was used as a positive control for transfection efficiency. The following day, 
HEK293T cells were transfected using a standard calcium phosphate protocol. DMEM 
growth medium was replaced with fresh growth medium 4 hours before transfection. A 
volume of 3.8µl CaCl2 (2.5M concentration), 1.52µg of BPIFA1-VR1255 construct and 
100ng of pEGFP-N1 were mixed together in the eppendorf tube. Subsequently, the 
DNA/CaCl2 mixture was added dropwise, while mixing gently, to a bijou tube containing 
38µl of 2x HEPES-buffered saline and incubated for 20 minutes at RT. Transfection-DNA 
mixture was added dropwise to HEK293T cells and the plate was returned to incubator 
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for 18 hours (37ºC/5% CO2). The next day, the medium containing transfection-DNA 
mixture was removed, and cells were washed with PBS (without calcium and magnesium 
chloride; Sigma-Aldrich), followed by addition of the fresh DMEM growth medium (500µl). 
Cells were then incubated for 30 hours (37ºC/5% CO2). Afterwards, the conditioned 
medium and cell samples were collected for SDS-PAGE analysis. Conditioned media 
samples were centrifuged for 5 minutes at 1000 RPM to remove debris. Subsequently, 
25µl of conditioned medium was lysed in 25µl of 2x SDS lysis buffer. Collected samples 
of transfected cells were lysed in 100µl of 2x SDS lysis buffer. Samples were analysed 
using western blotting. After verification of BPIFA1 production and secretion, large-scale 
co-transfections were used to generate large quantities of secreted human and mouse 
BPIFA1-FLAG proteins. Co-transfections were performed in T75 and T175 flasks. 
Volumes of transfection reagents and DNA were increased accordingly to the surface 
area of the flask. Conditioned medium samples were collected every day for four days. 
After collection of conditioned media containing FBS serum, cells were washed with PBS 
and fresh serum-free medium was added to the cells. Serum-free conditioned medium 
samples were collected every day for three days. Cell lysate samples were collected for 
the western blotting analysis on the last day of the conditioned media collection. 
Appendix I (Table II) shows detailed preparation of all stock solutions used in 
transfections of HEK293T cells. 
 
2.11 Fluorescence microscopy 
 
Fluorescence microscopy was used to visually determine transfection efficiency and 
observe BPIFA1 recombinant proteins within the cells.  
 
2.11.1 Cells transfected with BPIFA1-GFP constructs   
 
Transfected NCI-H292 and Flp-In-CHO cells were seeded onto the glass chamber slides 
when the transfection assays were completed. The aim was to determine transfection 
efficiency. Cells were grown until almost confluent and then fixed with 10% formalin and 
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stained with DAPI. Images of NCI-H292 cells were taken using Olympus epifluorescence 
microscope, whereas images of Flp-In-CHO cells were taken using Zeiss Axioplan 2 
imaging microscope. Cells were visualised at 20x and 60x magnification. Images were 
processed using ImageJ-win32 program.  
 
2.11.2 Analysis of FLAG-tagged BPIFA1 proteins within the cells 
 
NCI-H292 cells were transfected with FLAG-tagged BPIFA1-VR1255 constructs for 
observation of recombinant proteins within the cells. Cells were seeded onto 6-well plate 
(4x105 cells/well) the day before calcium phosphate transfection. The day after 
transfection, cells were seeded onto the glass chamber slides and grown until almost 
confluent. Cells were fixed by immersion in the ice-cold methanol (100%; Fisher 
Chemical) for 10 minutes at -20ºC. Methanol was removed, and cells were washed with 
1x PBS (Gibco® by Life technologies). Subsequently, the staining of cells was 
performed. Triton X-100 (Sigma) in PBS (0.5%) was added to the cells for 5 minutes at 
RT. Afterwards, cells were washed with 1x PBS. For the blocking step, cells were 
incubated in the goat serum (Sigma) diluted (1:10) in 1x PBS with 0.5% Triton X-100 
(blocking buffer) for 1 hour on the orbital shaker (80 RPM) at RT. Subsequently, the 
blocking buffer was removed, and cells were washed with 1x PBS.  Mouse monoclonal 
ANTI-FLAG® M2 antibody (Sigma-Aldrich) was diluted 1:500 in the blocking buffer and 
added to the cells for 2 hours on the orbital shaker (80 RPM) at RT. Control cell samples 
were incubated in the blocking buffer only (without primary antibody). After incubation, 
the primary antibody mixture was removed, and cells were washed with 1x PBS. The 
primary antibody was detected with secondary Alexa Flour 488 conjugated goat anti-
mouse IgG (H+L) cross-adsorbed antibody (ThermoFisher Scientific) diluted 1:1000 in 
the blocking buffer and incubated for 1 hour in the dark on the orbital shaker (80 RPM) at 
RT. The secondary antibody mixture was aspirated, and cells were washed with 1x PBS. 
The frames of glass chamber slides were removed, and cells were stained with DAPI. 
Images of the cells were taken at 100x magnification using Zeiss Axioplan 2 imaging 
 63 | P a g e  
 
immunofluorescence microscope and processed using ImageJ-win32 program. Fields for 
imaging were chosen randomly. After images were taken, ten imaged fields of 
transfected cells were analysed by counting total number of cells per field as well as 
counting cells positive for BPIFA1. The aim was to determine the ratio of BPIFA1 
transfected cells with and without fluorescent granules.  Ratio was calculated by using 
equation: 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 % 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ 𝑔𝑟𝑎𝑛𝑢𝑙𝑒𝑠
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 % 𝑐𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑔𝑟𝑎𝑛𝑢𝑙𝑒𝑠
 = 𝑅𝑎𝑡𝑖𝑜 
 
2.12 Purification of BPIFA1-FLAG recombinant proteins 
 
BPIFA1-FLAG proteins were purified from 15ml of serum-free conditioned media using 
anti-FLAG® M2 affinity gel (Sigma-Aldrich) according to established protocols. FLAG® 
peptide (Sigma-Aldrich) instead of 3X FLAG peptide was used for the elution of proteins, 
because BPIFA1 proteins of interest were fused to the FLAG tag. Purified BPIFA1-FLAG 
proteins were stored at -20ºC. Samples of purified proteins were collected for SDS-
PAGE analysis as were conditioned medium samples before and after purification, and 
anti-FLAG® M2 affinity gel beads before and after purification.  
 
2.13 Bacterial pull-down assays 
 
Bacterial pull-down assays were used to investigate the ability of BPIFA1 to bind to the 
respiratory bacteria. Binding of BPIFA1 to S. aureus, S. pneumoniae, and NTHi were 
studied. Both FLAG-tagged BPIFA1 recombinant proteins and endogenous BPIFA1 
proteins were used. Mouse endogenous BPIFA1 was collected as apical secretion 
washes from WT mTECs differentiated at the ALI conditions (section 2.14.4). Human 
endogenous BPIFA1 was collected as the apical secretion washes from normal and 
asthmatic bronchial epithelial cells differentiated at the ALI conditions (kindly gifted to us 
by Synairgen (Southampton)). The list of BPIFA1 proteins used in bacterial pull-down 
assays is provided in the Table 2.6. 
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Table 2.6: The list of BPIFA1 proteins used in the bacterial pull-down assays. 
Protein Amount 
Mouse endogenous BPIFA1 25µl of ALI wash 
Mouse recombinant BPIFA1-FLAG 50µl of serum-free conditioned medium 
Purified mouse recombinant BPIFA1-FLAG 10µl of purified protein in TBS 
Human endogenous BPIFA1 (Synairgen) 10µl of ALI wash 
Human recombinant full-length BPIFA1-
FLAG 
50µl of serum-free conditioned medium 
Human recombinant cysteine mutant 
BPIFA1-FLAG 
50µl of serum-free conditioned medium 
Human recombinant S18 deletion BPIFA1-
FLAG 
50µl of serum-free conditioned medium 
 
 
2.13.1 BPIFA1 binding to S. aureus 
 
S. aureus strain SH1000, a laboratory strain derived from S. aureus strain NCTC 8325 
(Baek et al., 2013, O'Neill, 2010) was used in the pull-down assays. S. aureus was 
grown on LB-agar (Sigma) plate overnight in the incubator (37ºC/5% CO2). Bacterial 
colonies were picked up and added into Brain-Heart Infusion (BHI) culture broth (Sigma-
Aldrich) for overnight incubation (37ºC/5% CO2) on the orbital shaker (200 RPM). The 
optical density (O.D.) of 1ml overnight bacterial culture was measured at a wavelength of 
600nm using Jenway 6300 spectrophotometer calibrated against 1ml of uninoculated 
BHI broth. Bacterial culture amounts equivalent to OD600 of 1 (approximately 2x108 of 
bacteria) were used for each reaction. Bacterial culture amount for an OD600 of 1 was 
calculated using equation: 
 
1
𝑂𝐷 − 600 𝑉𝑎𝑙𝑢𝑒
 = 𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑐𝑢𝑙𝑡𝑢𝑟𝑒 (𝑚𝑙) 
Bacterial samples were centrifuged at 13000 RPM for 5 minutes to collect bacterial 
pellet. The broth was removed, and bacteria were washed three times in 1ml of PBS and 
centrifuged (13000 RPM/5mins) to collect a pellet. The pellet was resuspended in the 
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samples containing BPIFA1 (Table 2.6) and incubated in the incubator (37ºC/5% CO2) 
for: 0, 10, 30, and 60 minutes. Samples were centrifuged (13000 RPM/5mins) to collect 
bacterial-protein pellets which were then washed three times in PBS. Bacterial-protein 
pellets were lysed in 2x SDS lysis buffer along with the recovered pull-down fluids and 
analysed using SDS-PAGE. 
 
2.13.2 BPIFA1 binding to S. pneumoniae  
 
S. pneumoniae strain D39, a clinical isolate obtained from the patient in 1916 (Lanie et 
al., 2007), was used in the pull-down assays. S. pneumoniae was grown on the blood 
agar plates overnight in the incubator (37ºC/5% CO2). Bacterial colonies were picked up 
and added into 20ml of BHI broth (Sigma-Aldrich) supplemented with 20% heat 
inactivated FBS (Sigma) for the overnight incubation (no shaking) in the incubator 
(37ºC/5% CO2). The optical density of 1ml bacterial culture was measured as described 
in the section 2.13.1. Bacterial culture amounts equivalent to OD600 of 1 (approximately 
8.5x107 of bacteria) were used for each reaction with the protein of interest (Table 2.6). 
Overnight bacterial culture samples which measured below OD600 0.7 were used in the 
bacterial pull-down assays. S. pneumoniae samples were prepared and bacterial pull-
downs were performed as described in the section 2.13.1.  
 
2.13.3 BPIFA1 binding to NTHi  
 
Streptomycin resistant NTHi strain 375-SR was used in the bacterial pull-downs. NTHi 
strain 375 is a clinical isolate obtained from the pneumococcal vaccine study (Cody et 
al., 2003). NTHi was grown on the BHI agar (Sigma-Aldrich) plates supplemented with 
10µg/ml hemin (Sigma-Aldrich), 2µg/ml NAD hydrate (Sigma-Aldrich) and 200µg/ml 
streptomycin sulphate (Melford Laboratories). Bacteria were streaked onto BHI plates 
and incubated overnight in the incubator (37ºC/5% CO2). Bacterial colonies were picked 
up and added into 4ml of BHI broth (Sigma-Aldrich) supplemented with NAD (2µg/ml) 
and hemin (10µg/ml) for 3 hours incubation on the orbital shaker at 200 RPM (37ºC/5% 
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CO2). The optical density (O.D.) of 1ml overnight bacterial culture was measured at a 
wavelength of 490nm using Jenway 6300 spectrophotometer calibrated against 
uninoculated BHI broth. Bacterial culture amounts equivalent to OD490 of 1 
(approximately 5x109 of bacteria) were used for each reaction with the protein of interest 
(Table 2.6).  Bacterial culture amount for an OD490 of 1 was calculated using equation: 
 
1
𝑂𝐷 − 490 𝑉𝑎𝑙𝑢𝑒
 = 𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑐𝑢𝑙𝑡𝑢𝑟𝑒 (𝑚𝑙) 
 
NTHi samples were prepared and bacterial pull-downs were performed as described in 
the section 2.13.1.  
 
Methods for the study of mTEC challenge with NTHi  
 
2.14 mTEC culture 
 
mTECs, isolated from WT and transgenic Bpifa1-/- mice, were used in NTHi challenge 
study. The aim was to investigate whether the loss of BPIFA1 in mTECs results to the 
enhanced NTHi infection. 
 
2.14.1 WT and transgenic Bpifa1-/- mice  
 
Mice deficient in Bpifa1 were generated by Prof Ralph Shohet at the University of Hawaii 
as described (Akram et al., 2018). Animal work with Bpifa1-/- mice was approved by the 
University of Liverpool Animal Welfare Committee and performed under UK Home Office 
Project Licences 40/2083 and 70/8599. Mice lacking Bpifa1 used in this study were at the 
age of 13-17 weeks, whereas WT C57BL/6J control mice were at the age of 20-31 
weeks. Wild-type C57BL/6J mice were obtained from Charles River. Animal work with 
WT mice was approved by the University of Sheffield Animal Welfare Committee and 
performed under Scientific procedures Act 1968 and UK Home Office Project License 
40/3726. 
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2.14.2 Harvesting of mouse tracheas 
 
Terminal intra-peritoneal injection of 100μL pentobarbital (50mg/ml, Henry Schein®) was 
used to euthanise mice which were then exsanguinated by cutting the inferior vena cava. 
The dissection method was adapted from the study by You et al. (You et al., 2002). 
Briefly, mice were kept on the ice and before dissection was started, they were sprayed 
with 70% Industrial Methylated Spirit (IMS). Dissection was performed in the class 2 
safety cabinet. Using sterile technique, a longitudinal, midline incision from the clavicles 
to the submandibular region was made to expose the trachea (Figure 2.2 B). The 
muscles overlying trachea were separated and midline incision in the sternum was made 
to access the trachea within the thoracic cavity (Figure 2.2 C). Trachea was lifted, and 
the oesophagus was dissected away from the posterior surface of the trachea. Resection 
of trachea was performed by cutting at the proximal part of trachea distal to the larynx 
(Figure 2.2 D) and by cutting trachea at the bifurcation of the mainstem bronchi (Figure 
2.2 E). Resected tracheas were placed in sterile ‘mTEC-basic media’: DMEM/Ham’s F-
12 media (containing HEPES and L-glutamine; Life Technology) supplemented with 
penicillin (100 μg /ml) and streptomycin (100 μg/ml) (Life Technology) and kept on the 
ice until the dissection of all mice was finished. Subsequently, the remaining adherent 
tissues were removed from the trachea under Olympus SZX10 dissecting microscope 
(Figure 2.2 H). Cleaned tracheas were placed in the fresh cold mTEC-basic media and 
kept on the ice until all tracheas were cleaned. Tracheas were cut open lengthwise and 
placed in the 15ml falcon tube containing 5ml of freshly made 0.15% pronase solution 
(Roche Applied Science) in mTEC-basic media for overnight (18-24 hours) incubation at 
4ºC. For each batch of mTECs, approximately six harvested tracheas were pooled in the 
one tube. 
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The removal of skin by the longitudinal, midline incision from the distal part of the rib cage to the 
submandibular region (A). Exposure of trachea (B). Separation of muscles from the trachea (C). 
Resection of trachea by cutting at the proximal part of trachea (PPT) distal to the larynx (D) and 
by cutting trachea at the bifurcation of the mainstem bronchi (BMB) (E). Resected trachea (F). 
Visualisation of tracheas under the dissection microscope (G). Removal of remaining adherent 
tissues from the trachea (H). 
 
 
  
Figure 2.2: Dissection of mouse trachea. 
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2.14.3 Isolation and submerged culture of mTECs 
 
The methodology for isolation and culture of mTECs was adapted from the previously 
described method (You et al., 2002, You and Brody, 2013). After overnight incubation, 
10% FBS (Life Technologies) was added in the tube, containing harvested tissues to 
neutralise the activity of pronase and the tube was gently inverted approximately 20 
times to dislodge epithelial cells that were attached to the tracheas. Tracheas were 
transferred into a new 15ml falcon tube, containing 2ml of warm mTEC-basic medium 
supplemented with 10% FBS and again inverted gently for approximately 20 times. This 
process was repeated four times. Harvested tissues were discarded and the contents of 
all tubes were combined in a new tube. To collect cells, the sample was centrifuged at 
1495 RPM for 15 minutes at 10ºC. The supernatant was aspirated, and the cell pellet 
was resuspended in 1ml of cold DNase solution, containing 0.5mg/ml pancreatic DNase I 
(Sigma-Aldrich) and 1mg/ml bovine serum albumin (Sigma-Aldrich). The cell suspension 
(15µl) was loaded on the Neubauer counting chamber for counting of the total number of 
cells and the rest of the cells were incubated in DNase solution for 5 minutes on the ice. 
During incubation, cell viability was assessed, and the total number of the cells was 
determined. Cells were centrifuged at 1495 RPM for 5 minutes at 10ºC and the pellet 
was resuspended in 5ml of mTEC-basic medium supplemented with 10% FBS. The cells 
were plated onto 60mm surface treated tissue culture dish (NuncTM Brand Products) and 
incubated for 3-4 hours in the incubator (37ºC/5% CO2) to allow fibroblasts to attach to 
the surface. After incubation, the tissue culture dish was gently swirled a few times and 
non-adherent epithelial cells were collected. Cells were centrifuged at 1495 RPM for 5 
minutes at 10ºC to collect cell pellet. During this time, 5ml of mTEC-basic medium 
containing 10% FBS was added to fibroblasts and cells were cultured till confluent. 
Epithelial cells were resuspended in ‘mTEC-plus medium’: mTEC-basic medium 
containing 5% FBS, 10μg/ml of insulin (Sigma-Aldrich), 5μg/ml of transferrin (Sigma-
Aldrich), 0.1μg/ml of cholera toxin (Sigma-Aldrich), 25ng/ml of mouse epidermal growth 
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factor (BD Biosciences), 30μg/ml bovine pituitary extract (Gibco® by Life Technologies), 
0.01μM of freshly added retinoic acid (Sigma-Aldrich), and 10µM of Rho Kinase inhibitor 
Y-27632 dihydrochloride (Tocris bioscience). Sample of epithelial cells (original cells) 
was taken for RNA extraction. The rest of isolated epithelial cells were seeded at the 
density of 3-3.5x104 (cells/transwell) onto 0.4μm pore sized transparent Polyethylene 
Terephthalate (PET) membranes coated with 50μg/ml of rat-tail collagen type I (BD 
Biosciences) in 24-well cell culture plates supporting transwell format (Corning 
Incorporated Costar®). Cells were cultured in the submerged conditions until confluent 
(mTEC-plus media: 200µl in the top chamber and 700µl in the bottom chamber). Cells 
were fed with fresh media every second day. 
 
2.14.4 ALI culture of mTECs 
 
mTECs were differentiated into upper airway-like epithelium in ALI conditions using a 
previously described method (You et al., 2002, You and Brody, 2013). After mTECs 
became confluent, mTEC-plus media was removed from the top and bottom chambers 
and 800µl of ‘mTEC-ALI media’ was added to the bottom chamber: mTEC-basic media 
containing 5μg/ml insulin, 5μg/ml transferrin, 0.025μg/ml cholera toxin, 5ng/ml mouse 
epidermal growth factor, 30μg/ml bovine pituitary extract, 1mg/ml BSA (Sigma-Aldrich) 
and 0.01μM of freshly made retinoic acid. Sample of Day 0 ALI cells was collected for 
RNA extraction. Epithelial cells were differentiated in ALI culture for 14 days (Figure 2.3). 
Cells were fed with fresh mTEC-ALI media and the apical surfaces were washed with 
200µl of warm Hank’s Balanced Salt Solution (HBSS; Gibco® by Life technologies) every 
48 hours and stored at -20ºC. Washes were analysed for BPIFA1 secretion using SDS-
PAGE. Samples of differentiated mTECs were collected on Day 14 ALI for RNA 
extraction and western blotting analysis. Transwells were also fixed on Day14 ALI for 
immunostaining and confocal microscopy. The rest of the differentiated mTECs were 
used in NTHi challenge study. 
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Figure shows chronology of mTEC culture. Mouse tracheas were dissected and subjected to 
proteolysis in pronase solution. mTECs were separated from fibroblasts and grown in the 
submerged culture until confluent. ALI conditions were induced upon the confluence. Samples 
were collected for analysis at the regular time points (A). Figure also shows a schematic diagram 
of submerged culture in which most of the cells present are basal cells (green). ALI conditions 
were induced when mTECs became confluent, promoting cell differentiation into secretory cells 
(red) and ciliated cells (blue) (B). 
 
2.14.5 Mouse fibroblast culture 
 
Adherent fibroblasts from mouse tracheas were cultured in 60mm surface treated tissue 
culture dishes (NuncTM Brand Products) containing mTEC-basic media supplemented 
with 10% FBS. Once confluent, cells were dissociated by Trypsin-EDTA (Sigma). The 
cell pellet was resuspended in 5ml of fresh mTEC-basic/10% FBS media and the cells 
were grown until confluence. Subsequently, fibroblasts were subjected to a second 
trypsinization and seeded in T25 flasks. Fibroblasts were then lysed in Trizol reagent 
(250µl/flask) for RNA extraction or in 2x SDS (100µl/flask) lysis buffer for SDS-PAGE. 
Figure 2.3: Chronology and method for ALI culture of mTECs. 
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2.15 NTHi challenge assays 
 
mTECs, isolated from WT and Bpifa1-/- mice, were exposed to streptomycin resistant 
GFP-tagged NTHi-375 aiming to understand the role of BPIFA1 in NTHi infection. 
 
2.15.1 Preparation of GFP-tagged NTHi-375-SR inoculum 
 
GFP-tagged NTHi-375-SR was grown as described in the section 2.13.3. Sample of 
bacterial culture (1ml) was centrifuged at 13,000 RPM for 5 minutes and resuspended in 
the required volume of PBS to achieve an inoculum concentration of 1x1010 bacteria/ml. 
The following formula was used to determine the volume of PBS required: 
𝑂𝐷 − 490 𝑣𝑎𝑙𝑢𝑒
0.4
× (2 × 109) = 𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑐𝑢𝑙𝑡𝑢𝑟𝑒 (𝑚𝑙) 
 
2.15.2 Exposure of mTECs to NTHi 
 
Differentiated mTECs (Day 14 ALI) were washed with warm HBSS and antibiotic free 
mTEC-ALI media was added to the plate 3 hours before NTHi challenge. The number of 
mTECs per well at Day 14 ALI was counted using a haemocytometer (n=3) and one well 
was determined to contain approximately 1.3x105 cells. An appropriate amount of NTHi 
inoculum was diluted into antibiotic free mTEC-ALI media and added to the transwells in 
the such way that the apical surfaces of the cells were exposed to bacteria. NTHi 
challenge assays were performed using a multiplicity of infection (MOI) of 1:200, 1:500, 
and 1:1000 (mTECs: bacteria). An equal amount of sterile PBS diluted into antibiotic free 
mTEC-ALI media was used to generate MOCK-challenged controls. mTECs were 
exposed to NTHi for 1 hour at 37ºC, 5% CO2. Subsequently, media was removed from 
the bottom and top chambers and cells were washed three times with warm PBS to 
remove non-adherent bacteria. Fresh antibiotic free mTEC-ALI media was added to the 
basal chambers and cells were returned to incubator for 24, 48, and 72 hours. After each 
incubation time point, immunofluorescence microscopy was used to analyse the cells. 
Subsequently, the following samples were collected: 1) apical secretion washes in 200µl 
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of HBSS for western blotting and dot blotting; 2) cell lysate in 250µl Trizol reagent for 
gene expression studies; and 3) one transwell for cell fixation, immunohistochemical 
staining and confocal microscopy analysis. 
 
2.16 Immunofluorescence (IF) microscopy 
 
Live mTECs exposed to GFP-tagged NTHi-375-SR were visualised under IF microscope 
for the determination of NTHi colonisation. Fluorescence immunohistochemical staining 
was used for the localisation of proteins produced by original, Day 14 ALI and NTHi 
exposed mTECs. Fixed and stained mTECs were imaged using confocal (IFC) 
microscope (Olympus Fluoview 1000).  
 
2.16.1 Visualisation of mTECs exposed to GFP-tagged NTHi-375-SR 
 
Live mTECs exposed to NTHi were imaged using Zeiss Axiovert 200M IF microscope at 
24, 48, and 72 hours post infection (hpi). Images were taken of six fields on every 
membrane at 20x magnification to define an area for quantification (Figure 2.4). The aim 
was to determine the intensity of NTHi colonisation in WT and Bpifa1-/- mTEC cultures. 
The intensity of bacterial colonisation was measured by the mean integrated intensity of 
the six fields using ImageJ-win32 program. Three individual batches of WT and Bpifa1-/- 
mTECs were analysed for quantification. 
 
 
 
 
 
 
 
 
 
 
 
 
Constant six fields were selected on the membrane for imaging at 24, 48, and 72hpi. The mean 
integrated intensity was measured of all six fields to define bacterial colonisation. 
 
 
Figure 2.4: Quantification of NTHi colonisation. 
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2.16.2 Immunohistochemical staining and confocal imaging 
 
mTECs on transwell membranes were fixed with 10% formalin. Cells were permeabilised 
by incubation in the goat serum diluted 1:10 in 1x PBS with 0.5% Triton X-100 (blocking 
buffer) for 1 hour on the orbital shaker (80 RPM) at RT. Afterwards, mTECs were 
washed with 1x PBS and primary antibody (Table 2.7) diluted in blocking buffer was 
added to the cells for overnight incubation on the orbital shaker (80 RPM) at 4ºC. Cells 
were washed three times with 1x PBS and secondary antibody (Table 2.7) diluted in the 
blocking buffer was added to the cells for 1 hour incubation in the dark on the orbital 
shaker (80 RPM) at RT. Subsequently, cells were washed three times with 1x PBS and 
membranes were cut from the transwell frames. The membrane was placed on a glass 
microscope slide and a drop of Vectashield mounting medium for fluorescence with DAPI 
(Vector Laboratories, Inc.) was added to stain nuclei. Stained cells were imaged using 
Olympus Fluoview 1000 IFC microscope. Images were processed using ImageJ-win32 
program.  
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Table 2.7: Primary and secondary antibodies used in immunohistochemical staining. 
 
 
2.17 Analysis of gene expression in mTEC cultures 
 
Gene expression by mTECs exposed to NTHi was analysed at 24, 48, and 72hpi. 
mTECs were lysed in 250µl Trizol. RNA extraction, RT and RT-PCR were performed as 
described. Expression of Oaz1, Tekt1, Ltf, and Bpifa1 was studied.  
 
2.18 Mouse cytokine array 
 
Mouse cytokine array was performed to generate a full profile of cytokines and 
chemokines produced by WT and Bpifa1-/- mTECs exposed to GFP-tagged NTHi-375-
SR. This assay was performed using Mouse Cytokine Array Panel A (R&D Systems) 
according to the manufacturer’s protocol. The assay was carried out using 1ml of the 
apical secretion wash from each WT and Bpifa1-/- mTEC cultures exposed to GFP-
Primary antibodies 
Antibody Dilution Type Manufacturer 
Anti-BPIFA1 1:200 Rabbit polyclonal Produced in lab (Musa et al., 
2012) 
Anti-β tubulin 1:100 Mouse monoclonal – Clone TUB2.1 
 
Sigma-Aldrich (Cat. # T5201) 
Anti-FOXJ1 1:200 Mouse monoclonal – Clone 2A5 eBioscience (Cat. # 14-9965-
82) 
Anti-MUC5B 1:100 Rabbit polyclonal – Clone H-300 Santa Cruz (Cat. # sc-20119) 
Anti-ZO1 
 
1:100 Rabbit polyclonal Thermo Fisher Scientific (Cat. # 
40-2200) 
Secondary antibodies 
Antibody Dilution Type Manufacturer 
Alexa Fluor 488 1:200 Goat anti-mouse Life technology (Cat. # A11011) 
Alexa Flour 568 1:200 Goat anti-mouse Life technology (Cat. # A11004) 
Alexa Flour 568 1:200 Goat anti-rabbit Life technology (Cat. # A11011) 
Alexa Flour 633 1:200 Goat anti-mouse Life technology (Cat. # A21050) 
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tagged NTHi-375-SR at MOI-1000 for 72 hours. Equal volumes of the apical secretion 
washes were pooled from four different batches of each WT and Bpifa1-/- mTEC cultures 
to produce a total volume of 1ml. Results were analysed using densitometry according to 
the manufacturer’s recommendations. Signal values (pixel density) of each dot were 
analysed using ImageJ-win32 program. Data was plotted and visualised using GraphPad 
Prism7 software.  
 
2.19 Dot blotting of mTEC samples  
 
Dot blotting was used to analyse the levels of secreted BPIFA1 in the apical secretions 
from NTHi exposed and MOCK-challenged mTEC ALI cultures. Apical secretion washes 
from four different batches of NTHi-exposed and MOCK-challenged WT mTECs were 
used in the dot blotting analysis. Apical secretion washes were used from WT mTECs 
exposed to NTHi at MOI-200, MOI-500, and MOI-1000 for 24, 48, and 72 hours. Apical 
secretion washes from MOCK-challenged WT mTECs collected at 24, 48, and 72hpi 
were used as controls. Dot blotting was performed as described in the section 2.5.2.  
 
2.20 Statistics 
  
Levene’s test was used prior to the statistical analysis to determine parametricity and 
variance of experimental groups. Levene’s test was performed using Microsoft Excel 
2016. GraphPad Prism (version 7.0) was used to plot graphs and perform statistical 
tests. Unpaired non-parametric two-tailed student’s t-test with Mann-Whitney test was 
used to compare two groups of interest. Two-way analysis of variance (ANOVA) with 
Sidak multiple comparison test was used to compare more than two groups. Significance 
threshold was set at p≤0.05. Data was presented as the mean ± standard deviation (SD) 
or as the mean ± standard error of the mean (SEM). Significance levels represented on 
graphs are as follows: ns - not significant; *p≤0.05; **p≤0.01; ***p≤0.001; ****p≤0.0001. 
  
 77 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3: GENERATION OF HUMAN AND MOUSE 
BPIFA1 EXPRESSION VECTORS 
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3.1 Introduction 
 
BPIFA1 is an abundantly secreted protein released by airway non-ciliated epithelial cells 
in the upper respiratory tract and pharynx (Bingle and Craven, 2002). As outlined in the 
introduction the function of BPIFA1 is not fully understood but available data supports its 
role in the airway defence. A multitude of defensive functions have been proposed for 
the protein ranging from roles in the regulation of ion transport, a contribution to the 
surfactant properties of airway secretions (Garcia-Caballero et al., 2009, Garland et al., 
2013, Liu et al., 2013, McGillivary and Bakaletz, 2010, Rollins et al., 2010), antimicrobial 
activities, including bacterial anti-growth (Chu et al., 2010, Chu et al., 2007, Gally et al., 
2011, Sayeed et al., 2013, Zhou et al., 2008) and anti-biofilm functions (Gakhar et al., 
2010, Liu et al., 2013), through to chemotactic (Gally et al., 2011, Liu et al., 2013, 
Lukinskiene et al., 2011, Sayeed et al., 2013) and immunomodulatory properties (Chu et 
al., 2007, Liu et al., 2013, Lukinskiene et al., 2011). Although data supports the role of 
BPIFA1 in airway defence some of mechanisms underpinning these functions remain 
undetermined. 
Previous studies aimed to answer this question and investigated the structure of BPIFA1 
protein. It was initially reported that BPIFA1 shares sequence and structure similarity 
with BPI/LBP protein superfamily (Bingle and Craven, 2002). Similarity of BPIFA1 to 
these proteins led to further investigations of protein structure with two groups having 
solved the crystal structure of the protein (Garland et al., 2013, Ning et al., 2014). 
Proceeding this, it was shown that BPIFA1 controls the cleavage and activation of ENaC 
and the region responsible for this is at the position of amino acids G22-A39, also known 
as S18 region (Garcia-Caballero et al., 2009, Garland et al., 2013, Rollins et al., 2010). 
The study by Ahmad et al. demonstrated BPIFA1 bacteriostatic and anti-biofilm functions 
against several Burkholderia cenocepacia complex clinical isolates. Alpha 4-helix 
(residues I76-I105) was identified as protein region responsible for this effect. It was also 
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highlighted that α4 peptide of BPIFA1 (residues K77-L101) exhibited antimicrobial 
activity (Ahmad et al., 2016).  
On the basis of what is known about the protein, I propose that BPIFA1 plays a role in 
the airway host defence by binding to respiratory pathogens and specific regions of 
protein are responsible for such function. 
 
 
3.2 Objectives of this chapter 
 
The aim of this chapter was to generate the tools required to begin functional analysis of 
BPIFA1. Therefore, this chapter has the following objectives: 
1. To analyse human and mouse BPIFA1 protein sequences using bioinformatic 
approach.  
2. To generate the series of GFP and FLAG tagged BPIFA1 constructs.  
3. To transfect NCI-H292, CHO and HEK293T cells with BPIFA1 constructs and 
obtain secreted recombinant proteins. 
4. To transfect NCI-H292 cells with FLAG-tagged BPIFA1-VR1255 constructs and 
visualise recombinant proteins in the cells. 
5. To purify recombinant BPIFA1 proteins from conditioned medium samples. 
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Figure 3.1: Study plan for this chapter. 
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3.3 Results 
 
3.3.1 Bioinformatic analysis of human BPIFA1 (hBPIFA1) and mouse 
BPIFA1 (mBPIFA1) proteins  
 
3.3.1.1 Human BPIFA1 and other lipid-transfer protein family members 
 
I used bioinformatic tools to analyse BPIFA1 protein sequence to understand which 
regions of BPIFA1 may be important for biological functions. Human BPIFA1 shares 
amino acid sequence similarity with the N-terminal domain of BPI, LBP, PLTP, and 
CETP (Figure 3.2), these all belong to a larger lipid-transfer protein family. Kalign and 
BoxShade tools were used to generate multiple sequences alignment to identify 
conserved residues. Conserved residues can provide clues for functionally important 
regions of BPIFA1. Cysteine residues forming the disulphide bond are completely 
conserved and appear at the same position among all proteins analysed, suggesting 
their importance for biological activity of BPIFA1. It is already known that the disulphide 
bond of BPI is essential for the secretion of biologically active BPI (Horwitz et al., 1996) 
and this may also be a case with BPIFA1. 
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A sequence similarity of hBPIFA1 with N-terminal regions of human BPI, LBP, CETP, and PLTP 
proteins. Cysteine residues forming disulphide bond of all proteins analysed are highlighted in 
red. Multiple sequences alignment was produced using Kalign and BoxShade version 3.2, written 
by K. Hofmann and M. Baron. Capital-case letter means that same amino acid appears in each 
sequence of that column and is conserved among all proteins analysed. Lower-case letter means 
that structurally similar amino acid (semi-conserved) is present in each sequence of proteins 
analysed. 
 
 
I used protein Homology/analogY Recognition Engine V 2.0 (Phyre2), SWISS-MODEL 
template library (SMTL version 2018-01-03), and ProMod3 modelling engine to build 3D 
models of proteins to enable visualisation of disulphide bond position within BPI and 
hBPIFA1 protein structures (Figure 3.3). PyMOL was used to construct superpositions of 
proteins. Residues 43-256 of hBPIFA1 were superposed on full-length human BPI. The 
root mean square distance (RMSD) value over 176 residues was of 5.77. The structure 
of BPI was obtained from RCSB PDB database with resolution of 1.7Å (DOI: 
10.2210/pdb1ewf/pdb). The disulphide bond of hBPIFA1 and BPI proteins was observed 
at the same position within the model structure (Figure 3.3). 
  
[BPI]        1 -----------------MRENMARGPCNAPRWVSLMVLVAIGTAVTAAV----NPGVVVRISQKGLDYASQQGTAALQKE 
[LBP]        1 -----------------MGALARALPS------ILLALLLTSTPEALGA----NPGLVARITDKGLQYAAQEGLLALQSE 
[CETP]       1 -----------------MLAA------------TVLTLALLGNAHACSKGTSHEAGIVCRITKPALLVLNHETAKVIQTA 
[PLTP]       1 -----------------MALF------------GALFLALLAGAHAE------FPGCKIRVTSKALELVKQEGLRFLEQE 
[BPIFA1]     1 MFQTGGLIVFYGLLAQTMAQF-GGLPV--P---LDQTLPLNVNPALPLS----PTGLAGSLTNALSNGLLSGGLLGILEN 
consensus    1                  Mg      p        ll L lig a a        pGvv rit kgl  l qegl alq e 
 
 
[BPI]       60 LKRIKIPDYSDSFKIKHLG----------KGHYSFYSMDIREFQLPSSQISMVPNVGLKFSISNANIKISGKWK---AQK 
[LBP]       54 LLRITLPDFTGDLRIPHVG----------RGRYEFHSLNIHSCELLHSALRPVPGQGLSLSISDSSIRVQGRWK---VRK 
[CETP]      52 FQRASYPDITGEKAMMLLG----------QVKYGLHNIQISHLSIASSQVELVEAKSIDVSIQNVSVVFKGTLKYGYTTA 
[PLTP]      46 LETITIPDLRGKE-----G----------HFYYNISEVKVTELQLTSSELDFQPQQELMLQITNASLGLRFRRQ---LLY 
[BPIFA1]    71 LPLLDILKPGGGTSGGLLGGLLGKVTSVIPGLNNIIDIKVTDPQLLELGLVQSPDGHRLYVTIPLGIKLQVNTP------ 
consensus   81 l ritipd sg   i  lG          kghy l  m ise ql ss l  vp   l lsisn siki gk k       
 
 
[BPI]      127 RFLKMSGNFDLSIE-GMSISADLKLGSNPTSGKPTITCSSCSSHINSVHVHISKSK--VG-----WLIQLFHKKIESALR 
[LBP]      121 SFFKLQGSFDVSVK-GISISVNLLLGSE-SSGRPTVTASSCSSDIADVEVDMS-GD--LG-----WLLNLFHNQIESKFQ 
[CETP]     122 WWLGIDQSIDFEIDSAIDLQINTQLTCD--SGRVRTDAPDCYLSFHKLLLHLQ-GEREPG-----WIKQLFTNFISFTLK 
[PLTP]     108 WFFYDGGYINASAE-GVSIRTGLELSRD-PAGRMKVSNVSCQASVSRMHAAFG-GT--FK-----KVYDFLSTFITSGMR 
[BPIFA1]   145 --LVGASLLRLAVK--LDITAEILAVRD-KQERIHLVLGDCTHSPGSLQISLL-DG--LGPLPIQGLLDSLTGILNKVLP 
consensus  161  fl m g idlsie gmsis  l l  d  sgrvrit  sCs si  v v i  g   vg     wliqlft  i s lr 
 
 
[BPI]      199 NKMNSQVCEKVTNSVSSKLQPYFQTLPVMTKIDSVAGINYGLVAPPATTAETLDVQMKGEFYSENHHN-PPPFAPPVMEF 
[LBP]      191 KVLESRICEMIQKSVSSDLQPYLQTLPVTTEIDSFADIDYSLVEAPRATAQMLEVMFKGEIFHRNHRS-PVTLLAAVMSL 
[CETP]     194 LVLKGQICKEI-NVISNIMADFVQTRAASILSDGDIGVDISLTGDPVITASYLESHHKGHFIYKNVSE-DLPL-PTFSPT 
[PLTP]     178 FLLNQQICPVLYHAGTVLLNSLLDTVPVRSSVDELVGIDYSLMKDPVASTSNLDMDFRGAFFPLTERNWSLPN-RAVEPQ 
[BPIFA1]   217 ELVQGNVCPLV--------------------NEVLRGLDITLVHD------IVNMLIHGLQFVIKV-------------- 
consensus  241  vln qiC mv   vs  lq ylqtlpv t id v gidysLv dp  ta  ldv  kG ff  n h   vp    v    
 
 
[BPI]      278 PAAHDRMVYLGLSDYFFNTAGLVYQEAGVLKMTLRDDMIPKESKFRLTTKFFG-----TFLPEVAKKFPNMKIQIHVSAS 
[LBP]      270 PEEHNKMVYFAISDYVFNTASLVYHEEGYLNFSITDDMIPPDSNIRLTTKSFR-----PFVPRLARLYPNMNLELQGSVP 
[CETP]     271 LLGDSRMLYFWFSERVFHSLAKVAFQDGRLMLSLMGD------EFKAVLETWGFNTNQEIFQEVVGGFPS-QAQVTVHCL 
[PLTP]     257 LQEEERMVYVAFSEFFFDSAMESYFRAGALQLLLVGDKVPHDLDMLLRATYFG-----SIVLLSPAVIDS-PLKLELRVL 
[BPIFA1]       -------------------------------------------------------------------------------- 
consensus  321      rmvy g sdy f ta  vy   g l mtl  d ip e   rl    fg       l  v   fp   i i v    
 
 
[BPI]      353 TPPHLSVQPTGLTFYPAVDVQAFAVLPNSSLASLFLIGMHTTGSMEVSAESNRLVGELKLDRLLLELKH-SNIGPFPVEL 
[LBP]      345 SAPLLNFSPGNLSVDPYMEIDAFVLLPSSSKEPVFRLSVATNVSATLTFNTSKITGFLKPGKVKVELKE-SKVGLFNAEL 
[CETP]     344 KMPKISCQNKGVVVNSSVMVKFLFPRPDQQHSVAYTFEEDIVTTVQASYSKKKL--FLSLLDFQITPKTVSNLTESSSES 
[PLTP]     331 APPRCTIKPSGTTISVTASVTIALVPPDQPEVQLSSMTMDARLSAKMALRGKALRTQLDLRRFRIYSNH-SALESLALIP 
[BPIFA1]       -------------------------------------------------------------------------------- 
consensus  401   phls  p gltv   v v    v p      lf i m    s  vs    rl   l l r  l  k  s i     e  
 
 
[BPI]      432 LQDIMNYIVPILVLPRVNEKLQKGF-PLPTPARVQLYNVV---LQPHQNFLLFGADVVYK-------------------- 
[LBP]      424 LEALLNYYILNTFYPKFNDKLAEGF-PLPLLKRVQLYDLG---LQIHKDFLFLGANVQYMRV------------------ 
[CETP]     422 IQSFLQSMITAVGIPEVMSRLEVVFTALMNSKGVSLFDIINPEIITRDGFLLLQMDFGFPEHLLVDFLQSLS-------- 
[PLTP]     410 LQAPLKTMLQIGVMPMLNERTWRGV-QIPLPEGINFVHEV---VTNHAGFLTIGADLHFAKG-LREVIEKNRPADVRAST 
[BPIFA1]       -------------------------------------------------------------------------------- 
consensus  481 lq  ln iv    lp vnekl  gf  lp    vqly vv   l  h  fl lgadv y                      
 
 
[BPI]          --------- 
[LBP]          --------- 
[CETP]         --------- 
[PLTP]     485 APTPSTAAV 
[BPIFA1]       --------- 
consensus  561           
 
 
 
Figure 3.2: Amino acid sequence similarity of human BPIFA1 with B I, LBP, CETP, and 
PLTP proteins. 
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Superposition of hBPIFA1 (green) and BPI (red) proteins. Amino acids 87 94, and 256 of hBPIFA1 are labelled for clarity, as are α helices 1, 2, 5 and 6. Helix 
α4 of hBPIFA1 is missing, but its predicted position is at residues 76-105. Disulphide bond of hBPIFA1 is shown in blue (residues: C180-C224), whereas 
disulphide bond of BPI is presented in yellow (residues: C135-C175). PyMOL Molecular Graphics System (version 2.0.6) and Phyre2 (version 2.0) were used 
for analysis. Similar superposition of human BPIFA1 and BPI proteins was published by Garland et al. (Garland et al., 2013), however the position of 
disulphide bond was not demonstrated. 
 
 
 
 
 
Disulphide bond 
Figure 3.3: Disulphide bond of human BPIFA1 and BPI proteins is at the same position within the structure. 
 84 | P a g e  
 
3.3.1.2 Analysis of human BPIFA1 protein sequence 
 
hBPIFA1 can be classified as alpha-beta protein as it contains:  α-helices > 30% and β-
strands > 20%. Data of predicted solvent accessibility composition of hBPIFA1 showed 
that 55% residues of hBPIFA1 are exposed with more than 16% of their surface. 
Additionally, residue composition of hBPIFA1 was analysed and showed that the most 
common amino acids in the protein sequence are leucine (22.7%) and glycine (12.9%). 
hBPIFA1 can, therefore, be described as leucine-glycine rich protein. To understand 
which regions of protein may be involved in the binding processes, the sequence was 
analysed through Predict Protein Open software to predict protein-protein and protein-
polynucleotide binding sites were. Five sites were identified, and these included: M1-Q3, 
Q30, L42, Q170-R172, and S183 (Figure 3.4).  
hBPIFA1 protein sequence, showing predicted binding sites of hBPIFA1 indicated with letter ‘P’ 
underneath the sequence. Analysis was performed using Predict Protein Open software 
(https://ppopen.informatik.tu-muenchen.de/). 
 
To obtain more detailed information about hBPIFA1, I analysed hBPIFA1 protein 
sequence for conserved sites and domains using ExPASy Prosite, EBI IterPro, and Motif 
Scan. These conserved domains and sites are represented in the Table 3.1. Analysis 
predicted that hBPIFA1 contains a Casein kinase II phosphorylation site and a N-
myristoylation site. Randomised probability value for these sites was lower than 1, 
suggesting the probability of significant match.  Leucine-rich region was also detected in 
the sequence of hBPIFA1, with the randomised probability value lower than 1. Analysis 
also revealed the presence of two conserved domains in the hBPIFA1 protein sequence: 
Figure 3.4: Predicted protein-protein and protein-polynucleotide binding sites for hBPIFA1. 
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1) lipid-binding serum glycoprotein, N-terminal domain, and 2) bactericidal permeability-
increasing protein, alpha/beta superfamily domain. These two conserved domains are 
the signature domains of the BPI/LBP protein superfamily (EMBL-EBI, 2019b, EMBL-
EBI, 2019a). 
Table 3.1: Conserved domains and sites of human BPIFA1. 
Name 
Pattern (if 
available) 
Access 
number 
Randomised 
probability E-
value (if 
available)  
Region 
Casein kinase II 
phosphorylation site 
[ST]-x(2)-[DE] PS00006 1.482e-02 190 to 193 (SLLD) 
N-myristoylation site 
G-
{EDRKHPFYW}-
x(2)-[STAGCN]-
{P} 
PS00008 1.397e-02 
46 to 51 (GLAGSL) 
49 to 54 (GSLTNA) 
58 to 63 (GLLSGG) 
62 to 67 (GGLLGI) 
66 to 71 (GILENL) 
80 to 85 (GGGTSG) 
82 to 87 (GTSGGL) 
85 to 90 (GGLLGG) 
86 to 91 (GLLGGL) 
89 to 94 (GGLLGK) 
202 to 207 (GLLDSL) 
233 to 238 (GLDITL) 
Leucine-rich region 
profile/ matrix 
 PS50319  58 to 234 aa 
Lipid-binding serum 
glycoprotein, N-
terminal domain 
 IPR017942  58 to 233 aa 
Bactericidal 
permeability-
increasing protein, 
alpha/beta domain 
superfamily 
 IPR017943  102-245aa 
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3.3.1.3 Bioinformatic analysis of mouse BPIFA1 protein sequence 
 
In this study, I also used a bioinformatic approach to analyse mBPIFA1 protein sequence 
and determine differences between mBPIFA1 and hBPIFA1. mBPIFA1 protein sequence 
was analysed through Predict Protein Open software. Results showed that mBPIFA1 can 
also be classified as an alpha-beta protein as it contains:  α-helices > 30% and β-strands 
> 20%. In addition, data of predicted solvent accessibility composition of mBPIFA1 
showed that 58% of mBPIFA1 residues are exposed with more than 16% of their 
surface. Residues C204 and C246 were defined to form a disulphide bond which is 
expected to be important for structure stability. The residue composition of mBPIFA1 
was determined using Predict Protein open software. Data showed that leucine accounts 
for the highest percentage of amino acids present within the protein sequence (23.7%) 
and glycine (12.2%) is the second most common amino acid present in the sequence. 
These data showed that mBPIFA1 same as hBPIFA1 is a leucine-glycine rich protein. To 
understand which regions of mBPIFA1 may be involved in the binding process, the 
protein sequence was analysed through Predict Protein Open software to predict protein-
protein and protein-polynucleotide binding sites. Four sites were identified, and these 
included: M1, Q46, G195, and P208 (Figure 3.5). This analysis suggests that binding 
sites of mBPIFA1 differ from the binding sites of hBPIFA1 (Figure 3.4). 
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mBPIFA1 protein sequence, showing predicted binding sites of mBPIFA1 indicated with letter ‘P’ 
underneath the sequence. Analysis was done using Predict Protein Open software 
(https://ppopen.informatik.tu-muenchen.de/). 
 
 
I also analysed the protein for conserved sites and domains using EBI InterPro and Motif 
Scan. These conserved domains and sites are listed in the Table 3.2. mBPIFA1, like 
hBPIFA1, contains Casein kinase II phosphorylation and N-myristoylation sites. In 
addition, mBPIFA1 contains N-glycosylation and Protein kinase C phosphorylation sites, 
which are not detected in hBPIFA1. Leucine-rich region was also detected in the 
mBPIFA1 protein sequence. Analysis also revealed the presence of proline-rich region in 
mBPIFA1, but the value of randomised probability was not significant (E-value > 1). The 
signature domains of BPI/LBP protein superfamily were detected in mBPIFA1.   
Figure 3.5: Predicted protein-protein and protein-polynucleotide binding sites for 
mBPIFA1. 
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Table 3.2: Conserved domains and sites of mouse BPIFA1. 
Name 
Pattern (if 
available) 
Access 
number 
Randomised 
probability E-
value (if 
available) 
Region 
Casein kinase II 
phosphorylation site 
[ST]-x(2)-[DE] PS00006  
224-227 (SFLD) 
254-257 (SGLD) 
N-myristoylation site 
G-
{EDRKHPFYW}-
x(2)-[STAGCN]-
{P} 
PS00008  
55-60 (GLPLAV) 
82-87 (GGLLSG) 
91-96 (GILENI) 
105-110 (GGGNSN) 
111-116 (GLVGGL) 
161-166 (GLTLNV) 
251-256 (GILSGL) 
N-glycosylation site N-{P}-[ST]-{P} PS00001  
182-185 (NITA) 
228-231 (NLTG) 
Protein kinase C 
phosphorylation site 
[ST]-x-[RK] PS00005  210-212 (SLK) 
Leucine-rich region 
profile/ matrix 
 PS50319 0.0036 3-181 aa 
Proline-rich region 
profile/ matrix 
 PS50099 3.1 25-68 aa 
Lipid-binding serum 
glycoprotein, N-
terminal domain 
 IPR017942  83-256 aa 
Bactericidal 
permeability-
increasing protein, 
alpha/beta domain 
superfamily 
 IPR017943  126-276 aa 
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3.3.1.4 Multiple sequences alignment of BPIFA1  
 
Multiple sequences alignment confirmed that the extreme N-terminal region of BPIFA1 
exhibits the highest variability among the species (Figure 3.6). The N-terminal region of 
mBPIFA1 contains a PLPL repeat which seems to be rodent specific as PLPL repeat 
region is also observed in BPIFA1 protein sequences of wood mouse and rat. This PLPL 
repeat is structured in rodent BPIFA1 but is missing from the sequence of hBPIFA1 and 
is not present in the crystal structure of hBPIFA1, suggesting that it is unstructured 
(Bingle and Craven, 2002, Garland et al., 2013). In addition, mBPIFA1 contains three N-
glycosylation sites, which are absent from hBPIFA1. Results suggest that the 
glycosylation status of the protein varies between species. However, the cysteine 
residues forming the disulphide bond of BPIFA1 are highly conserved among all species 
(Figure 3.6). 
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PLPL repeat region of mBPIFA1 is highlighted with green line underneath. N-glycosylation sites 
are highlighted in red rectangles. Conserved cysteine residues are highlighted with orange line 
underneath. Multiple sequences alignment was produced using Kalign and BoxShade version 3.2, 
written by K. Hofmann and M. Baron. Capital letters mean that same amino acid appears in each 
sequence and lower-case letters mean that structurally similar amino acid is present in each 
sequence. 
 
 
Figure 3.6: The N-terminal sequence of BPIFA1 exhibits the highest variability among the 
species. 
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3.3.2 Full-length human BPIFA1 (FL-hBPIFA1) and pcDNA3.1 vector 
system 
 
3.3.2.1 Establishment of a stable NCI-H292 cell line expressing GFP-tagged 
hBPIFA1 
 
A human pulmonary mucoepidermoid carcinoma cell line NCI-H292 was transfected with 
pcDNA3.1 plasmid containing FL-hBPIFA1 cDNA (Figure 3.7 A-B) to obtain secreted 
BPIFA1-GFP fusion protein for functional analysis. NCI-H292 cells were chosen for 
these experiments due to their reported ability to express BPIFA1 (Chu et al., 2010) and 
previous successful usage in tranfection assays with plasmids containg BPIFA1 cDNA 
(Chu et al., 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure shows a schematic diagram of FL-hBPIFA1 tagged with GFP (A) and plasmid map of 
hBPIFA1-GFP fusion construct (B). Plasmid map was generated using a plasmid editor program 
ApE (Version 8.5.2.0). 
A. 
Human BPIFA1 (256aa) GFP tag 
B. 
Figure 3.7: Generation of full-length hBPIFA1-GFP fusion construct. 
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Transfection of NCI-H292 cells was performed using FuGENE® HD and G418 selection 
was used to isolate positively transfected cells. However, G418 selection did not work 
efficiently and consequently, a serial dilutions method was used to isolate BPIFA1-
positive single cell colonies. These single cell colonies were expanded, and some were 
seeded onto 8-well glass chamber slides for visualisation under a fluorescent 
microscope to determine the isolation efficiency of positive transfectants. This showed 
that only a small number of cells were FL-hBPIFA1-GFP positive (Figure 3.8 A), 
suggesting that the process had not achieved clonal selection of high expressing cells. 
However, I was able to detect FL-BPIFA1-GFP production by transfected cells (Figure 
3.8 B). A band of approximately 52kDa size was detected with anti-human BPIFA1 
antibody and it represented FL-hBPIFA1 tagged with GFP (BPIFA1: 25 kDa, and GFP 
tag: 26.9 kDa). The amount of protein produced was small and appeared to be 
insufficient for future assays. Therefore, I decided to remove BPIFA1 negative cells from 
the stable cell line to increase BPIFA1 production.  
 
 
 
 
 
 
 
 
 
 
 
Images taken of NCI-H292 cells indicated an unsuccessful establishment of stable cell line using 
G418 selection and isolation of single cell colonies. Negative cells are blue (nuclei counterstained 
with DAPI), whereas BPIFA1 positive cells are green (GFP fluorescence). Images were taken at 
20x and 60x magnification using Olympus epifluorescence microscope (scale bar: 20x 
magnification - 100µm; 60x magnification - 20µm). Images were processed using ImageJ-win32 
program (A). Results of western blotting showed the production of FL-hBPIFA1-GFP (indicated by 
red arrow (~52kDa): 25 kDa BPIFA1 and 26.9kDa GFP tag) by transfected NCI-H292 cells. 
Production of protein was detected using anti-human BPIFA1 antibody (B). 
Figure 3.8: NCI-H292 cells transfected with FL-hBPIFA1/pcDNA3.1 construct. 
60x 
60x 
20x 
20x 
DAPI/BPIFA1 DAPI/BPIFA1 
DAPI/BPIFA1 DAPI/BPIFA1 
52kDa 
Transfected cells  ◼ 
Control cells            ◼ 
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3.3.2.2 Cell sorting of FL-hBPIFA1-GFP positive cells  
 
As isolation of positively transfected clones using G418 selection and serial dilutions 
methods was not efficient, I used cell sorting to enrich for hBPIFA1-GFP positive cells. A 
population of transfected cells was sorted into BPIFA1 positive and negative cells (Figure 
3.9 A). Highly fluorescent cells were selected as BPIFA1 positive cells, accounting for 
approximately 20% of the cells from the cell population (6x106 cells were taken for 
sorting). BPIFA1-GFP positive and negative cells were seeded into different T75 flasks 
and grown until almost confluent. Isolation efficiency of BPIFA1-GFP positive cells was 
determined by fluorescence microscopy and data showed a highly efficient isolation of 
positive cells (Figure 3.9 B-C). Subsequently, the conditioned medium (serum containing 
and serum-free) samples from BPIFA1-GFP positive and negative cells were collected 
for protein secretion analysis. The western blotting membrane was probed with anti-
human BPIFA1 antibody. The results demonstrated that a small quantity of protein was 
secreted by positive cells incubated in serum supplemented medium whereas no 
secretion of protein was observed by cells incubated in the serum-free conditions. 
BPIFA1-GFP was not detected in the conditioned medium samples collected from 
negative cells (Figure 3.9 D). On the basis of the above results, I concluded that 
pcDNA3.1-BPIFA1 construct was not useful for my work as using it I could not generate 
large amounts of secreted BPIFA1-GFP. Thus, I decided to change pcDNA3.1 vector 
system into of Flp-InTM System which is suggested to be highly effective in the generation 
of stable cell lines, constitutively expressing recombinant proteins (Invitrogen, 2010). 
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A FL-hBPIFA1-GFP mixed cell population was sorted into BPIFA1-GFP positive and negative 
cells. Cells in the first field are blue and they represent negative cells. Cells in the second field are 
green and they are BPIFA1 positive cells. Black colour cells are debris, while red colour cells 
represent cell population which did not show high level of fluorescence. Approximately 1% of the 
negative control cells were auto-fluorescent (A). BPIFA1-GFP positive cells (B: negative cells; C: 
BPIFA1-GFP positive cells). Images were taken at 20x magnification (scale bar: 100µm) using 
fluorescence microscope (Axioplan 2 Imaging, Zeiss). Images were processed using ImageJ-
win32 program (B-C). Secretion of FL-BPIFA1-GFP (~52 kDa size band (25kDa BPIFA1 and 
26.9kDa GFP tag) – boxed in red) by positive cells incubated overnight in serum containing 
medium. Second band (~25kDa) circled in the red represents a positive control for BPIFA1. Other 
bands on the blot are a result of non-specific binding. Protein of interest was detected using anti-
human BPIFA1 antibody (D). 
 
 
 
 
 
 
 
Figure 3.9: BPIFA1 expression and secretion by positively selected NCI-H292 cells. 
B
. 
C
. 
D
. 
A. 
Negative control NCI-H292 transfected cells 
DAPI/BPIFA1 DAPI/BPIFA1 
DAPI/BPIFA1 DAPI/BPIFA1 
 95 | P a g e  
 
3.3.3 Human BPIFA1 and pcDNA5/FRT vector system 
 
3.3.3.1 Generation of hBPIFA1 constructs into pcDNA5/FRT vector system 
 
On the basis of the above data, I chose pcDNA5/FRT plasmid instead of pcDNA3.1, 
because it is highly effective in generation of stable cell lines expressing gene of interest. 
In this system a pcDNA5/FRT construct is integrated in the genome of a Flp-InTM System 
host cell line via an FRT site (Invitrogen, 2010). Consequently, usage of Flp-InTM System 
should provide effective and time efficient way for generation of stable cell lines. To 
generate GFP-tagged hBPIFA1-pcDNA5/FRT constructs, I subcloned full length (length: 
256aa), F/R1 (length: 39aa), and F/R2 (length: 58aa) hBPIFA1-pcDNA3.1 constructs into 
pcDNA5/FRT vector system. All BPIFA1 constructs contain N-terminal region. F/R1 
construct was designed to analyse the functional importance of the S18 region (G22-
A39), whereas F/R2 construct was designed to study the importance of the leucine-
glycine rich region. A schematic representation of the BPIFA1 constructs is shown in 
Figure 3.10 A-C.  
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Figure shows a schematic diagram of series of different sizes hBPIFA1-GFP constructs (A). 
Protein sequences of hBPIFA1-GFP constructs (FL: 256aa; F/R1: 39aa; and F/R2: 58aa) are also 
shown in the FASTA format (B). Plasmid map of GFP-tagged hBPIFA1-GFP-pcDNA5/FRT 
construct is also represented (C). Plasmid map was generated using a plasmid editor program 
ApE (Version 8.5.2.0). 
 
 
To prepare hBPIFA1 constructs for cloning into pcDNA5/FRT system, E. coli cells were 
transformed with DNA of BPIFA1-pcDNA3.1 constructs and miniprepped. Minipreps 
were digested with HindIII and BamHI to verify the quality of DNA products. Restriction 
 hBPIFA1 (256aa) GFP tag 
hBPIFA1 (58aa) GFP tag 
hBPIFA1 (39aa) GFP tag 
>Human 39aa BPIFA1 
MFQTGGLIVFYGLLAQTMAQFGGLPVPLDQTLPLNVNPA 
 
>Human 58aa BPIFA1 
MFQTGGLIVFYGLLAQTMAQFGGLPVPLDQTLPLNVNPALPLSPTGLAGSLTNALS
NG 
 
>Human 256aa BPIFA1 
MFQTGGLIVFYGLLAQTMAQFGGLPVPLDQTLPLNVNPALPLSPTGLAGSLTNALS
NGLLSGGLLGILENLPLLDILKPGGGTSGGLLGGLLGKVTSVIPGLNNIIDIKVTD
PQLLELGLVQSPDGHRLYVTIPLGIKLQVNTPLVGASLLRLAVKLDITAEILAVRD
KQERIHLVLGDCTHSPGSLQISLLDGLGPLPIQGLLDSLTGILNKVLPELVQGNVC
PLVNEVLRGLDITLVHDIVNMLIHGLQFVIKV 
A. 
B. 
Figure 3.10: Generation of GFP-tagged hBPIFA1-pcDNA5/FRT constructs. 
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digest products were visualised on an agarose gel. Digestion of FL-BPIFA1 was 
expected to produce three fragments when cut with HindIII (207bp, 795bp and ~6kb) and 
BamHI (557bp, 826bp, and ~6kb), whereas the restriction digest of F/R1-BPIFA1 was 
expected to produce two fragments (HindIII: 355bp and ~6kb; BamHI: 736bp and ~6kb). 
Digestion of F/R2-BPIFA1 with HindIII and BamHI was also expected to produce two 
fragments (HindIII: 207bp and ~6kb; BamHI: 776bp and ~6kb). All fragments of the 
correct sizes were detected (Figure 3.11).   
 
Restriction digests of all hBPIFA1-GFP-TOPO constructs suggested that human BPIFA1 was 
inserted in the forward orientation for the gene to be transcribed and translated into the protein as 
the fragments of expected sizes were observed.  
 
 
 
Subsequently, all constructs were sent for Sanger sequencing to verify the orientation of 
the insert and scan for any possible mutations. The FL-hBPIFA1 construct was 
sequenced from forward and reverse direction (to ensure that all required sequence was 
read through), whereas the smaller hBPIFA1 constructs (F/R1 and F/R2) were 
sequenced only from forward direction. Results showed no mutations in hBPIFA1-GFP 
sequences and that all sequences read through into the GFP tag (Appendix II: S1-S3). 
 
3.3.3.2 Cloning hBPIFA1-GFP constructs into pcDNA5/FRT  
 
To prepare DNA of BPIFA1 constructs for cloning, the coding region of FL-, F/R1-, and 
F/R2-BPIFA1-GFP constructs was amplified using primers flanking the CT-GFP-TOPO 
Figure 3.11: Restriction digests of GFP-tagged hBPIFA1/pcDNA3.1 constructs. 
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cloning site. This showed successful amplification of hBPIFA1-GFP constructs as 
fragments of approx. 1.5 kb and 1 kb sizes were observed (Figure 3.12). 
 
 
 
 
 
 
 
Fragment of approx. 1.5kb size represents FL-BPIFA1 construct, whereas fragments of approx. 
1kb size represents F/R1- and F/R2-BPIFA1 constructs. 
 
 
Subsequently, PCR products were cloned into pcDNA5/FRT vector system to generate 
FL-, F/R1-, and F/R2-BPIFA1-GFP expression plasmids. Minipreps were digested with 
NcoI to verify the orientation of the insert. Restriction digests were expected to produce 
four fragments as following (if inserts were the correct way round):  
FL-BPIFA1 – 4740bp, 1608bp, 938bp, and 416bp;  
F/R1-BPIFA1 – 3740bp, 1608bp, 416bp, and 290bp;  
F/R2-BPIFA1 – 3740bp, 1608bp, 416bp, and 347bp. 
Fragments of the expected sizes were detected (Figure 3.13 A-B), suggesting the 
insertion of gene in the forward orientation in some minipreps and allowing it to be 
transcribed and translated into the protein. 
  
Figure 3.12: Amplification of the coding region of hBPIFA1-GFP constructs with PCR. 
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Results of GFP-tagged FL- (A), F/R1- (B), and F/R2-hBPIFA1-pcDNA5/FRT (B) restriction 
digestion. Fragments of correct sizes are highlighted in red rectangles.  
 
 
All constructs were sent for sequencing to validate the orientation of insert and to scan 
for any possible mutations. Results showed no mutations in hBPIFA1-GFP sequences 
and all sequences read through into the GFP tag (Appendix: S4-S6). 
 
3.3.3.3 Transfected Flp-In-CHO cells did not secrete hBPIFA1-GFP proteins 
 
For transfection assays, I used Flp-In-CHO cell line which contains an integrated FRT 
site for establishing gene expression from a Flp-InTM System expression vector. I 
produced maxipreps of all hBPIFA1-pcDNA5/FRT constructs and used them in co-
transfections of CHO cells with pOG44 expression plasmid (Appendix II: S7). Co-
transfections were performed using Lipofectamine® and the following day medium 
containing hygromycin B was added to the cells to select positive transfectants. After 
establishment of stable cell lines, cell samples were analysed using fluorescence 
microscopy and data showed that selection of positive cells with hygromycin B was not 
successful as only a small number of BPIFA1-GFP positive cells were observed. It 
Figure 3.13: Restriction digests of GFP tagged hBPIFA1-pcDNA5/FRT constructs. 
A. 
B. 
 100 | P a g e  
 
meant that stable cell lines consisted of BPIFA1 positive and negative cells, and cells 
that expressed low levels of the GFP fusion protein (Figure 3.14). 
 
 
Images showed unsuccessful establishment of stable cell-lines expressing BPIFA1 as only a 
small number of BPIFA1-GFP positive cells were observed. Scale bar: 100µm. 
 
Since I could observe some GFP positive cells in the stable cell lines, I decided to find 
out whether integration of BPIFA1-pcDNA5/FRT DNA into the genome of the CHO cells 
had occurred and whether proteins were produced and secreted by the cells. Genomic 
DNA was amplified using PCR and the results showed that transfection of CHO cells 
was successful as genomic DNA of hBPIFA1-GFP constructs was detected (Figure 
3.15). 
 
  
Figure 3.14: CHO cells transfected with GFP-tagged hBPIFA1-pcDNA5/FRT constructs after 
selection with hygromycin B. 
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PCR results, showing a successful integration of GFP-tagged hBPIFA1-plasmid DNA into the 
genome of CHO cells. Plasmid DNA of all hBPIFA1 constructs was used as positive control. 
Negative control was used to verify quality of PCR reaction regarding any possible contamination. 
 
 
 
Western blotting probed with anti-GFP tag antibody for detection of BPIFA1 proteins 
appeared to show that BPIFA1-GFP recombinant proteins were produced by CHO cells 
in small amounts but none of the proteins were secreted into the media (Figure 3.16 A-
D). Full-length and F/R2-BPIFA1-GFP proteins were produced in smaller quantities 
compared to the production of F/R1-BPIFA1-GFP (8x105 cells were used for analysis).  
 
  
Figure 3.15: Genomic DNA analysis of CHO cells transfected with GFP-tagged hBPIFA1-
pcDNA5/FRT constructs. 
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Western blotting results, showing FL-hBPIFA1-GFP (~52kDa size: FL-BPIFA1 25kDa and GFP 
tag 26.9kDa) (A) and F/R2-hBPIFA1-GFP (~34kDa size: F/R2-hBPIFA1 ~7kDa and GFP tag 
26.9kDa) (B) production in smaller quantities compared to the production of F/R1-BPIFA1-GFP 
(~31kDa size: F/R1-hBPIFA1 ~4kDa and GFP tag 26.9kDa) (A). Secretion of hBPIFA1 proteins 
was not observed (C-D). Positive control (GFP tag positive sample: 26.9 kDa) was used for 
western blot quality verification. Western blots were probed with anti-GFP tag antibody. 
Production of proteins is highlighted in red boxes. Other bands on the blots are a result of non-
specific binding. Data is representative of results from two independent transfection experiments 
(n=2).  
 
This data suggested that this method was for some reason not suitable for my uses as 
stable cell lines did not secret hBPIFA1-GFP proteins. Therefore, I decided to use a 
different vector system and I chose the mammalian expression VR1255 plasmid for my 
future experiments. I also speculated that GFP tag may have caused a negative effect 
on BPIFA1 production and secretion, consequently I decided to change it into smaller tag 
(FLAG tag) to eliminate possibilities of protein misfolding and degradation. 
 
 
  
Figure 3.16: Analysis of FL-, F/R1, and F/R2-BPIFA1-GFP production and secretion. 
Cell lysates Cell lysates 
Conditioned media Conditioned media 
52kDa 
31kDa 34kDa 
A. B. 
C. D. 
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3.3.4 BPIFA1 and VR1255 vector system 
 
3.3.4.1 Production of VR1255 DNA for the cloning reactions 
 
The mammalian expression vector VR1255 (Figure 3.17), was previously used for the 
production and secretion of recombinant proteins (Jayawardane et al., 2008). VR1255 
was originally developed as a DNA vaccine delivery vector (Hartikka et al., 1996). 
However, it is widely used for in vitro experiments aiming to generate large quantities of 
recombinant proteins (Hartikka et al., 1996, Norman et al., 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VR1255 DNA was transformed into E. coli and maxipreparation was carried out. The 
plasmid was digested with NotI and BamHI to generate a linear DNA for the cloning 
reactions. The expected 1652bp and 4761bp bands were detected (Figure 3.18 A) and 
the linearised VR1255 DNA fragment of 4761bp size was recovered from the gel. The 
quality of DNA was verified using agarose gel electrophoresis (Figure 3.18 B). 
 
 
Figure 3.17: Map of mammalian VR1255 plasmid. 
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VR1255 maxiprep was digested with NotI and BamHI and fragments of correct sizes were 
observed (1652bp and 4761bp) (A). DNA fragment of 4761bp size was recovered from the 
agarose gel and quality of plasmid DNA was tested using agarose gel electrophoresis (B). 
 
 
 
3.3.4.2 Generation of human FLAG-tagged S18 deletion BPIFA1-VR1255  
 
DNA sequence of the FLAG-tagged S18 deletion Bpifa1 construct was synthesised by 
GeneArtTM Gene Synthesis service. S18 deletion BPIFA1 missing amino acids 22-42 of 
BPIFA1 with a C-terminal FLAG tag (Figure 3.19) was used to investigate the importance 
of S18 region for the protein’s bacterial binding properties. 
 
The part of full-length BPIFA1 highlighted in the red indicates a region of protein which was 
deleted to generate S18 deletion BPIFA1. 
 
 
This was transformed into E. coli and the DNA was purified and digested with NotI and 
BglII to enable recovery of the fragment (773bp) from an agarose gel (Figure 3.20 A) The 
quality of recovered BPIFA1 construct DNA was verified by gel electrophoresis (Figure 
3.20 B). 
  
>Human full-length hBPIFA1 
MFQTGGLIVFYGLLAQTMAQFGGLPVPLDQTLPLNVNPALPLSPTGLAGSLTNALSNGLLSG
GLLGILENLPLLDILKPGGGTSGGLLGGLLGKVTSVIPGLNNIIDIKVTDPQLLELGLVQSP
DGHRLYVTIPLGIKLQVNTPLVGASLLRLAVKLDITAEILAVRDKQERIHLVLGDCTHSPGS
LQISLLDGLGPLPIQGLLDSLTGILNKVLPELVQGNVCPLVNEVLRGLDITLVHDIVNMLIH
GLQFVIKV  
A. B. 
Figure 3.19: Human S18 deletion BPIFA1. 
Figure 3.18: Production of VR1255 DNA for the cloning reactions. 
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Miniprep of S18 deletion BPIFA1-pMA-T construct was digested with restriction endonucleases to 
enable a recovery of construct DNA. Fragments of correct sizes were observed (773bp and 
2361bp) (A). DNA of interest (773bp) was recovered from agarose gel and its quality was verified 
(B). 
 
 
 
The recovered DNA of S18 deletion BPIFA1-FLAG was used in the ligation reactions 
with linear VR1255 vector (digested with BamHI and NotI) to generate a S18 deletion 
BPIFA1-VR1255 construct. Following ligation reaction, E. coli cells were transformed and 
miniprepped. The minipreps were verified using EcoRV and KpnI, and BamHI and XbaI 
digestions. Results showed the expected sizes of DNA fragments (EcoRV and KpnI: 
818bp and 4644bp; BamHI and XbaI: 315bp and 5147bp), suggesting that a FLAG-
tagged S18 deletion BPIFA1-VR1255 construct was generated (Figure 3.21). 
 
 
 
 
 
 
 
 
Fragments of interest (BamHI and XbaI: 315bp and 5147bp; EcoRV and KpnI: 818bp and 
4644bp) were observed, meaning that S18 deletion BPIFA1-FLAG DNA was successfully ligated 
with linear VR1255 DNA. 
500b
p 
A. B. 
Figure 3.20: Restriction digestion of FLAG-tagged S18 deletion BPIFA1-pMA-T DNA and 
recovery of S18 deletion BPIFA1-FLAG DNA from agarose gel. 
Figure 3.21: Restriction digestion of FLAG-tagged S18 deletion BPIFA1-VR1255 DNA. 
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The DNA was sent for sequencing to verify the orientation of the insert and scan for any 
possible mutations. No mutations were found and the sequence read-through into the 
FLAG tag. Subsequently, a maxiprep was performed and digested to verify the quality of 
DNA: 1) BamHI; 2) KpnI and BamHI; 3) EcoRV and KpnI. Results confirmed DNA 
fragments of the correct sizes (BamHI: 5462bp; KpnI and BamHI: 349bp and 5113bp; 
EcoRV and KpnI: 818bp and 4644bp) (Figure 3.22). 
 
 
 
 
 
 
 
 
 
Fragments of interest (BamHI: 5462bp; KpnI and BamHI: 349bp and 5113bp; EcoRV and KpnI: 
818bp and 4644bp) were observed meaning that quality of maxiprep sample was good.  
 
 
 
3.3.4.3 Preparation of human FLAG-tagged full-length and cysteine mutant 
BPIFA1-VR1255 constructs for transfection assays 
 
To examine the importance of the disulphide bond for hBPIFA1’s functions, I used a 
cysteine mutant hBPIFA1-FLAG. This mutant BPIFA1 has cysteine 224 residue mutated 
into glycine, meaning that protein does not contain disulphide bond (Figure 3.23). A 
single base pair mutation was used to make this change in which original T nucleotide 
(741) was mutated into G nucleotide.  
 
 
Figure 3.22: Restriction digestion of FLAG-tagged S18 deletion BPIFA1-VR1255 maxiprep. 
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Glycine amino acid is highlighted in the red colour and it represents a location where single 
nucleotide mutation was done, leading to the replacement of cysteine residue by glycine residue. 
 
 
To prepare the FLAG-tagged cysteine mutant and full-length hBPIFA1-VR1255 
constructs for transfection assays, I transformed E. coli cells with DNA of constructs and 
digested them with NotI and BamHI. The results showed fragments of the correct sizes 
(534bp and 5879bp) (Figure 3.24 A). Subsequently, both constructs were maxiprepped 
and these were digested with NotI and BamHI. DNA fragments of the expected sizes 
were detected (Figure 3.24 B). 
Miniprep samples (A) and maxiprep samples (B) of FLAG-tagged full-length and cysteine mutant 
hBPIFA1-VR1255 were digested with NotI and BamHI to verify a quality of product. Restriction 
digests were run on agarose gel and fragments of correct sizes were observed (534bp and 
5879bp).  
 
3.3.4.4 DNA amplification of mouse BPIFA1 and cloning into pCRII-TOPO  
 
I also generated FLAG-tagged mBPIFA1-VR1255 construct. cDNA from WT mTECs was 
used for amplification of mBPIFA1 DNA. The primer pair used in PCR contained BamHI 
and NotI restriction sites for ligation into VR1255 (digested with BamHI and NotI). The 
reverse primer also encoded a FLAG tag to enable generation of a FLAG-tagged 
Figure 3.24: Restriction digestion of FLAG-tagged full-length and cysteine mutant 
hBPIFA1-VR1255 construct DNA. 
>Human cysteine mutant BPIFA1 
MFQTGGLIVFYGLLAQTMAQFGGLPVPLDQTLPLNVNPALPLSPTGLAGSLTNALSNGLLSG
GLLGILENLPLLDILKPGGGTSGGLLGGLLGKVTSVIPGLNNIIDIKVTDPQLLELGLVQSP
DGHRLYVTIPLGIKLQVNTPLVGASLLRLAVKLDITAEILAVRDKQERIHLVLGDCTHSPGS
LQISLLDGLGPLPIQGLLDSLTGILNKVLPELVQGNVGPLVNEVLRGLDITLVHDIVNMLIH
GLQFVIKV 
Figure 3.23: Human cysteine mutant BPIFA1. 
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mBPIFA1 construct. After PCR amplification, the DNA fragment was visualised (Figure 
3.25 A) and cloned into pCRII-TOPO. DNA was miniprepped and digested with BamHI 
and NotI. Five (of six) contained DNA fragments of the correct size (41, 46, 878, and 
3897bp). Fragments of 41 and 46bp were impossible to observe, therefore, cloning was 
verified by detecting fragments of 878bp and 3897bp sizes (Figure 3.25 B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mouse BPIFA1 DNA was amplified (A) and cloned into pCRII-TOPO. Five (1-5) clones contained 
DNA fragments of correct sizes (878 and 3897bp), following digestion with BamHI and NotI (B). 
 
 
 
3.3.4.5 Ligation of mBPIFA1-FLAG with VR1255  
 
DNA fragments of mBPIFA1-FLAG (878bp) (samples 1-5; Figure 3.25) were extracted 
and verified using gel electrophoresis (Figure 3.26). DNA of linear VR1255 vector 
(digested with BamHI and NotI) was run on the same gel (Figure 3.26). This enabled 
determination of VR1255 and mBPIFA1 DNA concentrations which were important to 
define for the ligation reactions. 
Figure 3.25: Amplification and cloning of mouse BPIFA1 into pCRII-TOPO. 
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Results show double cut vector DNA (BamHI and NotI digested) and mBPIFA1-FLAG DNA 
samples.  Samples 1 and 2 were used for ligation reactions. 
 
Ligation reactions of mBPIFA1-FLAG DNA with VR1255 vector were performed at ratios 
of 1:1, 1:3, and 3:1. Subsequently, DNA was extracted and digested with EcoRV and 
KpnI or HindIII to verify successful cloning. Detection of the correct size DNA fragments 
(HindIII: 2153 and 3438bp; EcoRV and KpnI: 947 and 4644bp) confirmed that mBPIFA1-
FLAG was present in four samples (Figure 3.27).  
 
 
Mouse BPIFA1-FLAG DNA was present in four samples of extracted plasmid DNA (highlighted in 
red rectangles), whereas other five samples of extracted plasmid did not contain DNA of interest. 
Abbreviations: V – vector, I – insert. 
 
 
 
Figure 3.26: Extracted DNA of mouse BPIFA1-FLAG and double cut VR1255 vector. 
Figure 3.27: Verification of mouse BPIFA1-FLAG in VR1255. 
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3.3.4.6 Preparation of FLAG-tagged mBPIFA1-VR1255 for transfection 
assays 
 
DNA samples were sequenced to validate the orientation of insert and scan for any 
possible mutations. Subsequently, a validated construct was maxiprepped to produce 
DNA for use in transfection assays. 
 
3.3.4.7 Production and secretion BPIFA1-FLAG recombinant proteins  
 
Transient transfections of HEK293T cells were performed with DNA of FLAG-tagged 
human and mouse BPIFA1-VR1255 constructs to generate recombinant proteins. 
Initially, I undertook a small-scale transfection (24-well plate) of HEK293T cells with DNA 
of all human FLAG-tagged BPIFA1-VR1255 constructs to determine which proteins 
would be produced and secreted. Cell lysates and conditioned media were collected and 
examined by SDS-PAGE analysis. Blots were probed with anti-FLAG tag antibody for 
detection of proteins. All BPIFA1-FLAG recombinant proteins were produced and 
secreted into the serum supplemented media (Figure 3.28 A-B). 
 
 
Production of all BPIFA1-FLAG recombinant proteins by transfected HEK293T cells was detected 
(A) as was a secretion of proteins into the serum supplemented media (B). Full-length and 
cysteine mutant BPIFA1 proteins: approximately 25.9kDa; S18 deletion BPIFA1: approximately 
23.7kDa. Cells transfected with pEGFP-N1 vector only were used as transfection efficiency 
control. Western blots were probed with anti-FLAG tag antibody. 
  
Figure 3.28: Small-scale transfection of HEK293T cells with human FLAG-tagged BPIFA1-
VR1255 constructs. 
Cell lysates Conditioned media 
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Next, large-scale transfections of HEK293T cells were performed to generate large 
quantities of secreted BPIFA1 proteins. Cell lysate and conditioned media samples were 
collected and analysed by SDS-PAGE as before. Again, all BPIFA1-FLAG recombinant 
proteins were produced and secreted (Figure 3.29 A-D). However, the secretion of 
proteins was lower in serum-free cell culture conditions compared to serum 
supplemented cell culture conditions. The levels of proteins were also variable in 
samples collected on different days. 
 
Production and secretion of human S18 deletion (A), cysteine mutant (B), and full-length (C) 
BPIFA1-FLAG recombinant proteins by transfected HEK293T cells were detected as were the 
production and secretion of mouse BPIFA1-FLAG recombinant protein (D). Full-length and 
cysteine mutant BPIFA1-FLAG: ~25.9kDa; S18 deletion BPIFA1-FLAG: ~23.7kDa; and mouse 
BPIFA1-FLAG: ~29.5kDa. Abbreviations: CM – conditioned medium, and SF – serum free. 
Western blots were probed with anti-FLAG tag antibody.  
Figure 3.29: Large-scale transfections of HEK293T cells with FLAG-tagged human and 
mouse BPIFA1-VR1255 constructs. 
S18 deletion hBPIFA1-FLAG (23.7kDa) Cysteine mutant hBPIFA1-FLAG (25.9kDa) 
Full-length hBPIFA1-FLAG (25.9kDa) mBPIFA1-FLAG (29.5kDa) 
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3.3.4.8 Observation of BPIFA1-FLAG proteins in NCI-H292 cells  
 
To visualise human and mouse BPIFA1-FLAG proteins in cells, the NCI-H292 cell line 
was chosen as they grow as a monolayer of cells and enable high quality imaging. NCI-
H292 cells were transfected with DNA and stained for immunofluorescence imaging. 
Anti-FLAG tag primary antibody was used for detection of BPIFA1-FLAG proteins and 
detected with an Alexa Flour 488 secondary antibody, which stained proteins green. 
Data appear to show some difference between full-length BPIFA1 proteins and mutant 
BPIFA1 proteins. Some transfected cells were observed to contain highly fluorescent 
granules and it appeared that cells transfected with mutant hBPIFA1 contained more of 
such cells compared to the cells transfected with full-length BPIFA1 (Figure 3.30 A-D). 
This experiment was performed twice, and similar results were obtained on the both 
occasions (Appendix II: S8).   
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Images were taken at 100x magnification with immunofluorescence microscope (Zeiss Axioplan 
2) (scale bar: 10µm). Nuclei of transfected NCI-H292 cells were stained by DAPI in blue and 
BPIFA1-FLAG proteins of interest (A: mBPIFA1-FLAG; B: FL-hBPIFA1-FLAG; C: cysteine mutant 
hBPIFA1-FLAG; D: S18 deletion hBPIFA1-FLAG) were stained in green using Alexa Flour 488. 
Images were processed using ImageJ-win32 program. Data is representative of results from two 
independent experiments (n=2). 
 
Subsequently, more detailed analysis was performed by analysing 10 imaged fields per 
well of transfected cells. The total number of cells per field were counted as well as the 
number of transfected cells positive and negative for fluorescent granules. This analysis 
Figure 3.30: Detection of human and mouse FLAG-tagged proteins in NCI-H292 cells. 
A. 
B. 
C. 
D. 
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suggested that cells transfected with cysteine mutant hBPIFA1-FLAG and S18 deletion 
hBPIFA1-FLAG contained over 5x more cells with fluorescent granules than cells 
transfected with full-length human and mouse BPIFA1-FLAG (Table 3.3). 
 
 
 
3.3.4.9 Purification of FLAG-tagged BPIFA1 proteins secreted by 
transfected HEK293T cells 
 
I aimed to purify BPIFA1-FLAG proteins from serum-free conditioned media for bacterial 
pull-down assays. Anti-FLAG® M2 affinity gel beads were used for purification of 
BPIFA1-FLAG proteins from serum-free conditioned media. After purification, samples of 
purified proteins, beads, and conditioned media were collected for SDS-PAGE analysis 
and membranes were probed with anti-FLAG tag antibody. All BPIFA1-FLAG proteins 
were isolated, but purification efficiency was low (Figure 3.31 A-D). Full-length human 
and mouse BPIFA1-FLAG proteins were still detected in the conditioned media after 
purification. Additionally, proteins were detected on the beads after elution, suggesting 
that elution of proteins from anti-FLAG® M2 affinity gel beads was not highly effective 
(Figure 3.31 A-D).  
 
 
 
NCI-H292 cells 
transfected with 
BPIFA1 construct 
Average % of cells 
with fluorescent 
granules 
Average % of cells 
without fluorescent 
granules 
Ratio of cells with 
granules vs cells 
without granules 
FL-hBPIFA1-FLAG 7.8% 4.2% 1.9 : 1 
mBPIFA1-FLAG 5.4% 5.9% 0.9 : 1 
Cysteine mutant 
hBPIFA1-FLAG 
13.8% 2% 6.9 : 1 
S18 deletion 
hBPIFA1-FLAG 
19.3% 1% 19.3 : 1 
Table 3.3: Percentages of transfected cells with and without fluorescent granules 
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Mouse (A), human cysteine mutant (B), human S18 deletion (C) and human full-length (D) 
BPIFA1-FLAG recombinant proteins were purified from serum-free conditioned media. All 
membranes were exposed for the appropriate period of time for visualisation (mouse BPIFA1-
FLAG: 3 minutes; human cysteine mutant BPIFA1-FLAG: 20 minutes; human S18 deletion 
BPIFA1-FLAG: 20 minutes; and human full-length BPIFA1-FLAG: 30 seconds). Full-length and 
cysteine mutant BPIFA1-FLAG: ~25.9kDa; S18 deletion BPIFA1-FLAG: ~23.7kDa; and mouse 
BPIFA1-FLAG: ~29.5kDa. Western blots were probed with anti-FLAG tag antibody. Abbreviations: 
B – beads; CM – conditioned medium. Additional fragments observed on SDS-PAGE membranes 
may be associated with non-specific binding of anti-FLAG tag antibody. 
 
 
 
Amounts of purified BPIFA1-FLAG proteins were compared using SDS-PAGE. The 
same volume of each purified protein was used for analysis. Results suggested that 
amounts of human cysteine mutant and S18 deletion BPIFA1-FLAG purified proteins 
Figure 3.31: Purification of BPIFA1-FLAG from the serum-free conditioned medium 
samples. 
S18 deletion hBPIFA1-FLAG (23.7kDa) 
mBPIFA1-FLAG (29.5kDa) 
Full-length hBPIFA1-FLAG (25.9kDa) 
Cysteine mutant hBPIFA1-FLAG (25.9kDa) 
 116 | P a g e  
 
were markedly lower compared to mouse and human full-length BPIFA1-FLAG proteins 
(Figure 3.32).  
 
 
 
 
 
 
 
 
 
Greater quantities of full-length human and mouse BPIFA1-FLAG purified proteins were obtained 
compared to the amounts of human mutant BPIFA1-FLAG purified proteins. Full-length and 
cysteine mutant BPIFA1-FLAG: ~25.9kDa; S18 deletion BPIFA1-FLAG: ~23.7kDa; and mouse 
BPIFA1-FLAG: ~29.5kDa. Western blots were probed with anti-FLAG tag antibody. Additional 
fragments present on SDS-PAGE membrane may represent degradation products of the proteins. 
 
 
 
Therefore, I decided that mouse BPIFA1 purified protein would be used in the bacterial 
pull-down assays, whereas human BPIFA1 purified proteins would not be used due to 
significantly limited amounts available. Interactions of BPIFA1 proteins with bacterial 
pathogens are described in Chapter 4. 
  
Figure 3.32: Amounts of BPIFA1-FLAG purified proteins. 
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3.4 Discussion 
 
3.4.1 Characteristics of human and mouse BPIFA1 proteins 
 
Protein sequences of mouse and human BPIFA1 were analysed using bioinformatic 
approach to acquire information about BPIFA1. Sequence and structure similarity of 
human BPIFA1 protein to BPI/LBP protein superfamily members is important as it 
suggests the role of hBPIFA1 in the host defence.  
My analysis demonstrated that the disulphide bond of hBPIFA1 and BPI is at the same 
position within the protein structures. I also showed that mouse BPIFA1 contains two 
cysteine residues (C204 and C246) which form a disulphide bond. BPIFA1 cysteine 
residues forming a disulphide bond are completely conserved among all species and it 
may be highly important for entire protein structure stability and proper folding. 
Furthermore, the disulphide bond of BPI was reported to be crucial for the secretion of 
biologically active BPI protein (Horwitz et al., 1996). It suggests that disulphide bond may 
also be crucial for the activity of BPIFA1. 
Human and mouse BPIFA1 protein sequences were also analysed in more detail 
searching for conserved domains, sites and residues. Casein kinase II phosphorylation 
site and N-myristoylation site were detected in both human and mouse BPIFA1, whereas 
N-glycosylation and Protein Kinase C phosphorylation sites were detected only within 
mBPIFA1. The presence of Casein kinase II phosphorylation site may suggest that 
BPIFA1 can be phosphorylated and regulated by Casein kinase II which is an active 
serine/threonine protein kinase, having a broad range of physiological targets and 
playing a role in the variety of cellular functions (e.g. cell viability maintenance) 
(Litchfield, 2003). The presence of an N-myristoylation site within BPIFA1 suggests that 
myristate (14-carbon fatty acid) can be attached onto glycine residues of BPIFA1 via N-
myristoyltransferase catalysation and may influence the localisation, structural 
conformation, and biological functions of BPIFA1 (Maurer-Stroh et al., 2002, Wright et 
al., 2010). Prediction of Protein Kinase C phosphorylation site within the mBPIFA1 
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suggests that mBPIFA1 can be phosphorylated by Protein Kinase C which is involved in 
a variety of the signalling pathways, regulating lipid hydrolysis and cellular functions 
(Freeley et al., 2011, Newton, 1995). This suggests that Protein Kinase C may be 
involved in the regulation of mBPIFA1 activity. In addition, N-glycosylation sites within 
mBPIFA1 were predicted, suggesting that mBPIFA1 protein can be N-glycosylated by 
attachment of an oligosaccharide to selected asparagine amino acid in the protein 
sequence. N-linked protein glycosylation may greatly affect the function of mBPIFA1 as it 
is known that N-glycosylation leads to post-translational modifications of protein which 
affect protein folding and biological activity (Aebi, 2013, Medus et al., 2017, Spiro, 2002). 
In contrast, no N-glycosylation sites were detected in hBPIFA1, suggesting a possible 
difference between the biological functions of human and mouse BPIFA1 proteins.  
Bioinformatic analysis confirmed that human and mouse BPIFA1 proteins contain a 
leucine-rich region, which may enable both proteins to interact with a variety of 
substrates and this, in turn, may allow them to function in host defence. It was also 
reported that a single leucine-rich region may have the ability to interact with several 
different substrates, including lipids, nucleic acids, and hormones (Helft et al., 2011, Ng 
and Xavier, 2011). Proteins containing leucine-rich repeats were reported to be involved 
in chemokine- and cytokine-mediated signalling, immunity and host defence. For 
instance, TLR and NOD-like receptors contain leucine-rich repeats which enable them to 
recognise a structurally diverse set of microbial elements (Ng and Xavier, 2011). 
Therefore, the leucine-rich region of BPIFA1 may be associated with a variety of 
important biological functions. Analysis of this region should be of high interest as it may 
provide information about the activity of BPIFA1.  
mBPIFA1 contains a proline-rich region which is not present in hBPIFA1. The region 25-
68aa of mBPIFA1 contains eight PL repeats and thirteen proline residues, whereas 
hBPIFA1 contains only three PL repeats and six proline residues. In addition, the region 
22-42aa of hBPIFA1 is unstructured whereas the same region in mBPIFA1 is structured 
(Garland et al., 2013). Hereby, these two traits of hBPIFA1 make it different from 
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mBPIFA1. Proline repeats were reported to be involved in the molecular conformation of 
proteins and peptides (Morgan and Rubenstein, 2013, Williamson, 1994). Proline is also 
known as a good ligand because of its large flat hydrophobic surface which enables 
binding to other hydrophobic surfaces. In addition, proline-rich regions were reported to 
enable peptides to bind rapidly to other proteins and this ability was suggested to be 
associated with the restricted mobility of proline amino acid (Williamson, 1994). Some 
proline-rich peptides were also reported to have antimicrobial activity (Casteels et al., 
1989, Falla et al., 1996). Therefore, this would suggest that proline-rich repeats may 
influence mBPIFA1 activity and this makes it of high interest to determine their 
importance for the biological activity of mBPIFA1. It is also interesting that some proline 
residues are accompanied by leucine residues in human and mouse BPIFA1 proteins 
and appears as proline-leucine repeats rather than only proline-repeats, suggesting that 
these unique combination of amino acids may be associated with the certain biological 
function or functions of BPIFA1. 
Potential protein-protein and protein-polynucleotide binding sites of mouse and human 
BPIFA1 were also predicted in this study. Prediction of residues involved in the protein 
binding is useful as it can provide the insights about interactions between BPIFA1 and 
other proteins. Understanding of such interactions is important because protein-protein 
interactions play a role in the variety of biological processes (Reichmann et al., 2007). 
For example, one of the predicted residues of hBPIFA1 involved in the binding is Q30. 
This residue is present in the S18 region (amino acids: G22-A39) of hBPIFA1 which 
specifically binds to the glycosylated β-subunit of ENaC and participates in regulation of 
β-ENaC processing (Garland et al., 2013, Hobbs et al., 2013). It may suggest that Q30 
residue plays a role in the binding of hBPIFA1 to β-ENaC. Therefore, understanding the 
roles of other BPIFA1 residues involved in the binding process would be of great interest.  
Overall, bioinformatic analysis of BPIFA1 provided important insights into possible 
functions of protein and revealed differences between mouse and human BPIFA1 
proteins.  
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3.4.2 The pcDNA3.1 system did not provide sufficient amounts of 
hBPIFA1  
 
In this study, I used the pcDNA3.1 expression system as this vector contains a human 
cytomegalovirus immediate-early promoter/enhancer which should have enabled   
expression of BPIFA1 in transfected mammalian cells (Invitrogen, 2004). In addition, 
pcDNA3.1 should have allowed establishment of stable cell lines using G418 selection. 
The NCI-H292 cell line used for transfection assays is known to express BPIFA1 but 
expression levels were shown to be approximately 32-fold lower than those of well-
differentiated primary airway epithelial cells (Chu et al., 2010, Thaikoottathil and Chu, 
2011). I transfected NCI-H292 cells with DNA of GFP-tagged hBPIFA1-pcDNA3.1 and 
attempted to select BPIFA1-positive cells using G418. G418 selection should kill cells 
which do not contain plasmid DNA (Gibco, 2015). However, my findings indicated 
ineffectiveness of G418 selection. This may have been caused by the usage of penicillin 
and streptomycin in the cell culture as it has been suggested that the use with G418 may 
lead to the low/no selection activity of G418 as they are competitive inhibitors of G418 
(Gibco, 2015). Consequently, I decided to use a serial dilutions method for the isolation 
of positive cells, but the single cell colonies which were generated consisted of BPIFA1-
GFP positive and negative cells. Production of BPIFA1-GFP by these cells was detected, 
but protein levels were very low. Subsequently, cell sorting by flow cytometry was used 
to sort the mixed cell population into positive and negative cells. Isolation efficiency of 
positive cells indicated great effectiveness of the method and secretion of BPIFA1-GFP 
was also detected, but again levels of protein were lower than expected. BPIFA1 should 
have been readily secreted into the media from the transfected cells but after cells were 
transferred into serum-free medium, no secretion of protein was observed. Absence of 
BPIFA1 secretion by cells cultured in serum-free conditions was unexpected but could 
be a result of cells being unhealthy or lacking nutrients which may cause impairment of 
cellular functions (Li et al., 2015, Rezaei et al., 2013). Due to low amounts of BPIFA1, I 
 121 | P a g e  
 
decided to change the method and use pcDNA5/FRT expression system in the attempt 
to obtain larger quantities of BPIFA1. 
 
3.4.3 No secretion of BPIFA1 using pcDNA5/FRT expression system  
 
A series of different sizes of BPIFA1-GFP constructs were generated in pcDNA5/FRT 
expression system and used for transfections of Flp-In-CHO cells. Stable cell lines were 
established using hygromycin B selection. Analysis of transfected cells showed a 
successful integration of BPIFA1-plasmid DNA into the genome of CHO cells. However, 
BPIFA1-GFP proteins were produced in extremely small quantities and again no 
secretion of proteins was observed. Stable cell lines appeared to contain only a small 
proportion of BPIFA1-GFP positive cells. A number of reasons might have caused this. 
Firstly, co-integration of the plasmid bacterial backbone with the gene of interest into 
FRT recombination site may have occurred and caused infectiveness of Flp-InTM system. 
Negative effects of plasmid bacterial backbone elements on the expression levels of 
transfected genes have been reported (Chen et al., 2003, Jakobsen et al., 2010). 
Expression levels of transfected gene could also be affected by lacZ-Zeocin selection 
marker gene which resides in the docking site, containing recombinase recognition 
sequences and a stably expressed gene (Invitrogen, 2010, Jakobsen et al., 2010). 
Furthermore, additional transgenes, such as enhanced green fluorescent protein 
(eGFP), in the site of the transfected gene have also been shown to cause a negative 
impact on the expression levels of the gene of interest in this system (Dalle et al., 2005). 
All of this suggests, that host cells transfected with DNA of BPIFA1-pcDNA5/FRT 
construct may be negative for BPIFA1 expression or express only low levels of BPIFA1 
but still be resistant to hygromycin B. It could of course be possible that the fusion 
protein itself is not optimal for secretion as the GFP may negatively influence production 
and secretion. I was not able to formally test this, and it was not considered to be 
important as it was clear that this system was not optimal for my needs. 
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3.4.4 Production, secretion, and purification of BPIFA1-FLAG proteins  
 
Human and mouse FLAG-tagged BPIFA1 constructs were, therefore, generated in the 
mammalian VR1255 vector system. BPIFA1 proteins were fused to a FLAG tag instead 
of GFP, as it approximately 30 times smaller than GFP. The aim here was to avoid any 
risks of protein misfolding and degradation caused by GFP (Stepanenko et al., 2008, 
Zimmer, 2002). This change in expression technology allowed production and secretion 
of all human and mouse BPIFA1-FLAG recombinant proteins. However, the yield of 
secreted BPIFA1 recombinant proteins by transiently transfected cells was variable. This 
might be the result of inconsistent transfection efficiency rates (Dalton and Barton, 2014). 
In addition, the amounts of secreted proteins were not as high as expected and it may be 
because of BPIFA1 being normally secreted into the apical cell surface (Campos et al., 
2004, Di et al., 2003). During this project, all cells were grown in submerged culture 
conditions and it may be a reason for the secretion of BPIFA1 being not as high as 
anticipated. Future studies aiming to achieve greater quantities of secreted BPIFA1 
could try to transfect cells cultured in ALI conditions. In addition some other stable cell 
expression system could be used. In my study, I also observed that secretion of 
recombinant proteins was reduced once cells were transferred to the serum-free culture 
conditions. Decreased levels of recombinant proteins in the serum-free cell culture 
conditions have been reported (Li et al., 2015, Rezaei et al., 2013). Despite finding 
reduced levels of recombinant proteins in the serum-free cell culture, I decided to use 
secreted proteins in serum-free media because of the nature of my experiments. It is well 
recognised that absence of serum in the cell culture considerably simplifies purification 
process of proteins and eliminates any potential contamination (Sinacore et al., 2000). I 
also required secreted proteins in the serum-free conditioned media to investigate 
BPIFA1 binding to bacteria. I purified mouse and human BPIFA1-FLAG recombinant 
proteins from the serum-free conditioned media using anti-FLAG® M2 affinity gel. All 
human and mouse BPIFA1-FLAG proteins were purified from media but amounts of 
 123 | P a g e  
 
purified proteins were low. Full-length mouse and human proteins were produced at 
highest levels, but some secreted protein was left in the media after purification. The 
efficiency of purification was always lower with mutant BPIFA1-FLAG proteins. In many 
cases the majority of the protein were not eluted from the beads, meaning that only small 
amounts of proteins were purified from the conditioned media. Mutations made to 
hBPIFA1 proteins could lead to the conformational changes of S18 deletion and cysteine 
mutant BPIFA1 proteins which, in turn, affected purification efficiency. In addition, the 
fusion of BPIFA1 proteins to FLAG tag instead of 3x FLAG tag might have caused a 
decrease in the purification rates.  Purification of recombinant proteins from media was 
described to improve when 3x FLAG tag was used (Terpe, 2003). Therefore, the use of 
3x FLAG tagged proteins should be considered in the future work requiring purified 
proteins. It is also possible that the protein per se has an ability to bind to the affinity 
resin without interaction through the FLAG domain. In this case FLAG peptide might not 
always elute the protein. This suggestion is supported by the fact that previous antibody 
affinity work in the laboratory has shown that the protein bound to affinity resin in the 
absence of specific antibody (unpublished).  
 
3.4.5 Subcellular localisation of BPIFA1-FLAG recombinant proteins  
 
The subcellular localisation of human and mouse BPIFA1-FLAG proteins appeared to be 
in the cell cytoplasm. However, some transfected cells were observed to contain highly 
fluorescent granule-shaped objects, which suggested that BPIFA1 was also localised 
within these granules. Quantitative analysis suggested that the number of cells 
containing fluorescent granules was greater in the cells transfected with mutant BPIFA1 
constructs compared to full-length BPIFA1 constructs. It also appeared that cells 
transfected with S18 deletion BPIFA1-FLAG contained a greater number of cells with 
fluorescent granules compared to the cells transfected with cysteine mutant BPIFA1-
FLAG. Thus, these data may suggest that mutant BPIFA1 proteins enter a different 
secretory pathway compared to the non-mutant BPIFA1. This change in the secretory 
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pathway may be associated with the masking of localisation targeting sequence and 
conformational change of protein (Bauer et al., 2015, Stadler et al., 2013). I speculate 
that the localisation targeting sequence may be present in G22-L42 region of hBPIFA1 
as it would explain the increased presence of the S18 deletion BPIFA1 in the granule-
shaped objects. Frequent presence of cysteine mutant BPIFA1 in the spherical-shaped 
objects may be a result of protein’s conformational change caused by deletion of the 
disulphide bond. I suggest that these spherical-shaped objects were cell vesicles. There 
are two possible reasons for mutant protein’s localisation within vesicles. Firstly, it might 
be a consequence of the increased load on the cell secretory system due to 
overexpression of BPIFA1 and secondly, it may be associated with the destruction of 
misfolded mutant BPIFA1. Cellular functions strictly regulate translation of mRNA into the 
protein and in the case of misfolding, newly produced protein may be translocated in the 
vesicles by protein quality control mechanism for re-folding or degradation to the cytosol 
(Bauer et al., 2015, Kaganovich, 2017). This may also be the cause for low levels of 
these two proteins being produced in the transfected cells described above. 
The correct protein localisation is crucial for the proper protein function and information 
on the protein localisation could provide the insights into cellular functions of protein. 
Therefore, in the future it will be of great interest to identify the subcellular localisation of 
native BPIFA1 and understand the factors that cause a change in the localisation of 
protein.  
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3.5 Key experimental conclusions 
 
• N-terminal region of BPIFA1 exhibits the highest variability among the species. 
• Bioinformatic analysis of mBPIFA1 showed that protein is leucine- and proline-
rich, whereas hBPIFA1 could only be determined as leucine-rich protein. In 
addition, mBPIFA1 can be N-glycosylated, whereas hBPIFA1 cannot be N-
glycosylated.  
• NCI-H292 cells were successfully transfected with GFP-tagged hBPIFA1-
pcDNA3.1 construct and cell sorting enabled the generation of hBPIFA1-GFP 
stable cell line. However, protein secretion was low. 
• No secretion of recombinant BPIFA1-GFP proteins was achieved using 
pcDNA5/FRT expression system. 
• Production and secretion of mouse and human BPIFA1-FLAG proteins were 
achieved using VR1255 plasmids and HEK293T cells. 
• Purification of BPIFA1-FLAG proteins was not highly effective. Amounts of 
purified FL-hBPIFA1-FLAG and mutant hBPIFA1-FLAG proteins were not 
sufficient for the functional studies of BPIFA1.  
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CHAPTER 4: THE BINDING OF BPIFA1 TO BACTERIA 
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4.1 Introduction 
 
Respiratory tract infections are one of the most common human infections, causing high 
morbidity and mortality globally. Over 17 billion incidences of upper respiratory tract 
infections were reported in 2015 (GBD, 2016) and over 2.7 million deaths were caused 
by lower respiratory tract infections in the same year (GBD, 2017). Annually pneumonia 
alone causes 1.8 million deaths of children under 5 years of age worldwide 
(WHO/UNICEF, 2009). S. pneumoniae, S. aureus, and H. influenzae are among the 
most common bacterial pathogens causing pneumonia (Siegel and Weiser, 2015). H. 
influenzae and S. pneumoniae are also a leading cause of otitis media (Pettigrew et al., 
2008). All of these microorganisms belong to the commensal flora of the nasopharynx. 
However, they can spread from their normal environmental niche into sterile sites of the 
respiratory tract (e.g. lungs, middle ear, and sinuses) and cause local and invasive 
bacterial infections. In such cases these microbes become opportunistic pathogens 
(Bosch et al., 2013, Pettigrew et al., 2008, Siegel and Weiser, 2015). Healthy humans 
whose nasopharynx is colonised by S. pneumoniae, H. influenzae, and S. aureus serve 
as reservoirs for bacterial transmission to the susceptible host. In a balanced state, the 
epithelial layer of the respiratory tract mucosa is the first line of the host defence against 
bacterial and viral invaders. However, the loss of barrier function may allow pathogens to 
cross through mucus layer and invade epithelial cells; where they can cause infection 
and induce the development of infectious disease (Bosch et al., 2013, Pettigrew et al., 
2008). In many cases, respiratory tract infections caused by bacteria are treated with 
specific antibiotics. However, the over-prescription and inappropriate use of antibiotics 
over decades have resulted in the emergence and spread of antibiotic-resistant bacterial 
strains (Fahey et al., 1998, Prat and Lacoma, 2016). Consequently, the development of 
new therapeutics is important for the treatment of bacterial respiratory tract infections. 
Potential alternative to antibiotics are natural host antimicrobial peptides and proteins 
secreted by airway epithelial cells which exhibit rapid action, bactericidal properties, 
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broad spectrum activity against bacteria, low bacterial resistance, and low 
immunogenicity (Bals, 2000, Czaplewski et al., 2016, Prat and Lacoma, 2016).  
As outlined in the introduction, BPIFA1 is an abundantly secreted protein released by 
airway epithelial cells in the upper respiratory tract and pharynx (Bingle and Craven, 
2002). BPIFA1 exhibits antimicrobial properties (Gally et al., 2011, Liu et al., 2013, 
Sayeed et al., 2013) and the S18 peptide derived from the N-terminal region of BPIFA1 
can regulate the cleavage and activation of ENaC (Garcia-Caballero et al., 2009, 
Garland et al., 2013, Rollins et al., 2010). Consequently, the S18 peptide has attracted a 
lot of interest and currently Spyryx Biosciences is developing S18 peptide-based therapy 
for the treatment of CF (Fellner et al., 2016). BPIFA1 proteins or BPIFA1 derived 
peptides could potentially be used in the future for the treatment of bacterial respiratory 
tract infections, but, firstly, the mechanisms by which BPIFA1 performs its antimicrobial 
activity must be determined.  
Therefore, I proposed to investigate the role of BPIFA1 in the host defence by examining 
BPIFA1’s binding to bacterial pathogens. To fulfil this task, I used secreted endogenous 
and recombinant BPIFA1 proteins in bacterial pull-down assays with S. aureus, S. 
pneumoniae, and NTHi. 
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4.2 Objectives of this study 
 
The overarching aim of this study was to investigate the binding ability of BPIFA1 to 
different types of bacteria. In order to perform the functional analysis of BPIFA1, the 
following objectives had to be accomplished:   
1. To investigate human BPIFA1’s binding to bacteria. 
2. To determine the importance of disulphide bond and S18 region for human 
BPIFA1’s binding to bacterial pathogens. 
3. To compare the bacterial binding functions of full-length mouse BPIFA1 with full-
length human BPIFA1.  
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Figure 4.1: Study plan for this chapter. 
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4.3 Results 
 
4.3.1 Analysis of BPIFA1 binding to bacteria 
 
Bacterial pull-down assays were performed to investigate the ability of human and 
mouse BPIFA1 proteins to bind to bacteria. I also aimed to determine the importance of 
disulphide bond and S18 region for bacterial binding activity of human BPIFA1. Human 
and mouse BPIFA1 proteins were used in the bacterial pull-downs using four different 
incubation time periods: 0, 10, 30, and 60 minutes. The types of human and mouse 
BPIFA1 proteins and the amounts of each protein used in the assays are listed in Table 
4.1. After the binding assays were performed, the bacterial-protein pellet and pull-down 
fluid samples were collected for SDS-PAGE analysis. Original protein samples and 
bacterial cells were used as controls. Membranes were probed with anti-human BPIFA1 
antibody for detection of human BPIFA1 and with anti-mouse BPIFA1 antibody for 
detection of mouse BPIFA1. 
 
Table 4.1: The list of BPIFA1 proteins used in the bacterial pull-down assays. 
Protein Amount 
Mouse endogenous BPIFA1 25µl of ALI wash 
Mouse recombinant BPIFA1-FLAG 
50µl of serum free 
conditioned media 
Purified mouse recombinant BPIFA1-FLAG 10µl of purified protein in TBS 
Human endogenous BPIFA1 10µl of ALI wash 
Human recombinant full-length BPIFA1-FLAG 
50µl of serum free 
conditioned media 
Human recombinant cysteine mutant BPIFA1-FLAG 
50µl of serum free 
conditioned media 
Human recombinant S18 deletion BPIFA1-FLAG 
50µl of serum free 
conditioned media 
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4.3.2 The binding of full-length human BPIFA1-FLAG to bacteria  
 
To determine whether recombinant hBPIFA1 could bind to bacteria, I performed bacterial 
pull-down assays using FLAG-tagged FL-BPIFA1 and three different types of bacteria: S. 
aureus, S. pneumoniae, and NTHi. The results suggested that recombinant hBPIFA1 
bound to bacteria at all time points (Figure 4.2 A-C). However, the binding of hBPIFA1 to 
microbes appeared to be weak as the majority of protein was detected in the bacterial 
pull-down fluid samples, meaning that the majority of protein did not bind to bacteria. 
 
 
The binding of FLAG-tagged FL-hBPIFA1 to S. aureus (2x108) (A), S. pneumoniae (8.5x107) (B), 
and NTHi (5x109) (C). All membranes were probed with anti-human BPIFA1 antibody and 
exposed for 30 mins. Additional bands represent non-specific binding of antibodies to bacteria. 
Pull-down experiments with S. aureus and S. pneumoniae were performed once (n=1). Data of 
NTHi pull-down is representitive of results from two independent experiments (n=2). Full-length 
hBPIFA1-FLAG: ~25.9kDa (demonstrated by a blue line). 
Figure 4.2: The binding of FL-hBPIFA1-FLAG to bacteria. 
S. aureus & FL-hBPIFA1-FLAG 
n=1 
S. pneumoniae & FL-hBPIFA1-FLAG 
n=1 
NTHi & FL-hBPIFA1-FLAG 
n=2 
• FL-hBPIFA1-FLAG 
~25.9kDa 
• T – time in minutes 
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4.3.3 The binding of cysteine mutant human BPIFA1-FLAG to bacteria 
 
To determine the importance of the disulphide bond in binding, I used the cysteine 
mutant BPIFA1-FLAG in the bacterial pull-down studies. The disulphide bond is 
completely conserved in all BPIF proteins and is assumed to be important for protein 
stability. The results demonstrated that hBPIFA1 lacking disulphide bond retained its 
ability to bind to Gram-negative and Gram-positive bacteria. Protein bound to bacteria at 
all incubation periods and binding activity appeared to increase over time (Figure 4.3 A-
C). However, the binding ability appeared to be weak as a lot of protein was still retained 
in the bacterial pull-down fluid samples. Overall, the ability of cysteine mutant hBPIFA1-
FLAG to bind bacteria resembled that of FL-hBPIFA1-FLAG. 
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The binding of FLAG-tagged cysteine mutant hBPIFA1 to S. aureus (2x108) (A), S. pneumoniae 
(8.5x107) (B), and NTHi (5x109) (C). All membranes were probed with anti-human BPIFA1 
antibody. Membranes A and C were exposed for 25 mins, and membrane C was exposed for 60 
mins. Additional bands represent non-specific binding of antibodies to bacteria. Pull-down 
experiments with S. aureus and S. pneumoniae were performed once (n=1). Data of NTHi pull-
down is representitive of results from two independent experiments (n=2). Cysteine mutant 
hBPIFA1-FLAG: ~25.9kDa (demonstrated by a blue line). 
 
 
 
 
 
 
 
 
Figure 4.3: The binding of cysteine mutant hBPIFA1-FLAG to bacteria. 
S. aureus & cysteine mutant 
hBPIFA1-FLAG 
n=1 
S. pneumoniae & cysteine 
mutant hBPIFA1-FLAG 
n=1 
NTHi & cysteine mutant 
hBPIFA1-FLAG 
n=2 
• Cysteine mutant 
hBPIFA1-FLAG ~25.9kDa 
• T – time in minutes 
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4.3.4 The binding of S18 deletion human BPIFA1-FLAG to bacteria 
 
Next, I examined the significance of the S18 region for the bacterial binding function of 
hBPIFA1 using the S18 deletion hBPIFA1-FLAG. The data showed that hBPIFA1 lacking 
residues 22-42 did not bind to bacteria (Figure 4.4 A-C). These findings suggest that S18 
region may be important for hBPIFA1’s ability to bind to bacteria.  
 
The binding of FLAG-tagged S18 deletion hBPIFA1 to S. aureus (2x108) (A), S. pneumoniae 
(8.5x107) (B), and NTHi (5x109) (C). All membranes were probed with anti-human BPIFA1 
antibody. Exposures of membranes: A – 8 mins; B – 15 mins; C – 10 mins. Additional bands 
represent non-specific binding of antibodies to bacteria. Pull-down experiments with S. aureus 
and S. pneumoniae were performed once (n=1). Data of NTHi pull-down is representitive of 
results from two independent experiments (n=2). S18 deletion hBPIFA1-FLAG: ~23.7kDa 
(demonstrated by a blue line). 
 
 
Figure 4.4: The binding of S18 deletion hBPIFA1-FLAG to bacteria. 
S. aureus & S18 deletion 
hBPIFA1-FLAG 
n=1 
S. pneumoniae & S18 deletion 
hBPIFA1-FLAG 
n=1 
NTHi & S18 deletion 
hBPIFA1-FLAG 
n=2 
• S18 deletion hBPIFA1-
FLAG ~23.7kDa 
• T- time in minutes 
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4.3.5 The binding of endogenous human BPIFA1 to bacteria 
 
The ability of endogenous hBPIFA1 (from HBEC ALI culture washes) to bind to 
respiratory pathogens was investigated to compare differences between the binding of 
the endogenous protein and recombinant hBPIFA1-FLAG. Results showed that 
endogenous hBPIFA1 bound to S. pneumoniae and NTHi, but no binding to S. aureus 
was detected (Figure 4.5 A-C). Some unbound protein was also detected in the pull-
down fluids from the experiments performed with S. pneumoniae and NTHi. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The binding of endogenous hBPIFA1 to S. aureus (2x108) (A), S. pneumoniae (8.5x107) (B), and 
NTHi (5x109) (C). All membranes were probed with anti-human BPIFA1 antibody. Exposures of 
membranes: A – 2 mins; B – 25 mins; C – 15 mins. Additional bands represent non-specific 
binding of antibodies to bacteria. Asterisk symbol indicates that an excess of control BPIFA1 
sample (T=0) was used. Pull-down experiments with S. aureus and S. pneumoniae were 
performed once (n=1). Data of NTHi pull-down is representitive of results from two independent 
experiments (n=2). Endogenous hBPIFA1: ~25kDa (demonstrated by a blue line). 
  
Figure 4.5: The binding of endogenous human BPIFA1 to bacteria. 
S. aureus & endogenous 
hBPIFA1 
n=1 
S. pneumoniae & endogenous 
hBPIFA1 
n=1 
NTHi & endogenous 
hBPIFA1 
n=2 
• Endogenous hBPIFA1 
~25kDa 
• T- time in minutes 
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4.3.6 The binding of recombinant mouse BPIFA1-FLAG to bacteria 
 
To determine the ability of mouse BPIFA1 to bind to bacteria, I investigated the binding 
of unpurified recombinant mBPIFA1-FLAG to respiratory pathogens. The binding of 
protein to S. aureus appeared to not to be present or very weak (Figure 4.6 A). The 
findings demonstrated that recombinant mBPIFA1-FLAG bound to S. pneumoniae and 
NTHi, but that some unbound protein was detected in the pull-down fluids (Figure 4.6 B-
C). Results also suggested that that the binding of mBPIFA1-FLAG to NTHi increased 
over the time (Figure 4.6 C).  
 
The binding of FLAG-tagged mBPIFA1 to S. aureus (2x108) (A), S. pneumoniae (8.5x107) (B), 
and NTHi (5x109) (C). All membranes were probed with anti-mouse BPIFA1 antibody and 
exposed for 2 mins. Additional bands represent non-specific binding of antibodies to bacteria. 
Pull-down experiments with S. aureus and S. pneumoniae were performed once (n=1). Data of 
NTHi pull-down is representitive of results from two independent experiments (n=2). Recombinant 
mBPIFA1-FLAG: ~29.5kDa (demonstrated by a blue line). 
Figure 4.6: The binding of recombinant mouse BPIFA1-FLAG to bacteria. 
S. aureus & recombinant 
mBPIFA1-FLAG 
n=1 
S. pneumoniae & recombinant 
mBPIFA1-FLAG 
n=1 
NTHi & recombinant 
mBPIFA1-FLAG 
n=2 
• Recombinant mBPIFA1-
FLAG ~29.5kDa 
• T- time in minutes 
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4.3.7 The binding of purified recombinant mBPIFA1-FLAG to bacteria 
 
Availability of purified mBPIFA1-FLAG enabled me to investigate the direct capability of 
mBPIFA1-FLAG to bind to bacteria. Using such samples meant that any other 
components present in the conditioned media would not influence binding of the protein 
to microbes as they were removed during protein purification process. Analysis of pull-
down samples showed that the binding of purified mBPIFA1-FLAG to S. aureus 
appeared to be limited (Figure 4.7 A). However, results also demonstrated that 
mBPIFA1-FLAG bound to S. pneumoniae and NTHi (Figure 4.7 B-C). The binding of 
purified mBPIFA1-FLAG to microbes appeared to be similar at all time points examined 
during this study. 
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The binding of purified mBPIFA1-FLAG to S. aureus (2x108) (A), S. pneumoniae (8.5x107) (B), 
and NTHi (5x109) (C). All membranes were probed with anti-mouse BPIFA1 antibody. Exposures 
of membranes: A – 20 sec; B – 30 sec; C – 10 sec. Additional bands represent non-specific 
binding of antibodies to bacteria. Pull-down experiments were performed once (n=1). Purified 
recombinant mBPIFA1-FLAG: ~29.5kDa (demonstrated by a blue line). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: The binding of purified recombinant mouse BPIFA1-FLAG to bacteria. 
S. aureus & purified 
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4.3.8 The binding of endogenous mouse BPIFA1 to bacteria 
 
The ability of endogenous mouse BPIFA1 (from mTEC ALI washes) to bind to bacteria 
was investigated. The results showed that endogenous mBPIFA1 bound to S. aureus 
and NTHi, but not to S. pneumoniae (Figure 4.8 A-C). The binding of endogenous 
mBPIFA1 to S. aureus appeared to increase over the time (Figure 4.8 A). The ability of 
endogenous mBPIFA1 (Figure 4.8 A) to bind to S. aureus is the opposite to the situation 
with recombinant mBPIFA1-FLAG (Figure 4.6 A) as this protein showed very limited 
binding to the pathogen. Contrasting results were also observed in the pull-downs with S. 
pneumoniae as recombinant mBPIFA1-FLAG (Figure 4.6 B) was shown to bind to the 
pathogen whereas endogenous mBPIFA1 did not (Figure 4.8 B). The findings also 
suggested that endogenous mBPIFA1 bound to NTHi much more efficiently than 
recombinant protein as no unbound protein was detected in the pull-down fluids at any 
time point (Figure 4.8 C). 
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The binding of endogenous mBPIFA1 to S. aureus (2x108) (A), S. pneumoniae (8.5x107) (B), and 
NTHi (5x109) (C). All membranes were probed with anti-mouse BPIFA1 antibody. Exposures of 
membranes: A – 10 mins; B – 2 mins; C – 2 mins. Additional bands represent non-specific 
binding of antibodies to bacteria. Data of S. pneumoniae pull-down is representative of results 
from two independent experiments (n=2). Data of S. aureus and NTHi pull-downs are 
representitive of results from three independent experiments (n=3). Endogenous mouse BPIFA1: 
~28.6kDa (demonstrated by a blue line). 
 
 
 
On the basis of the above data, I decided to investigate whether a reduced number of 
NTHi would cause a decrease in the binding of endogenous mBPIFA1 to bacteria. The 
same amount of protein was used for the binding assays with 5x109 (Figure 4.9 A), 1x109 
(Figure 4.9 B), and 2x108 (Figure 4.9 C) of NTHi. The results showed that the binding of 
endogenous mBPIFA1 gradually decreased with the lower numbers of NTHi (Figure 4.9 
Figure 4.8: The binding of endogenous mouse BPIFA1 to bacteria. 
S. aureus & endogenous 
mBPIFA1 
n=3 
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endogenous mBPIFA1 
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NTHi & endogenous 
mBPIFA1 
n=3 
• Endogenous mBPIFA1 
~28.6kDa 
• T- time in minutes 
 
 143 | P a g e  
 
A-C). Results also suggested that more protein was detected in the fluids from bacterial 
pull-downs in which 5x (Figure 4.9 B) and 25x (Figure 4.9 C) times less of NTHi bacteria 
were used compared to the amounts of protein detected in the fluids obtained from 
binding assays with the highest number of bacteria (5x109 NTHi) (Figure 4.9 A).  
 
The binding of endogenous mBPIFA1 to 5x109 (A), 1x109 (B), and 2x108 (C) of NTHi. All western 
blot membranes were probed with anti-mouse BPIFA1 antibody. Exposures of membranes: A – 2 
mins; B – 3 mins; C – 8 mins. Additional fragments present on SDS-PAGE membranes was a 
result of non-specific binding of antibodies to NTHi. Data of pull-downs are representative of 
results from two independent experiments (n=2). Endogenous mouse BPIFA1: ~28.6kDa 
(demonstrated by a blue line). 
 
 
 
 
 
Figure 4.9: The binding of endogenous mBPIFA1 to different numbers of NTHi. 
• Endogenous mBPIFA1 
~28.6kDa 
• T- time in minutes 
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Overall, the results from the pull-down experiments suggest that human BPIFA1 can 
bind to S. aureus, S. pneumoniae, and NTHi. Deletion of the disulphide bond appeared 
not to affect the binding activity of human BPIFA1. However, human BPIFA1 lacking S18 
region (22-42aa) did not bind to bacteria. In addition, the binding activity of recombinant 
human BPIFA1 to S. aureus appeared to be different from endogenous human BPIFA1. 
The data also suggest that the binding of human BPIFA1 to the pathogens is similar to 
the binding of mouse BPIFA1. Mouse BPIFA1 bound to Gram-positive and Gram-
negative bacteria, however different preparations of mouse BPIFA1 appeared to 
influence the protein’s binding activity to bacteria. Ability of endogenous mouse BPIFA1 
to bind to NTHi appeared to decrease with the reducing amounts of bacteria, suggesting 
that protein’s binding may be dose-dependent. Findings from this study also showed that 
mouse and human BPIFA1 binding to pathogens increased over the time, suggesting 
that protein’s bacterial binding may be influenced by the length of exposure.  
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4.4 Discussion 
 
Experiments in this chapter were performed to look at the ability of BPIFA1 to bind to the 
commensal bacteria. Recombinant and endogenous BPIFA1 proteins were used in the 
bacterial pull-down assays to investigate BPIFA1’s binding to bacteria, including S. 
aureus strain SH1000, NTHi-375-SR, and S. pneumoniae strain D39. NTHi-375-SR 
strain and S. aureus strain SH1000 were chosen for the work because of their previous 
use in our group investigating the role of BPIFA1 in the bacterial infections of middle ear 
epithelial cells (Mulay et al., 2016) and human bronchial epithelial cells (Chloe Marshall, 
unpublished), respectively. S. pneumoniae strain D39 was chosen for binding assays 
because of its broad use in the studies investigating mucosal and invasive bacterial 
infections, and its extreme virulence in murine infection models (Lanie et al., 2007, 
Marriott et al., 2012). Using simple bacterial pull-downs, I aimed to identify if BPIFA1 had 
the ability to bind to bacteria and to compare binding activity of human BPIFA1 with 
mouse BPIFA1. I also examined the importance of disulphide bond and S18 region for 
microbial binding activity of human BPIFA1. Bacterial pull-down technique was chosen 
for its usefulness in the identification of direct protein-protein interactions (Louche et al., 
2017). The results from this work appear to show some differences in the protein’s 
bacterial binding activity, which may be influenced by the different preparations of 
BPIFA1. 
 
4.4.1 The binding ability of human BPIFA1 to bacteria  
 
Findings from this study suggest that hBPIFA1 can bind to S. aureus, S. pneumoniae, 
and NTHi. However, the binding function of hBPIFA1 seemed to be affected by different 
preparations of protein and modifications made to the protein sequence. It was observed 
that recombinant full-length hBPIFA1-FLAG bound to all microbes, but endogenous 
hBPIFA1, secreted by HBECs, appeared to lack the ability of binding to S. aureus. Yet, it 
should be highlighted that S. aureus bacterial-pull down was performed only once in this 
study due to the limited availability of secreted endogenous hBPIFA1. It is also 
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interesting that some studies have shown that recombinant hBPIFA1 does not exhibit 
anti-growth and anti-biofilm functions against S. aureus (Ahmad et al., 2016, Walton et 
al., 2016). However, more recent study by Yu et al., showed that BPIFA1 shows 
antimicrobial properties against S. aureus (Yu et al., 2018). Based on these conflicting 
findings, I suggest that the activity of hBPIFA1 against S. aureus should be further 
investigated to determine the true antimicrobial functions of hBPIFA1 against this 
pathogen. 
My data also showed that cysteine mutant hBPIFA1 can bind to bacteria, suggesting that 
the absence of disulphide bond does not lead to the loss of BPIFA1’s bacterial binding 
activity. It implies that disulphide bond may not have a great influence on this biological 
activity of hBPIFA1. This is in contrast to data from work with BPI, as it was shown to 
become biologically inactive after disulphide bond removal (Horwitz et al., 1996). 
However, it has also been reported that exposure of BPIFA1 to the cigarette smoke 
triggers a disulphide bond modification which alters BPIFA1 structure. This disulphide 
bond modification was shown to inhibit BPIFA1’s ability to bind and control ENaC activity 
(Moore et al., 2018). Therefore, this may imply that disulphide bond does not have 
impact on BPIFA1’s bacterial binding activity, but it may influence other biological 
functions of protein. However, more detailed investigation should be performed to fully 
confirm that deletion of disulphide bond does not have any influence on the BPIFA1’s 
bacterial binding function. In this study, pull-down assays were performed only with three 
different microbes and the number of pull-down replicates was low. In addition, the 
nature of pull-down experiments do not allow to determine if the strength of the protein’s 
binding to pathogens has been affected after removal of disulphide bond. To answer this 
question, other types of assays (e.g. immunoprecipitation), allowing more quantitative 
analysis of results, should be used in the future. 
BPIFA1 with deletion of S18 region was shown to lack binding ability, suggesting that the 
S18 region (22-42aa) of hBPIFA1 plays an important role in the protein’s bacterial 
binding activity. However, further investigation is required to fully determine the 
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importance of S18 region for BPIFA1’s bacterial binding activity. It is possible that 
deletion of S18 region may result in conformational changes of BPIFA1 which may cause 
the loss of bacterial binding function. Interestingly, it was recently shown that the S18 
peptide (22-39aa) did not possess antimicrobial activity against Gram-negative pathogen 
and that BPIFA1 mutant protein lacking amino acids M1-S43 retained full antimicrobial 
activity (Ahmad et al., 2016). In addition, it was reported that human BPIFA1 lacking S18 
region retains its ability to bind LPS from Gram-negative pathogens (Walton et al., 2016). 
Based on my results and the findings reported in the above studies, the importance of 
S18 region for biological activity of human BPIFA1 requires further investigation. 
 
4.4.2 The binding of mouse BPIFA1 to bacteria 
 
The binding of mouse BPIFA1 to pathogens was analysed in this study to understand the 
possible differences in the bacterial binding between mouse and human proteins. It was 
observed that mouse BPIFA1’s bacterial binding activity was similar to that of human 
BPIFA1 as mouse BPIFA1 also bound to S. aureus, S. pneumoniae, and NTHi. Bacterial 
binding of mBPIFA1 differed with the different preparations of the protein. Endogenous 
mBPIFA1 bound to S. aureus and NTHi, whereas recombinant mBPIFA1-FLAG, 
including the purified protein, bound to S. pneumoniae and NTHi. This change in the 
bacterial binding activity of mBPIFA1 may be caused by the different preparations of the 
protein. The ability of endogenous mBPIFA1 to bind S. aureus compared to recombinant 
mBPIFA1-FLAG may be conferred by other naturally secreted proteins and peptides 
(e.g. lactoferrin, beta-defensins, mucins) found in the apical cell secretions from mTECs. 
In the study by Ventura et al., mouse host proteins were eluted from S. aureus recovered 
from the airways of mice 6 hours following intranasal inoculation. Direct binding ability of 
mBPIFA1 to S. aureus was detected (Ventura et al., 2008). My results are in the 
agreement with this study, suggesting that mBPIFA1 binds to S. aureus, but for this 
binding to happen other naturally secreted components of epithelial cell secretions may 
be required. However, the same proteins and peptides found in the apical cell secretions 
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may inhibit rather than enhance the binding of endogenous mBPIFA1 to S. pneumoniae. 
Inability of endogenous mBPIFA1 to bind to S. pneumoniae could also be caused by S. 
pneumoniae D39 strain itself as it is highly virulent in murine infection models (Lanie et 
al., 2007), meaning that it may be negatively affecting other naturally secreted mouse 
proteins and peptides in the apical secretions, and this, in turn, negatively alters the 
binding ability of endogenous mBPIFA1. Other naturally secreted mouse proteins and 
peptides were not present in recombinant mBPIFA1 preparation and it may be a reason 
for the ability of recombinant mBPIFA1 to bind to S. pneumoniae. This may suggest that 
mBPIFA1 performs its biological activity to the full extent in the presence of other natural 
components of the airway secretions.  
The ability of mBPIFA1 to bind to NTHi appeared to be similar with the different 
preparations of protein, as endogenous and recombinant mBPIFA1, including the 
purified protein bound to NTHi. However, it should be mentioned that all-input 
endogenous mBPIFA1 bound to NTHi during bacterial binding assays, whereas some 
unbound recombinant mBPIFA1 was detected in the pull-down fluids. This may suggest 
that endogenous mBPIFA1 is better at binding to NTHi than recombinant mBPIFA1. The 
binding of endogenous mBPIFA1 may be enhanced because of other naturally secreted 
proteins and peptides found in the apical secretions of mTECs or it may be associated 
with the lack of FLAG tag. It is possible that tagging of recombinant mBPIFA1 with FLAG 
may cause some conformational changes of the protein which may affect the bacterial 
binding function.  
 
 
Taking all results into consideration, I suggest that mouse and human BPIFA1 proteins 
exhibit bacterial binding ability and this may be one of the functions that the protein plays 
in host defence against bacterial infections. It appears that bacterial binding of 
recombinant BPIFA1 proteins differ from endogenous BPIFA1 proteins because of the 
presence of other naturally secreted molecules in the apical cell secretions. It may also 
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be suggested that the usage of endogenous BPIFA1 together with other naturally 
secreted components of the airway secretions may mimic better in situ antimicrobial 
functions of BPIFA1. In addition, it appeared that the binding of mouse and human 
BPIFA1 to bacteria was time-dependent. I was unable to quantify whether a larger 
amount of protein associated with bacteria over the time, because of limitations of my 
experimental design: 1) different amounts of different protein preparations were used in 
the bacterial pull-downs; 2) western blotting analysis of pull-down samples was 
performed without a loading control; and 3) small number of pull-down replicates. 
Consequently, more quantitative investigation is required to fully determine whether 
BPIFA1’s binding activity increases with the longer exposures to bacteria. 
In this study, I also showed that mouse BPIFA1 binds to NTHi and Jiang et al. reported 
that BPIFA1 deficiency in mice leads to the increase of bacterial burden in the murine 
lungs after NTHi challenge (Jiang et al., 2013b). It suggests that mouse BPIFA1 plays a 
role in the host defence against this pathogen. The ability of mouse BPIFA1 to bind to 
NTHi may be conferred by the proline-rich region which is found in the sequence of 
protein. It was reported that proline-rich regions enable peptides to bind to other proteins 
(Williamson, 1994) and that proteins, containing proline-rich region, have broad 
antimicrobial properties and exhibit specific activity against Gram-negative bacteria 
(Casteels et al., 1989, Falla et al., 1996). It is also possible that ability of mouse BPIFA1 
to bind to NTHi may be associated with the fact that mouse BPIFA1 can be N-
glycosylated. N-glycosylation is known to affect the biological activity of proteins and 
glycoproteins are well recognised to have an ability to bind to bacteria and serve as the 
vehicle for bacterial clearance (Kukuruzinska and Lennon, 1998, Lee et al., 2015, Lis 
and Sharon, 1993). I suggest that post-translational modification of mBPIFA1 with N-
linked glycans may be important for its binding functions to NTHi. Based on my findings, 
showing the binding ability of mouse BPIFA1 to NTHi and currently existing data, 
demonstrating the importance of mouse BPIFA1 in the host defence, I decided to further 
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investigate the function of mouse BPIFA1 against NTHi using an in vitro infection model 
which is described in Chapter 5. 
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4.5 Key experimental conclusions 
 
• Human and mouse BPIFA1 proteins bound to S. aureus, S. pneumoniae, and 
NTHi. 
• Recombinant mouse and human BPIFA1 appeared to exhibit a different binding 
abilities to the microbes when compared with endogenous mouse and human 
BPIFA1 proteins, respectively. These findings suggest that BPIFA1’s binding may 
be influenced or modified by the presence of other naturally secreted 
components of epithelial cell secretions. 
• Removal of disulphide bond did not influence the binding of human BPIFA1 to 
bacteria, but deletion of residues 22-42 inhibited binding to the pathogens, 
suggesting that S18 region may influence biological activity of protein. 
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CHAPTER 5: INVESTIGATING THE SUSCEPTIBILITY OF 
WT AND Bpifa1-/- mTECs TO NTHi INFECTION 
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5.1 Introduction  
 
The mouse is one of the most used animal model for the study of respiratory infections 
and is widely used for in vivo and in vitro studies. The respiratory tract of mice exhibits 
similarities to the human respiratory tract, meaning that it can be used as the laboratory 
model to investigate human respiratory system and diseases. However, there are also 
interspecies differences in the respiratory tract which should be considered when 
translating results from the animal study to the humans. For example, the human nasal 
airway and nasal turbinates are of less complex structure than they are in the mouse; the 
reason for this may be associated with the main functions of nasal airway (Harkema et 
al., 2006, Reznik, 1990). The primary function of human nasal airway is breathing 
whereas olfaction and breathing are the main functions of mouse nasal airway (Harkema 
et al., 2006, Reznik, 1990). In addition, although the distribution of nasal epithelium (i.e. 
squamous, respiratory, transitional, and olfactory) from nasal passages to the 
nasopharynx is similar in the mice and humans, the proportion of each epithelium type 
and cell types differ (Harkema et al., 2006, Reznik, 1990). The trachea of the mouse and 
human also share similarities as they both contain cartilage rings and submucosal 
glands, and both are lined by pseudostratified ciliated epithelium. However, there are 
differences between mouse and human tracheas too (Reznik, 1990, Rock et al., 2010). 
In humans, the cartilage rings extend for several bronchial generations, but, in mice, they 
are found only in the extrapulmonary airways. Submucosal glands are only present in the 
upper section of mouse trachea, whereas, in humans, their presence extends deeper 
into the lung. Furthermore, mouse trachea is lined by pseudostratified epithelium which 
later changes into a simple cuboidal epithelium in the mainstem bronchi, whereas, in 
humans, the pseudostratified epithelium is present up to the terminal bronchioles 
(Reznik, 1990, Rock et al., 2010). Mouse lower respiratory tract also shares similarities 
with human lower respiratory tract, but, generally, the structure of mouse lower airways 
is greatly different from human lower airways (Irvin and Bates, 2003, Miller et al., 1993, 
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Suarez et al., 2012). For example, mouse and human lungs contain lobes. However, 
right lung of mice consists of four lobes, whereas right lung of humans is divided into 
three lobes. Mouse left lung has only a single lobe, whereas human left lung consists of 
two lobes (Suarez et al., 2012). In addition, although mouse and human have lung 
pleura, mouse lung pleura is thin, whereas human lung pleura is thick (Irvin and Bates, 
2003). Airway branching is a feature of mouse and human respiratory tract, but, in mice, 
airway branching follows monopodial pattern, whereas, in humans, it follows 
dichotomous pattern (Irvin and Bates, 2003, Miller et al., 1993). The number of airway 
generations also differ in mouse and human: mouse lung consists of 13-17 airway 
generations, whereas human lung consists of 17-21 airway generations (Irvin and Bates, 
2003). Therefore, similarities and differences exist between mouse and human 
respiratory tract. These differences may be a reason for mouse not being a very good 
animal model to study human respiratory diseases such as COPD, CF, and asthma 
(Persson, 2002, Williams and Roman, 2016).  
Despite these differences, mice are still commonly used for investigation of human 
respiratory tract diseases and infections due to their relatively low cost, size, and 
availability of good murine genetic information. In addition, mouse model allows the 
usage of in vivo experimental techniques which would not be ethically appropriate to be 
used in human studies. There are examples of in vivo studies performed using mouse 
models to study a variety of viral (Akram et al., 2018, Cormier et al., 2010) and bacterial 
(Bayes et al., 2016, Pilloux et al., 2016) infections. In recent years, techniques were 
developed to obtain murine epithelial cells from respiratory tract tissues for differentiation 
into the upper airway-like epithelium (Davidson et al., 2000, Mulay et al., 2016, You et 
al., 2002, You and Brody, 2013). These cells were shown to express airway epithelium 
specific genes, meaning that they consist of non-ciliated (e.g. secretory cells) and ciliated 
cells. Expression of Zo-1 indicated that cellular tight-junctions are also formed (Davidson 
et al., 2000, Mulay et al., 2016, You et al., 2002, You and Brody, 2013). Development of 
in vitro mouse cell culture models, mimicking the in vivo host airway epithelium and its 
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microenvironment, provide unique possibilities to study behaviour, morphology, and 
immune responses of airway epithelium to bacterial and viral stimuli. In our laboratory 
these models were applied to investigate host-pathogen interactions in studies 
examining IAV infection of mouse tracheal epithelium (Akram et al., 2018) and NTHi  
infection of mouse middle ear epithelium (Mulay et al., 2016).  
In addition, genetic approaches have been employed to generate murine targeted gene 
knockouts which enabled investigation of specific molecular pathways and genes 
involved in the host defence against bacterial and viral infections (Buer and Balling, 
2003). Human BPIFA1 is produced and secreted by the upper respiratory tract 
epithelium and its orthologue is present in mice (Weston et al., 1999). Mouse Bpifa1 
knockouts have been generated and provide possibilities to study biological functions of 
BPIFA1. A role of BPIFA1 in airway host defence against microbial pathogens was 
investigated in the several in vivo and in vitro studies using Bpifa1-/- models (Akram et 
al., 2018, Jiang et al., 2013, Liu et al., 2013b, Mulay et al., 2016). Understanding the 
biological activity of mouse BPIFA1 in host defence against viral and bacterial infections 
could provide important insights in the understanding the functions of human BPIFA1. 
My results in Chapter 4 suggested that mouse BPIFA1 can bind to NTHi. Therefore, I 
undertook to investigate whether the loss of BPIFA1 in mTEC culture would lead to the 
greater susceptibility of the cells to NTHi infection. To fulfil this task, I used mTECs 
isolated from WT and Bpifa1-/- mice and exposed both types of mTEC cultures to NTHi. 
Host defence responses against this microbial pathogen were studied and compared.  
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5.2 Objectives of this chapter 
 
The overarching aim of this chapter was to determine whether the loss of BPIFA1 in 
mTEC culture would lead to the enhanced susceptibility of the cells to NTHi infection. To 
examine this, the following objectives were required to be completed: 
1. To isolate mTECs, from WT and Bpifa1-/- mice, and differentiate cells into the 
upper airway-like epithelium. 
2. To assess the effect of loss of BPIFA1 on the susceptibility of mTEC culture to 
NTHi challenge. 
3. To compare immune responses generated by WT and Bpifa1-/- mTECs to 
bacterial stimulus. 
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Figure 5.1: Study plan for this chapter. 
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5.3 Results 
 
5.3.1 Characterisation of mTECs 
 
Growth and morphology of mTECs were observed during submerged and ALI cultures. 
3x105 of cells were seeded per transwell and only a small number of cells were seen 
attached to the membrane three days after seeding (Figure 5.2 A-B). Epithelial cells 
appeared elongated, establishing a contact with nearby cells and forming epithelial cell 
islands. Cells proliferated in the submerged culture and formed a confluent monolayer 
within seven days of seeding (Figure 5.2 C-D). ALI was induced on confluence, revealing 
compactly arranged mTECs (Figure 5.2 E-F). After seven days of ALI culture, cells 
started changing morphology and movement of cilia was observed (Figure 5.2 G-H). Two 
major types of mTECs, flat non-ciliated cells and ciliated cells, were observed in the 
monolayer of cells on day fourteen of ALI culture (Figure 5.2 I-J). Morphology of non-
ciliated cells was of a cobble-stone appearance which is a characteristic of upper airway 
epithelium. Well-defined cell boundaries were observed in differentiated mTECs by day 
fourteen. No apparent differences in the growth and morphology of the cells were 
identified in Bpifa1-/- mTECs compared to WT mTECs. Mouse tracheal fibroblasts were 
cultured to obtain a pure population of fibroblasts (Figure 5.2 K-L) and used as a 
negative control for gene expression and immunoblotting studies.  
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Phase contrast pictures demonstrating WT and Bpifa1-/- mTECs in the submerged and ALI culture 
conditions (A-J). mTECs in the submerged cell culture three days after seeding (A-B). 
Monolayers of WT and Bpifa1-/- cells in the submerged culture seven days after seeding (C-D). 
Cells compactly arranged after induction of ALI (E-F). Different types of cells observed, including 
ciliated cells on day 7 in ALI culture (G-H). WT and Bpifa1-/- mTECs in ALI culture on the day 14. 
No apparent differences observed (I-J). Growth of fibroblasts on the treated tissue culture dishes 
(K-L). Abbreviations: WT- wild-type; SUB – submerged; D – day; ALI – air liquid interface; Fibro – 
fibroblasts. Images were taken at 10x and 20x magnifications with light microscope (Nikon Eclipse 
TS100; scale bar: 100µm) and processed using ImageJ-win32. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Characteristics of mTEC growth in the cell culture. 
 161 | P a g e  
 
5.3.2 Epithelial markers of mTEC cultures  
 
The expression of cell-type specific genes was studied in the isolated mTECs and 
mTECs in the culture at day 0, and day 14 ALI using PCR. Isolated mouse fibroblast 
cDNA was used in PCR reactions as a negative control (Figure 5.3 A). The expression of 
Oaz1 (ornithine decarboxylase antizyme 1), which is involved in the regulation of cell 
growth and proliferation in all types of tissues (Mangold, 2005), was assessed and used 
as a housekeeping gene in all PCR reactions. Expression of Tekt1 (tektin 1 – ciliated cell 
marker) was detected in the isolated and ALI-day 14 culture differentiated WT and 
Bpifa1-/- mTECs, suggesting that ciliated cells were present in the cell populations. No 
expression of Tekt1 was observed in ALI-day 0 cell cultures. Expression of Bpifa1 
(secretory cell marker) was strong in the isolated and ALI-day 14 culture differentiated 
WT mTECs compared to ALI-day 0 WT mTECs. The expression of Ltf (lactoferrin – 
secretory cell marker) was detected in the isolated mTECs and mTECs in the culture 
conditions at ALI-day 0, and ALI-day 14. This expression data verified that ALI-day 14 
cells differentiated into the upper airway-like epithelium. In addition, western blotting 
showed that BPIFA1 was detected in apical secretion washes collected on ALI-day 7, 9, 
and 14, but not on the second day in ALI WT cell culture (Figure 5.3 B). No secreted 
BPIFA1 was detected in differentiated Bpifa1-/- mTECs (Figure 5.3 C).  
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PCR results, showing the expression of upper airway epithelium specific genes in isolated mTECs 
and cultured mTECs at ALI-day 0, and ALI-day 14 (A). Identification of BPIFA1 secretion by 
differentiating WT mTECs using western blotting analysis. Data are representative of the results 
from two independent batches of WT mTECs (n=2) (B). The absence of secreted BPIFA1 in the 
apical secretion washes from four batches of ALI-day 14 differentiated Bpifa1-/- mTECs compared 
with the apical secretion wash from ALI-day 14 differentiated WT mTECs, as a positive control 
(C). 
 
 
Unpublished RNA-Seq data from our laboratory showed that Bpifa1 deletion did not 
cause alterations in gene profile of Bpifa1-/- mTECs compared to WT mTECs. RNA-Seq 
results demonstrated that Bpifa1-/- mTECs differed from WT mTECs by the expression of 
only four genes (excluding Bpifa1): Prg4 (approx. three-fold increase), Spp1 (approx. 
two-fold increase), Wfdc18 (approx. two-fold increase), Plekhs1 (approx. two-fold 
increase). Prg4 encodes for proteoglycan 4 which has been reported to be involved in 
the protection of articulating joints by controlling the lubrication of the cartilage surfaces 
and regulating the synovial cell growth (Rhee et al., 2005). It has also been suggested 
Figure 5.3: Epithelial markers of mTECs. 
BPIFA1 
BPIFA1 
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that proteoglycan 4 influences the proliferation of hematopoietic progenitor cells by 
controlling parathyroid hormone functions (Novince et al., 2011). Spp1 encodes for 
osteopontin, which is found in all body fluids and in the proteinaceous matrix of 
mineralized tissues. It has been suggested that osteopontin may be important to cell-
matrix interactions and immune responses (Denhardt et al., 2001, Manabe et al., 2008). 
Osteopontin is known as signalling molecule, having inflammatory and anti-inflammatory 
properties. It has been reported that osteopontin can influence the release of IL-12, IFN-
γ, and IL-10 (Denhardt et al., 2001). Mouse Wfdc18 gene codes for WAP four-disulphide 
core domain protein 18 and Plekhs1 gene codes for pleckstrin homology domain-
containing family S member 1 protein. Currently, both of these proteins are 
uncharacterised (UniProt, 2019a, UniProt, 2019b). However, the existing protein 
sequence analysis of WAP four-disulphide core domain protein 18 suggests that it may 
act as proteinase inhibitor (UniProt, 2019a).  
 
 
5.3.3 Localisation of airway epithelium specific proteins in mTEC 
cultures 
 
I used IFC microscopy to confirm a successful differentiation of WT mTECs into the 
upper airway-like epithelium. ALI-day 14 cells were processed and stained with IFC 
antibodies for BPIFA1 (Akram et al., 2018, Mulay et al., 2016, Musa et al., 2012), β-
tubulin (Akram et al., 2018), and zonula occludens-1 (ZO-1) (Mulay et al., 2016); nuclei 
were counterstained with DAPI (Figure 5.4). I successfully detected BPIFA1 (marker of 
non-ciliated cells) (Figure 5.4 A) and β-tubulin (marker of ciliated cells; present in the 
cilia) (Figure 5.4 B) in WT mTEC cultures. ZO-1 staining was also positive in WT 
mTECs, suggesting establishment of cellular tight-junctions within the cell cultures 
(Figure 5.4 C). Tight-junction formation further confirmed successful differentiation of WT 
mTECs into the upper airway-like epithelium.  
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ALI-day 14 mTECs were processed and stained for BPIFA1 (A), β-tubulin (B), and ZO-1 (C). 
Nuclei were counterstained with DAPI. Detection of these epithelial markers confirmed a 
successful differentiation of mTECs. Images were processed using ImageJ-win32. Scale bar: 
50µm. Data are representative of results from two independent batches of WT mTECs. 
 
 
 
Differentiation of WT and Bpifa1-/- mTECs was previously validated in our laboratory 
(Figure 5.5 A-D). Data also demonstrated that BPIFA1 is not localised within ciliated cells 
and is present within non-ciliated cells (Akram et al., 2018) (Figure 5.5 A). 
  
ALI-day 14 WT mTECs  
A. B. 
C. 
20x 60x 
20x 
Figure 5.4: Differentiation of WT mTECs into the upper airway-like epithelium. 
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ALI-day 14 differentiated mTECs showed successful mTEC differentiation into the upper airway-
like epithelium. Cells stained for β-tubulin, BPIFA1, and nuclei counterstained with DAPI (A, B). 
Cells stained for MUC5B and nuclei counterstained with DAPI (C, D). Images were re-used and 
modified with permission from (Akram et al., 2018), copyright 2017 Mucosal Immunology. Scale 
bar: 50µm. 
 
 
 
 
 
Figure 5.5: Validation of WT and Bpifa1-/- mTEC differentiation. 
 WT Bpifa1-/- 
A B 
C D 
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5.3.4 NTHi colonises Bpifa1-/- mTECs more rapidly than WT mTECs  
 
Results from bacterial pull-down assays suggested that mouse BPIFA1 bound to NTHi 
after short incubation periods. Consequently, I decided to expose mTECs to live NTHi to 
understand the effect of BPIFA1 loss on the susceptibility of mTECs to NTHi. I used live 
NTHi in my studies, as it has been suggested that live bacteria causes more biologically 
relevant immunostimulation of cells (King et al., 2008, Kirkham et al., 2013, Pizzutto et 
al., 2014). Differentiated mTECs isolated from WT and Bpifa1-/- mice were exposed to 
GFP-tagged NTHi at MOI of 200, 500, and 1000 for 1 hour and after exposure cells were 
incubated for 24, 48, and 72 hours. The sizes of bacterial inoculum and periods of cell 
exposure to NTHi were chosen based on the study by Mulay et al. (Mulay et al., 2016). 
Before washing of cell apical surfaces and fixation of cells, NTHi-exposed mTECs were 
imaged using IF microscope at 24, 48, and 72 hours post-infection (hpi) to observe the 
ability of NTHi to colonise mTECs. Bacterial colonisation was visible in WT (Figure 5.6 
A1) and Bpifa1-/- (Figure 5.6 D1) mTEC cultures exposed to GFP-tagged NTHi at MOI-
200 at 72 hpi, however the intensity of NTHi colonisation appeared to be greater in 
Bpifa1-/- mTECs. As expected, NTHi colonisation appeared higher in mTEC cultures 
exposed to NTHi at MOI-500 (Figure 5.6 B1, E1) and MOI-1000 (Figure 5.6 C1, F1) 
compared to mTECs exposed to NTHi at MOI-200 (Figure 5.6 A1, D1). Bacterial 
colonisation did not cause a substantial damaged to WT and Bpifa1-/- mTEC monolayers 
as no development of holes/gaps in mTEC cultures were observed even after 72 hours 
post-exposure (Figure 5.6 A2-F2). 
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IF images, showing GFP-tagged NTHi (green) colonisation at 72hpi in day-14 ALI WT (A1, B1, C1) and Bpifa1-/- (D1, E1, F1) mTECs with the corresponding 
phase contrast images of WT cell monolayers (A2, B2, C2) and Bpifa1-/- cell monolayers (D2, E2, F2). Scale bar: 100µm. Images were processed using 
ImageJ-win32. Data are representative of the results from three independent batches of mTECs (n=3). 
Figure 5.6: NTHi colonisation did not cause a substantial damage to the monolayer of mTECs. 
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After observing a potential difference in the bacterial colonisation intensity between WT 
and Bpifa1-/- mTECs cultured in ALI conditions, I investigated whether WT mTECs are 
more resistant to NTHi colonisation than Bpifa1-/- mTECs by measuring integrated 
intensity of green fluorescence in 3 batches of WT and Bpifa1-/- mTECs exposed to GFP-
tagged NTHi at MOI-200, MOI-500, and MOI-1000. Intensity of green fluorescence was 
measured of six fields on every membrane using ImageJ-win32 program (Figure 2.4). IF 
images of mTECs exposed to NTHi at MOI-200 suggested that WT mTECs are more 
resistant to NTHi colonisation than Bpifa1-/- mTECs (Figure 5.7 A-F). The values of green 
fluorescence integrated intensity were measured and analysed using two-way ANOVA 
with Sidak multiple comparison tests. Results showed that there was no statistically 
significant difference in the bacterial colonisation level between WT and Bpifa1-/- mTECs 
at all time points (24hpi: p=0.32; 48hpi: p=0.14; 72hpi: p=0.27) (Figure 5.7 G). However, 
a trend towards an increased NTHi colonisation in Bpifa1-/- mTECs compared to WT 
mTECs was observed (Figure 5.7 G). Data showed a great variation in NTHi colonisation 
between individual batches of mTECs. Two-way ANOVA also indicated a clear 
progression in the bacterial colonisation of NTHi-exposed mTECs from 24hpi to 72hpi 
(p=0.005).  
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IF images, showing the progression of NTHi (GFP-tagged, fluorescent green) colonisation in day-
14 ALI WT (A, B, C) and Bpifa1-/- (D, E, F) mTEC cultures at 24hpi (A, D), 48hpi (B, E), and 72hpi 
(C, F). Each panel demonstrates 2 fields at 20x magnification. Scale bar: 100µm. Images were 
processed using ImageJ-win32. The mean green fluorescence intensity in WT and Bpifa1-/- mTEC 
cultures exposed to NTHi was quantified using 20x magnification IF images. The difference in the 
mean colonisation intensity (n=3) (measured using ImageJ-win32) between WT and Bpifa1-/- 
mTECs was not statistically significant. Two-way ANOVA with Sidak multiple comparison tests 
were used to analyse the data (G) mean ± SD, n=3 individual batches of mTEC culture. Each 
black dot and black square in the graphs represent an independent batch of mTEC culture. 
Figure 5.7: Progression of bacterial colonisation in mTECs exposed to NTHi at MOI-200. 
G. 
Differentiated mTECs challenged with NTHi at MOI-200 
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Subsequently, I analysed the intensity pattern of NTHi colonisation in mTEC cultures 
exposed to NTHi at MOI-500. IF images of bacterial-exposed mTECs again suggested 
that WT mTECs are more resistant to NTHi colonisation than Bpifa1-/- mTECs (Figure 5.8 
A-F). Again, no statistically significant difference in the bacterial colonisation level 
between WT and Bpifa1-/- mTECs were detected at any time points (24hpi: p=0.44; 
48hpi: p=0.40; 72hpi: p=0.45) (Figure 5.8 G). However, a trend towards an increased 
NTHi colonisation in Bpifa1-/- mTECs compared to WT mTECs was again observed 
(Figure 5.8 G). Two-way ANOVA also indicated a clear progression in the bacterial 
colonisation of NTHi-exposed mTECs from 24hpi to 72hpi (p=0.003).  
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IF images, showing the progression of NTHi (GFP-tagged, fluorescent green) colonisation in day-
14 ALI WT (A, B, C) and Bpifa1-/- (D, E, F) mTEC cultures at 24hpi (A, D), 48hpi (B, E), and 72hpi 
(C, F). Each panel demonstrates 2 fields at 20x magnification. Scale bar: 100µm. Images were 
processed using ImageJ-win32. The mean green fluorescence intensity in WT and Bpifa1-/- mTEC 
cultures exposed to NTHi was quantified using 20x magnification IF images. The difference in the 
mean colonisation intensity (n=3) (measured using ImageJ-win32) between WT and Bpifa1-/- 
mTECs was not statistically significant. Two-way ANOVA with Sidak multiple comparison tests 
were used to analyse the data (G) mean ± SD, n=3 individual batches of mTEC culture. Each 
black dot and black square in the graphs represent an independent batch of mTEC culture. 
Figure 5.8: Progression of bacterial colonisation in mTECs exposed to NTHi at MOI-500. 
Differentiated mTECs challenged with NTHi at MOI-500 
G. 
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Bacterial colonisation intensity of mTECs exposed to NTHi at MOI-1000 at 24hpi, 48hpi, 
and 72hpi was also investigated. Again, IF images of bacterial-exposed mTECs 
appeared to suggest that NTHi colonisation was greater in Bpifa1-/- mTECs than in WT 
mTECs (Figure 5.9 A-F). However, this difference between two phenotypes was not that 
clear as it may have been in mTECs exposed to NTHi at MOI-200 (Figure 5.7 A-F) and 
MOI-500 (Figure 5.8 A-F). No statistically significant difference in the bacterial 
colonisation level between WT and Bpifa1-/- mTECs was detected (24hpi: p=0.78; 48hpi: 
p=0.53; 72hpi: p=0.83) (Figure 5.9 G). However, a trend towards an increased NTHi 
colonisation in Bpifa1-/- mTECs compared to WT mTECs was again observed at all time 
points (Figure 5.9 G). Two-way ANOVA indicated a clear progression in the bacterial 
colonisation of NTHi-exposed mTECs from 24hpi to 72hpi (p=0.001).  
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IF images, showing the progression of NTHi (GFP-tagged, fluorescent green) colonisation in day-
14 ALI WT (A, B, C) and Bpifa1-/- (D, E, F) mTEC cultures at 24hpi (A, D), 48hpi (B, E), and 72hpi 
(C, F). Each panel demonstrates 2 fields at 20x magnification. Scale bar: 100µm. Images were 
processed using ImageJ-win32. The mean green fluorescence intensity in WT and Bpifa1-/- mTEC 
cultures exposed to NTHi was quantified using 20x magnification IF images. The difference in the 
mean colonisation intensity (n=3) (measured using ImageJ-win32) between WT and Bpifa1-/- 
mTECs was not statistically significant. Two-way ANOVA with Sidak multiple comparison tests 
were used to analyse the data (G); mean ± SD, n=3 individual batches of mTEC culture. Each 
black dot and black square in the graphs represent an independent batch of mTEC culture. 
  
Figure 5.9: Progression of bacterial colonisation in mTECs exposed to NTHi at MOI-1000. 
Differentiated mTECs challenged with NTHi at MOI-1000 
G. 
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5.3.5 mTECs exhibit resistance to NTHi infection  
 
After images of NTHi colonisation in WT and Bpifa1-/- mTECs were taken, cells were 
washed to remove loosely associated bacteria with the apical surface of cells and fixed 
for immunofluorescent staining to evaluate what I considered to be bacterial infection. 
Four central fields of the filter were imaged using the confocal microscope at 10x 
magnification at 72hrs post-exposure. No clear difference in the intensity of NTHi 
infection between WT and Bpifa1-/- mTECs was observed (Figure 5.10 A-F). The data 
also suggest that deletion of Bpifa1 did not cause sudden NTHi infection of the cells. A 
seemingly inverse response of mTECs to MOI was also observed as the intensity of 
intracellular bacterial infection appeared to increase in the direction of MOI-1000 to MOI-
200. Analysis also suggested that mTECs exhibit resistance to NTHi infection as only a 
small number of fields were observed to be positive for NTHi infection at 72hrs post-
exposure. 
 175 | P a g e  
 
 
IFC images, showing patchy NTHi infection in WT mTEC culture exposed to NTHi at MOI-200 
(A1-A4), MOI-500 (B1-B4), and MOI-1000 (C1-C4). Patchy pattern of NTHi infection also 
demonstrated in IFC images of Bpifa1-/- mTEC culture exposed to NTHi at MOI-200 (D1-D4), 
MOI-500 (E1-E4), and MOI-1000 (F1-F4). Images of four central fields of the filter were taken at 
72hpi using confocal microscope at 10x magnification. Scale bar: 100µm. Data are representative 
of the results from four independent batches of WT and Bpifa1-/- mTECs. 
Figure 5.10: NTHi caused a patchy infection of WT and Bpifa1-/- mTECs. 
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I next analysed the apical secretion washes from NTHi exposure experiments to 
investigate if increasing amounts of NTHi were present over time. As the NTHi used in 
the challenge studies was GFP tagged, I used an anti-GFP antibody as a surrogate to 
detect NTHi in washes. Results showed the presence of NTHi in all apical secretion 
washes collected at 48hpi and 72hpi (Figure 5.11). Some NTHi also appeared to be 
present in the washes collected from Bpifa1-/- mTECs at 24hpi but not in the washes 
collected from WT mTECs at 24hpi. The data also suggested that the number of NTHi 
increased over time as the intensity of band was greater in apical washes collected at 
the later time points. These results suggest that the majority of bacteria observed on the 
live cells were loosely associated with the surface and not causing intracellular infection 
of mTECs.  
 
 
Results of western blotting, demonstrating the presence of NTHi in the apical secretion washes 
from WT and Bpifa1-/- mTECs. Data are representative of four independent batches of WT and 
Bpifa1-/- mTEC cultures (n=4). Both membranes were exposed for the same length of time. 
 
  
Figure 5.11: Bacteria in the apical secretion washes from mTECs exposed to NTHi. 
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Subsequently, I analysed the western blotting results using densitometry and two-way 
ANOVA with Sidak multiple comparison tests to determine if bacterial colonisation 
differed between WT and Bpifa1-/- mTECs. No statistically significant difference in the 
bacterial colonisation between two phenotypes of mTECs were detected (Figure 5.12 A-
C). However, there appeared to be a trend towards an increased amount of NTHi in the 
apical washes from Bpifa1-/- mTECs compared to WT mTECs, with exception of this 
trend being opposite at 48hpi with mTECs exposed to NTHi at MOI-500 (Figure 5.12 B) 
and MOI-1000 (Figure 5.12 C). In addition, two-way ANOVA indicated a clear 
progression in the bacterial colonisation of mTECs from 24hpi to 72hpi (MOI-200: 
p<0.0001; MOI-500: p<0.0001; MOI-1000: p=0.0004). The results from this analysis are 
similar to the results obtained from the analysis of IF images using ImageJ-win32 (Figure 
5.7-5.9).  
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NTHi in the apical washes from mTECs exposed to NTHi at MOI-200 (A), MOI-500 (B), and MOI-
1000 (C). Each black dot and black square in the graphs represent an independent batch of 
mTEC culture. Pixel density values obtained from densitometry analysis of western blotting 
membranes were analysed using two-way ANOVA with Sidak multiple comparison tests; mean ± 
SD, n=4 individual batches of mTEC culture. 
  
A. 
B. 
C. 
Figure 5.12: Bacteria in the apical washes from mTECs exposed to NTHi. 
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5.3.6 NTHi associates with multiple cell types of mouse tracheal 
epithelium 
 
I next imaged fields of WT and Bpifa1-/- mTECs positive for NTHi infection and analysed 
IFC images using ImageJ-win32 program, aiming to determine the type of cells NTHi 
associates with. First of all, I analysed NTHi-exposed mTECs stained for FOXJ1 and β-
tubulin (markers of ciliated cells: FOXJ1 – nuclear marker of ciliated cells; β-tubulin – 
marker of cilia) using confocal microscopy and ImageJ-win32. Results appeared to 
suggest that NTHi can associate with ciliated cells as some co-localisation between 
GFP-tagged NTHi and ciliated cells stained for FOXJ1 (Figure 5.13 A-B) and β-tubulin 
(Figure 5.14 A-B) was observed. However, this association was not specific as bacteria 
was also associated with non-FOXJ1 expressing cells. No clear differences were 
observed in the ability of NTHi to associate with WT and Bpifa1-/- cells. 
 
 
 
IFC images of WT mTECs (A) and Bpifa1-/- mTECs (B) exposed to NTHi at MOI-200, showing the 
ability of NTHi (GFP – green) to associate with ciliated cells (FOXJ1 – white) at 72hpi. NTHi 
association with ciliated cells is demonstrated with the red arrows. Scale bar: 50µm. Data are 
representative of two independent batches of cell culture (n=2).  
 
 
 
 
Figure 5.13: Association of GFP-tagged NTHi with ciliated cells of mTEC culture. 
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IFC images of Bpifa1-/- mTECs exposed to NTHi at MOI-200 (A) and MOI-500 (B), showing the 
ability of NTHi (GFP – green) to associate with the cilia of ciliated cells (β-tubulin – red) at 48 and 
72hpi. Z-stack images of cross sections of mTECs demonstrating the internalisation of bacteria 
within mouse tracheal epithelial cells. Examples of internalised bacteria are highlighted with red 
arrows in enlarged sections of Z-stacks. Co-localisation between NTHi and β-tubulin is seen in 
yellow. Data are representative of two independent batches of cell culture (n=2). Scale bar: 50µm. 
Figure 5.14: Association of GFP-tagged NTHi with ciliated cells of Bpifa1-/- mTEC culture. 
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Secondly, I aimed to determine whether NTHi associated with MUC5B-positive cells. I 
stained NTHi-exposed mTECs for MUC5B (a marker of the goblet cells) and analysed 
the samples using confocal microscopy and ImageJ-win32. Results suggested that NTHi 
can associate with goblet cells in Bpifa1-/- (Figure 5.15 A-B) and WT (Figure 5.16 A-C) 
cultures as some co-localisation between GFP-tagged NTHi and MUC5B-positive cells 
was observed. However, this association of NTHi with MUC5B-positive cells was not 
specific as NTHi was also associated with some non-MUC5B positive cells. No clear 
differences were observed in the ability of NTHi to associate with WT and Bpifa1-/- goblet 
cells. Having IFC images, showing a greater staining for MUC5B in NTHi-exposed 
Bpifa1-/- mTECs compared to NTHi-exposed WT mTECs, analysis of MUC5B staining 
intensity was also performed. Results showed that increased staining of MUC5B was not 
a specific feature of Bpifa1-/- cells but was a result of cell batch-to-batch variation 
(Appendix II: S9-10).   
Therefore, overall analysis of IFC images suggested that NTHi was capable of 
associating with the multiple epithelial cell types of mouse tracheal epithelium and did 
not exhibit specific preference for certain type of cells.  
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IFC images of Bpifa1-/- mTECs exposed to NTHi at MOI-200 (A) and MOI-1000 (B), showing the 
ability of GFP-tagged NTHi (GFP – green) to associate with MUC5B-positive cells (MUC5B – red) 
at 72hpi. Examples of NTHi association with goblet cells are demonstrated with white arrows. Z-
stack images of cross sections of mTECs, suggesting NTHi internalisation within mouse tracheal 
epithelial cells (examples demonstrated with black arrows in enlarged sections of Z-stacks). Data 
are representative of two independent batches of Bpifa1-/- mTECs (n=2). Scale bar: 50µm. 
Figure 5.15: Association of GFP-tagged NTHi with Bpifa1-/- MUC5B-positive cells (goblet 
cells). 
Bpifa1-/- mTECs MOI-200 72hpi 
Bpifa1-/- mTECs MOI-1000 72hpi 
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IFC images of WT mTECs exposed to NTHi at MOI-200 (A-C), showing the ability of GFP-tagged 
NTHi (GFP – green) to associate with MUC5B-positive cells (MUC5B – red) at 72hpi. Examples of 
NTHi association with MUC5B-positive cells are highlighted in white rectangles (A-B). Z-stack 
images of cross section of WT mTECs (C), suggesting NTHi internalisation within mouse tracheal 
epithelial cells (example demonstrated with black arrow in the enlarged section of Z-stack). Data 
are representative of two independent batches of WT mTEC cultures (n=2). Scale bar: A-B: 
100µm; C: 50µm.  
 
Figure 5.16: Association of GFP-tagged NTHi with WT MUC5B-positive cells (goblet cells). 
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5.3.7 NTHi exposure of mTECs affects cellular tight-junctions  
 
I next investigated whether NTHi was capable of associating with and disrupting cellular 
tight-junctions. I stained NTHi-exposed mTECs for ZO-1 (marker of cellular tight-
junctions) and analysed samples using confocal microscopy and ImageJ-win32 program. 
No apparent specific association of NTHi with cellular tight-junctions was observed 
(Figure 5.17 A-D). However, analysis of IFC Z-stacks suggested that exposure of 
mTECs to NTHi caused a disruption of cellular tight-junctions as bacteria was observed 
to get into the spaces between the cells and reach the bottom layer of the cells (Figure 
5.17 A-D). Damage to cellular tight-junctions caused by NTHi infection of mTECs was 
confirmed by analysis of IFC images using a staining for ZO-1 (Figure 5.18 A-B).  
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IFC images of Bpifa1-/- mTECs exposed to NTHi at MOI-200 (A-B) and MOI-500 (D-E), showing 
no specific association of GFP-tagged NTHi (GFP – green) with cellular tight-junctions (ZO-1 – 
red) at 72hpi. Z-stack images of cross sections of mTECs, demonstrating NTHi between the 
spaces of cells and at the bottom layer of cells. Examples of NTHi present within the gaps of cells 
and at the bottom layer of cells are demonstrated with black and white arrows. Data are 
representative of two independent batches of WT mTEC cultures (n=2). Scale bar: 50µm. 
 
 
  
Figure 5.17: NTHi did not show association with cellular tight-junctions, stained for ZO-1. 
Bpifa1-/- mTECs MOI-200 72hpi 
Bpifa1-/- mTECs MOI-500 72hpi 
 186 | P a g e  
 
 
IFC images of Bpifa1-/- mTECs exposed to NTHi at MOI-200 (A) and MOI-500 (B), showing a 
damage of tight-junctions (ZO-1 – red) at 72hpi caused by NTHi infection. Images are 
representative of the fields shown in the Figure 5.17: Image A of Figure 5.18 is corresponding 
field of Image B of Figure 5.17; and Image B of Figure 5.18 is corresponding field of Image C of 
Figure 5.17. Examples of tight-junction disruption by NTHi infection are highlighted in the white 
rectangles. Data are representative of two independent batches of WT mTEC cultures (n=2). 
Scale bar: 50µm. 
 
 
Subsequently, Z-stacks were taken using the confocal microscope to further investigate 
the ability of NTHi to cross through the layers of cells (Figure 5.19). Results showed the 
presence of NTHi throughout all layers of mTECs imaged (Figure 5.20). The observation 
of NTHi from the top to the bottom layers of cells suggested that microorganism was able 
to pass through layers of mTECs. Therefore, overall analysis suggested NTHi infection 
of mTECs damaged cellular tight-junctions and allowed the microbe to cross through the 
layers of cells. 
 
 
 
 
 
Each cross-line (black) represents a section of Z-stack (1 to 6 slices).  
Figure 5.18: NTHi infection causes a damage to cellular tight-junctions, stained for ZO-1. 
Figure 5.19: Representation of Z-stack imaging using confocal microscopy for analysis of 
NTHi crossing through the layers of mTECs. 
NTHi infection of mTECs causes a damage to cellular tight-junctions 
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Z-stack images of WT mTECs exposed to NTHi at MOI-200 (A), showing the presence of GFP-
tagged NTHi (GFP – green) from the top to the bottom layers (left to right) of cells at 72hpi. 
Images were taken at 120x magnification using confocal microscope and were processed using 
ImageJ- win32. Data are representative of two independent batches of WT mTEC cultures (n=2). 
Scale bar: 20µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20: Montage view of Z-stack sections, showing NTHi crossing through the layers 
of WT mTECs. 
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5.3.8 BPIFA1-positive cells are resistant to initial NTHi infection 
 
WT mTECs were stained for BPIFA1 to investigate whether BPIFA1-positive cells were 
susceptible to NTHi infection. BPIFA1 is produced and secreted by non-ciliated epithelial 
cells. Analysis of IFC images suggested that BPIFA1-positive cells are resistant to initial 
NTHi infection as no association or internalisation of NTHi was observed with BPIFA1-
positive cells (Figure 5.21). 
 
IFC images of WT mTECs exposed to NTHi at MOI-200 (A-D), demonstrating no association of 
GFP-tagged NTHi (green) with BPIFA1-positive cells (red) of WT mTECs at 72hpi. Z-stack 
images of cross sections of mTECs (C, D), showing no internalisation of NTHi within BPIFA1-
positive cells. Data are representative of two independent batches of mTECs (n=2). Scale bar: A-
B: 100µm; C-D: 20µm. 
 
 
Figure 5.21: Lack of association of NTHi with BPIFA1-positive cells. 
 189 | P a g e  
 
5.3.9 Secretion of BPIFA1 by mTECs exposed to NTHi 
 
Analysis of IFC images suggested that BPIFA1-positive cells were resistant to initial 
NTHi infection. Consequently, I decided to find out whether the secretion of BPIFA1 was 
affected after mTEC exposure to NTHi. Apical secretions collected from MOCK-infected 
and NTHi-challenged WT mTECs at 24, 48, and 72 hpi were analysed for BPIFA1 
secretion using dot blotting. The membrane of the dot blot was probed with anti-mouse 
BPIFA1 antibody. Analysis was performed using densitometry and the two-way ANOVA 
with Sidak multiple comparison tests were used to compare secretion of BPIFA1 by 
MOCK-infected and NTHi-exposed mTECs (Figure 5.22 A-C). Secretion of BPIFA1 was 
significantly reduced in mTEC culture exposed to NTHi at MOI-1000 at 72hpi compared 
to MOCK-infected mTECs (p=0.04). No statistically significant differences were detected 
at other time points, however, the trend towards the reduced secretion of BPIFA1 by 
mTECs exposed to NTHi was observed at all incubation time points (Figure 5.22 A-C). 
The figure showing dot blot results can be found in Appendix II (S11). A variability in 
secretion of BPIFA1 by different batches of WT mTECs was also observed (Appendix II: 
S11).   
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Secretion of BPIFA1 by WT mTECs challenged with NTHi at MOI-200 (A), MOI-500 (B), and 
MOI-1000 (C) was compared to the secretion of protein by MOCK-infected mTECs at 24, 48, and 
72hpi. The difference in the secretion of BPIFA1 by MOCK-infected mTECs at 72hpi and mTECs 
exposed to NTHi at MOI-1000 at 72hpi was statistically significant (p=0.04). Each black dot and 
red square in the graphs represent an independent batch of mTEC culture. Data was analysed 
using two-way ANOVA with Sidak multiple comparison tests. *p<0.05; mean ± SD, n=4 individual 
batches of mTEC culture. 
 
  
Figure 5.22: BPIFA1 secretion by NTHi-challenged WT mTECs. 
A. 
B. 
C. 
* 
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5.3.10 NTHi exposure affects expression of Bpifa1 and Tekt1  
 
Having results, suggesting that BPIFA1-positive cells were more resistant to NTHi 
infection than other cells and that secretion of BPIFA1 by mTECs was reduced after 
NTHi exposure, I decided to investigate whether Bpifa1 expression was also affected 
after NTHi challenge at 24 and 48 hours post-exposure. The PCR results suggested that 
NTHi slightly influenced the expression of Bpifa1 as some down-regulation was observed 
in mTECs exposed to NTHi compared to MOCK-infected mTECs (Figure 5.23). 
However, a clear variation among the batches of WT mTECs was also detected. 
Expression of Oaz1 was assessed in all batches of the cells and used as a 
housekeeping gene in all PCR reactions. 
PCR results, suggesting that NTHi exposure influences expression of Bpifa1 by WT mTECs as 
some slight down-regulation of Bpifa1 expression was observed. Variation among the batches of 
WT mTECs was also observed. Data are representative of PCR results from four independent 
batches of WT mTEC cultures (n=4). 
 
 
I also assessed the expression of Tekt1, a marker for ciliated cells, to investigate if it was 
affected after bacterial exposure. Data showed that NTHi influenced Tekt1 expression 
with down-regulation being observed at 24 hours post-exposure. However, variability 
among the samples was seen (Figure 5.24). I also looked at the expression of Ltf, which 
Figure 5.23: NTHi exposure appears to influence Bpifa1 expression in WT mTECs. 
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is a component of the immune system and exhibits antimicrobial activity. NTHi caused 
no obvious change in the Ltf expression (Figure 5.24). Expression of Oaz1 was used as 
a housekeeping gene in all PCR reactions.  
 
Expression of the upper airway epithelium specific genes by NTHi- and MOCK-exposed WT and 
Bpifa1-/- mTEC cultures at 24 hours post-challenge. Data are from four independent batches of 
Bpifa1-/- and WT mTEC cultures (n=4). 
 
 
Figure 5.24: mTEC gene expression induced by NTHi at 24hpi. 
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5.3.11 Cytokine and chemokine production by NTHi exposed mTECs 
 
Apical secretion washes collected from mTEC cultures challenged with NTHi were 
pooled (n=4) and analysed using Mouse Cytokine Array Panel A to determine whether 
the immune response to NTHi differed between WT and Bpifa1-/- mTECs. For this 
analysis, I decided to compare the levels of signalling molecules released 72 hours after 
exposure to NTHi at MOI-1000. The results show that NTHi-challenge induced a release 
of immune mediators from both WT (Figure 5.25) and Bpifa1-/- (Figure 5.26) mTECs. 
Levels of signalling molecules released by MOCK-exposed mTECs were used to 
establish basal levels.  
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Apical secretion washes from four independent batches of WT mTECs were pooled and used for 
analysis. Immune mediators released by cells exposed to NTHi (MOI-1000) and MOCK-
challenged cells at 72 hours post-challenge.  
  
Figure 5.25: Cytokine array analysis of signalling molecules released by NTHi-exposed WT 
mTECs. 
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Apical secretion washes from four independent batches of Bpifa1-/- mTECs were pooled and used 
for analysis. Immune mediators released by Bpifa1-/- cells exposed to NTHi (MOI-1000) and 
MOCK-exposed cells at 72 hours post-challenge.  
Figure 5.26: Cytokine array analysis of signalling molecules released by NTHi-exposed 
Bpifa1-/- mTECs. 
Bpifa1-/- MOI-1000 72hpi 
Bpifa1-/- MOCK 72hpi 
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The data was analysed by densitometry and graphs were plotted using GraphPad Prism. 
Levels of signalling molecules released by WT and Bpifa1-/- mTECs exposed to NTHi at 
MOI-1000 were compared after 72 hours post-challenge. Analysis of the results showed 
that secretion of variety of immune mediators by NTHi-exposed WT mTECs was induced 
(Figure 5.27 A). The same pattern was observed in Bpifa1-/- mTECs (Figure 5.27 B). 
Differences in the immune response generated by NTHi-exposed WT and Bpifa1-/- 
mTECs were assessed to determine whether the absence of BPIFA1 had an impact on 
the immune defences against microorganism (Figure 5.28). Analysis of results revealed 
no differences in the overall secretion of immune mediators by WT and Bpifa1-/- mTECs 
in response to NTHi challenge. Similar production of IL-7 and CXCL12 was observed by 
both types of mTECs. Secreted levels of IL-1α and IFN-γ cytokines by both type of cells 
were not high compared to the levels of other pro-inflammatory cytokines such as IL-6 
and TNF-α. WT mTECs also generated slightly greater amounts of G-CSF and GM-CSF 
compared to NTHi-exposed Bpifa1-/- mTECs but produced levels of M-CSF were slightly 
lower in WT mTECs. CXCL1 and CXCL2 chemokines were produced by both types of 
mTECs in the greatest levels compared to the levels of all other signalling molecules 
released by mTECs in response to NTHi. Up-regulation in the production of CCL1, 
CCL2, and CCL5 was observed in both types of NTHi-exposed cells. TIMP-1 and CD54 
production was also up-regulated in both types of NTHi-exposed mTECs. However, up-
regulation of these immune mediators was small in NTHi-exposed WT mTECs compared 
to the basal levels produced in MOCK-infected WT mTECs. Overall produced levels of 
TIMP-1 and CD54 were slightly greater in NTHi-exposed Bpifa1-/- mTECs compared to 
NTHi-exposed WT mTECs.  
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Results of Mouse Cytokine Array Panel A, showing a generation of immune response by WT (A) 
and Bpifa1-/- (B) mTECs exposed to NTHi (MOI-1000) after 72 hours post-challenge. The levels of 
signalling molecules released by MOCK-exposed mTECs were used as the basal levels. Apical 
secretion washes from four individual mTEC batches were pooled. Mouse cytokine array was 
performed once (n=1). 
 
Figure 5.27: Comparison of immune mediators released by NTHi-exposed mTECs (MOI-
1000). 
Bpifa1-/- MOCK 72hpi vs MOI-1000 72hpi 
WT MOCK 72hpi vs MOI-1000 72hpi A. 
B. 
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Results of Mouse Cytokine Array, showing amounts of signalling molecules released by WT and 
Bpifa1-/- mTECs exposed to NTHi (MOI-1000) after 72 hours post-challenge. Apical secretion 
washes from four individual batches of cell cultures were pooled. Mouse cytokine array was 
performed once (n=1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.28: Comparison of the levels of immune mediators released by NTHi-exposed WT 
and Bpifa1-/- mTECs (MOI-1000) after 72 hours post-challenge. 
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5.4 Discussion  
 
5.4.1 mTEC cultures replicate an upper airway-like epithelium 
 
For this study, I dissected tracheal tissues from WT and Bpifa1-/- mice, isolated mTECs, 
and differentiated these in the ALI culture for 14 days. I decided to use mTEC model in 
this study as it was shown to mimic in vivo host airway epithelium and its 
microenvironment. The methods for dissection of tracheas and growth of cells were 
adapted from the study by You et al. (You et al., 2002). These methods were previously 
established in our laboratory (Akram et al., 2018). I successfully applied these methods 
and differentiated mTECs to generate an upper airway-like epithelium. Differentiation of 
cells was verified using light and confocal microscopy techniques, PCR, and western 
blotting. The expression of airway epithelial markers such as MUC5B, FOXJ1, β-
TUBULIN, BPIFA1, ZO-1 was analysed in the samples of differentiated mTEC cultures 
using confocal microscopy. MUC5B is known as a marker of goblet cells (Roy et al., 
2014, Thai et al., 2008), whereas FOXJ1 and β-TUBULIN are the markers of ciliated 
cells (Eenjes et al., 2018, Jain et al., 2010, Stewart et al., 2012). BPIFA1 is characterized 
as marker of non-ciliated secretory cells (Musa et al., 2012), whereas ZO-1 is the marker 
of cellular tight-junctions (Eenjes et al., 2018, Stewart et al., 2012). Detection of the 
expression of all these epithelial markers in mTEC cultures confirmed the differentiation 
of cells in the upper airway-like epithelium. No obvious differences were observed in the 
expression of these epithelial markers between WT and Bpifa1-/- mTECs. In addition, 
secretion of BPIFA1 by differentiated WT mTECs was confirmed by western blotting as 
was Bpifa1 expression by PCR. I also detected Tekt1 (marker of ciliated cells) 
expression in WT and Bpifa1-/- mTEC cultures using PCR and did not observed any 
differences in the expression pattern between two different populations of the cells. After 
verification of differentiation of the WT and Bpifa1-/- mTEC cultures into the upper airway-
like epithelium, I exposed both types of cells to NTHi to determine the effect of BPIFA1 
loss on the susceptibility of cells to bacterium. 
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5.4.2 Bpifa1-/- deficiency does not cause increased NTHi colonisation  
 
In this study, I investigated the effect of BPIFA1 loss on the susceptibility of mTECs to 
NTHi colonisation. My data showed a great variation in NTHi colonisation between 
individual batches of mTECs. As determined by GFP fluorescence, there was no 
statistically significant difference in the bacterial colonisation between WT cells and 
Bpifa1-/- cells. However, a trend towards increased NTHi colonisation in Bpifa1-/- mTECs 
was observed. When GFP-tagged NTHi in the apical washes was detected by western 
blotting, the data again showed a trend towards increased bacterial colonisation in 
Bpifa1-/- mTECs compared to WT mTECs. My data was variable using these two 
different experimental techniques. Other types of methods providing more quantitative 
analysis of samples or different type of the cells (e.g. non-primary cells) may be required 
to be used in the future studies to obtain more accurate and detailed results.  
The absence of BPIFA1 may impair airway epithelial homeostasis and cause alterations 
in the composition of ASL leading to increased susceptibility of the cells to NTHi 
colonisation ( Chu et al., 2007, Garland et al., 2013, Liu et al., 2013b, McGillivary and 
Bakaletz, 2010, Mulay et al., 2018). In previous studies, BPIFA1 was shown to be 
important for the mucosal homeostasis of the upper respiratory tract and its absence in 
airway secretions in the presence of bacterial stimulus or inflammation was reported to 
cause the progression of Otitis media and reduce mucociliary clearance in the ET 
(McGillivary and Bakaletz, 2010, Mulay et al., 2018). Detection of NTHi within the mucus 
layer of mTECs was expected because NTHi is a mucosal pathogen capable of binding 
to the mucus. Interactions of NTHi with mucus of respiratory epithelium has been 
reported in previous studies that showed that mucins secreted by mouse and human 
airway epithelium bound to NTHi (Kubiet and Ramphal, 1995, Read et al., 1991, Reddy 
et al., 1996, Val et al., 2015). In addition, previous studies showed that BPIFA1 is able to 
associate with mucins and form multimolecular complexes (Kesimer et al., 2013, 
Radicioni et al., 2016). On this basis, I suggest that BPIFA1 may form complexes with 
mucins and provide initial protection for mTECs by acting against NTHi in the mucus gel 
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layer. This feature of innate defence against NTHi was reduced in the cultures lacking 
BPIFA1. Consequently, bacterial colonisation showed a trend towards an increase in 
Bpifa1-/- mTECs compared to WT mTECs. It is also possible that absence of BPIFA1 
altered viscoelasticity of mucus and surface tension in mTEC culture, leading to 
intensified NTHi colonisation in Bpifa1-/- cells. Previous studies reported that the loss of 
BPIFA1 was associated with increased surface tension, allowing greater bacterial biofilm 
formation on the apical surfaces of epithelial cells (Liu et al., 2013a, Liu et al., 2013b). It 
may also explain the observed trend towards an increased NTHi colonisation in Bpifa1-/- 
compared to WT cells. BPIFA1 deficiency may also alter viscoelasticity of mucus 
because the absence of BPIFA1 is associated with impaired ENaC function, causing an 
increase in the absorption of ASL and dehydration of mucus (Garcia-Caballero et al., 
2009, Garland et al., 2013). Altered biophysical properties and viscoelasticity of mucus 
may be other factors contributing to the trend towards increased NTHi colonisation in 
Bpifa1-/- cells compared to WT cells. However, the suggestion that loss of BPIFA1 is 
associated with a change in viscoelasticity of mucus requires further investigation.  
I also observed that secretion of BPIFA1 reduced when WT mTECs were exposed to 
larger bacterial inoculum. Secretion of BPIFA1 was the most reduced in WT mTECs 
exposed to NTHi at MOI-1000. Expression of Bpifa1 was also affected in NTHi 
challenged mTECs. It seems likely that the larger bacterial inoculum generated a greater 
inflammatory response compared to mTECs challenged with a smaller number of 
bacterial cells (MOI-200). Enhanced release of inflammatory mediators into the apical 
secretions could down-regulate expression of Bpifa1 (Chu et al., 2007, Wei et al., 2014) 
which, in turn, leads to decreased secretion of BPIFA1, meaning that mucosal 
homeostasis of tracheal epithelium was impaired. Impaired mucosal homeostasis within 
tracheal epithelium could allow NTHi to multiple and colonise a larger area of epithelial 
cells. These data suggest that BPIFA1 may play an initial role in the host defence 
against NTHi, but once mucosal homeostasis of airway epithelium is impaired, other 
mechanisms of the immune system are required to clear bacteria from the airways. 
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Reduced levels of BPIFA1 secretion in the BAL fluid of WT mice after bacterial exposure 
have been reported (Britto et al., 2013, Jiang et al., 2013).  
Therefore, this work suggests that BPIFA1 may play a role in the innate protection 
against NTHi and mTECs appear to be more susceptible to NTHi colonisation in the 
absence of BPIFA1. NTHi colonisation is important for the initiation of tissue infection as 
it allows the formation of stable and persistent bacterial communities which are able to 
cross the mucus layer and cause infection of epithelial cells (Clementi and Murphy, 
2011, Marrazzo et al., 2016). 
 
5.4.3 NTHi causes a patchy infection of mTECs 
 
In this study, I observed that mTECs exposed to NTHi were not readily infected and 
infection displayed a patchy pattern and did not depend on the bacterial inoculum size. 
My findings are similar to results reported in the study by Read et al., which showed that 
NTHi caused an infection of human nasopharyngeal mucosa organ culture, ranging from 
mild and patchy to severe (Read et al., 1991). However, in contrast to my work, severe 
epithelial disruption was also observed in this study. These differences could arise from 
different cell culture model, bacterial inoculum size, and type of NTHi strain used. The 
period of cell exposure to NTHi also could cause a great difference. I exposed mTECs to 
NTHi for 1 hour and non-adherent bacteria were washed off after incubation, whereas 
Read et al. exposed human nasopharyngeal mucosal organ cultures to NTHi for 24hrs 
and only after 24hrs were non-adherent bacteria washed off (Read et al., 1991). In 
addition, another study examining ability of NTHi to cross cell layers of 3D human airway 
mucosa cell culture did not report high infectivity of NTHi and only showed bacterial 
ability to associate with the mucus layer of cells and cross the layers of cells (Marrazzo 
et al., 2016). This study exposed human airway mucosal cell culture to NTHi for 2hrs and 
this period of bacterial exposure is similar to the bacterial exposure time used in my 
study. I chose the sizes of bacterial inoculum and periods of cell exposure to NTHi 
according to the study by Mulay et al., which challenged mouse middle ear epithelial 
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cells with GFP-tagged NTHi 375 strain and showed that exposure of epithelial cells to 
NTHi at MOI-100 resulted in the gradual progression of infection over the period from 
24hrs to 72hrs post-exposure (Mulay et al., 2016). However, I was unable to see similar 
results and these differences may be associated with the type of cells used in my study. 
Mouse tracheal epithelial cells may be more resistant to NTHi strain 375 than mouse 
middle ear epithelial cells and different strains of NTHi should be used in the future to 
determine whether they could cause a greater tracheal epithelial infection. 
 
5.4.4 BPIFA1 may contribute to the maintenance of airway mucosal 
homeostasis and provide an initial defence for cells against NTHi  
 
BPIFA1 is secreted into apical secretions and its presence in the secretions of airway 
epithelial cells has been shown to be important for mucosal homeostasis within the 
airway surface microenvironment (McGillivary and Bakaletz, 2010, Mulay et al., 2018). In 
this study, I observed the trend towards increased bacterial colonisation in Bpifa1-/- 
mTEC cultures compared to WT mTEC cultures and BPIFA1-positive cells appeared to 
be less susceptible to NTHi invasion than other types of epithelial cells. I speculate that 
BPIFA1 is able to provide an initial protection for mTECs against NTHi by contributing to 
the maintenance of mucosal homeostasis of tracheal epithelium and directly binding to 
bacteria. As mentioned before, BPIFA1 can associate with mucins and form complexes 
(Kesimer et al., 2013, Radicioni et al., 2016), which may provide an initial protection for 
epithelial cells by acting against NTHi in the mucus gel layer. I suggest that bacterial 
cells which were able to cross the mucus layer into periciliary liquid, may be directly 
confronted by BPIFA1. My bacterial pull-down data has shown that mouse BPIFA1 can 
bind to NTHi, which may mean that BPIFA1 is able to exhibit its antimicrobial properties 
against the microorganism once protein is bound to it. Number of different studies 
reported BPIFA1’s ability to exhibit antimicrobial properties against bacterial pathogens 
(Ahmad et al., 2016, Chu et al., 2010, Gakhar et al., 2010, Gally et al., 2011, Sayeed et 
al., 2013, Walton et al., 2016, Zhou et al., 2008). In this study, the mechanisms used by 
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mouse BPIFA1 to bind to NTHi were not directly studied, but I postulate that sialic acid 
residues found on postranslationally modified BPIFA1 as reported in the work by 
Ghafouri et al. (Ghafouri et al., 2006), may enable the binding of the protein to the 
bacterium. In addition, the importance of sialic acid residues in the binding to 
microorganisms was reported in the study by Reddy et al., which showed that sialic acid-
containing oligosaccharides of mucins were responsible for the mucins ability to interact 
with NTHi (Reddy et al., 1996). It was demonstrated that these mucins specifically bound 
to several NTHi outer membrane proteins. Therefore, I suggest that mouse BPIFA1 may 
use the same mechanisms to interact with NTHi as mucins containing sialic acid 
residues. Investigation of this hypothesis should be addressed in future studies. 
In this study, I also showed that epithelial cells positive for BPIFA1 appeared to be less 
susceptible to NTHi invasion as no association of bacterium with BPIFA1 positive cells 
was observed. I postulate that NTHi invasion into BPIFA1 positive cells was prevented 
by the protein’s antimicrobial properties. BPIFA1 has been demonstrated to exhibit 
antimicrobial properties against multiple bacterial pathogens, including P. aeruginosa, M. 
pneumoniae, and B. cepacia. BPIFA1 has the ability to inhibit the growth of bacteria and 
the formation of bacterial biofilms (Ahmad et al., 2016, Chu et al., 2010, Gally et al., 
2011, Gakhar et al., 2010, Liu et al., 2013b, Sayeed et al., 2013, Zhou et al., 2008). To 
test the hypothesis that BPIFA1 is able to prevent the initial entry of the pathogens to the 
cells, a stable cell line expressing BPIFA1 and control cell line negative for BPIFA1 could 
be exposed to the bacterial pathogen and the ability of the bacteria to cause an 
intracellular infection over the time could be evaluated. Data from the such type of 
experiment may provide some important information about BPIFA1’s biological functions. 
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5.4.5 NTHi associates with the multiple cell types of mouse tracheal 
epithelium 
 
In this study, NTHi appeared to associate with the multiple cell types of mouse tracheal 
epithelium. My data suggested that NTHi was capable of attaching to ciliated, goblet 
cells, and other unidentified type of secretory cells.  
Some association of NTHi with ciliated cells was observed in both phenotypes of mTEC 
cultures, but no apparent differences in the ability of NTHi to adhere to WT and Bpifa1-/- 
ciliated cells was observed. NTHi has been reported to cause the clumping of cilia and 
loss of cilia in human respiratory epithelium  (Ketterer et al., 1999, Read et al., 1991). In 
addition, heat-stable lipid A of NTHi lipooligosaccharide was shown to reduce cilia 
activity, cause disorganisation of cilia, and loss of cilia in the rat tracheal organ cultures 
(Denny, 1974, Johnson and Inzana, 1986). NTHi surface-exposed lipoprotein, known as 
protein D, was also reported to cause the impairment of ciliary function and the 
considerable loss of cilia in the organ culture of human nasopharyngeal mucosa (Janson 
et al., 1999). Therefore, these findings suggest that the function of cilia may be 
weakened by exposure to NTHi, which would eventually increase a susceptibility of 
ciliated cells to NTHi. The binding of NTHi to structurally damaged epithelial cells in vitro 
was reported in a study which also showed that NTHi was not able to associate with 
normal respiratory epithelium (Read et al., 1991). In addition, my data showed that NTHi 
exposure of mTECs caused a reduction in Tekt1 expression (marker of ciliated cells). 
This may be caused by both NTHi and inflammatory response generated by mTECs. 
Therefore, it appears that different types of mechanisms can predispose ciliated cells to 
NTHi infection.  
In this study, I also observed some association of NTHi with the patches of goblet cells 
(MUC5B-positive cells). This seemed not to be influenced by the absence of BPIFA1 as 
NTHi adherence to the goblet cells was observed in both WT and Bpifa1-/- mTEC 
cultures. Several studies showed NTHi invasion within human non-ciliated epithelial cells 
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(St Geme and Falkow, 1990, Ketterer et al., 1999, van Schilfgaarde et al., 1995). 
However, none of these studies identified a type of non-ciliated cells being affected by 
NTHi. Here, I suggest that one type of non-ciliated cell affected by NTHi was goblet cells. 
However, it was obvious that another type of unidentified, non-ciliated cell was also 
infected with NTHi and these non-ciliated cells appeared to be more susceptible to NTHi. 
Consequently, identification of these other types of non-ciliated epithelial cells should be 
determined in the future investigations. In this study, I did not analyse the mechanisms 
used by NTHi to enter epithelial cells, but previous studies suggested that NTHi uses 
micropinocytosis and microfilament-dependent processes to invade non-ciliated 
epithelial cells (St Geme and Falkow, 1990, Ketterer et al., 1999). 
Overall, data from this study suggested that NTHi associates with the multiple cell types 
of mouse tracheal epithelium in order to initiate infection. My results also suggested that 
BPIFA1-positive non-ciliated secretory cells are more resistant to initial NTHi infection 
compared to the other types of mTEC cells. Based on the existing evidence, showing 
that internalised NTHi can survive within cells over extended period and remain intact (St 
Geme and Falkow, 1990, Virji et al., 1991), I suggest that NTHi invades epithelial cells to 
avoid host defence responses and enhance the spread of infection.  
 
5.4.6 NTHi infection causes a disruption of cellular tight-junctions  
 
Immunofluorescence analysis of NTHi-exposed mTECs revealed the presence of 
bacterial cells between Bpifa1-/- and WT mTECs, suggesting that BPIFA1 did not 
influence ability of bacteria to penetrate the tracheal epithelium. However, the time taken 
by bacteria to cross the tracheal epithelium in the presence and absence of BPIFA1 was 
not measured in this study and could be investigated in the future. Confocal microscopy 
Z-stack data showed that NTHi was able to cross through the apical layer of cells and 
reach the bottom layer cells. In agreement with my findings, NTHi has been shown to 
cross through human airway epithelium in vitro (Marrazzo et al., 2016, van Schilfgaarde 
et al., 1995). Additionally, it was demonstrated that the ability of NTHi to cross the 
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epithelium in vitro was not influenced by fimbriae or other bacterial adhesins promoting 
adherence, but it was dependant on bacterial protein synthesis (van Schilfgaarde et al., 
1995).  
The ability of NTHi to enter the spaces between mTECs should protect the bacteria from 
the host defence responses and facilitate bacterial spreading. I suggest that NTHi 
exposure of mTECs caused a dysfunction of epithelial barrier allowing bacteria to cross 
the apical surface of cells and reach the basolateral layer. In contrast, van Schilfgaarde 
et al. showed that NTHi crossed airway epithelium into basolateral compartment without 
causing a death of cells and disrupting integrity of epithelium (van Schilfgaarde et al., 
1995). In addition, another study also demonstrated that the exposure of HBEC culture 
to NTHi endotoxin did not increase permeability of the cells (Khair et al., 1994). However, 
my data showed that NTHi exposure caused an alteration in ZO-1 staining in mTEC 
cultures, suggesting that cellular tight-junctions and integrity of murine tracheal 
epithelium were disrupted. I speculate that an inflammatory response generated by 
tracheal epithelium to NTHi led to this disruption of cellular tight-junctions. The presence 
of inflammatory mediators in the microenvironment of epithelium has previously been 
reported to affect epithelial barrier by increasing its permeability and altering the 
expression of epithelial junctional proteins (Al-Sadi et al., 2009, Capaldo and Nusrat, 
2009, Georas and Rezaee, 2014, Ramezanpour et al., 2016). My data showed that NTHi 
exposure of mTECs induced a great release of cytokines such as: CXCL1, CXCL2, IL-6, 
and TNF-α. The secretion of these inflammatory mediators by mTECs to NTHi could 
affect epithelial barrier function. It has been reported that human IL-8/CXCL8, which is 
related to murine CXCL1 and CXCL2 molecules, plays a role in the regulation of 
epithelial barrier (Capaldo and Nusrat, 2009, Mukaida, 2003, Sorrentino et al., 2008). In 
the study by Sorrentino et al., it has been shown that addition of CXCL8 to epithelial cell 
line A549 culture caused an increased permeability of epithelial cell monolayer 
(Sorrentino et al., 2008). Interleukin-6 has also been found to control epithelial barrier 
function by causing alterations in the permeability of epithelium and reducing 
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transepithelial electrical resistance (Al-Sadi et al., 2009, Capaldo and Nusrat, 2009). The 
presence of TNF-α in the microenvironment of epithelium also causes a barrier 
dysfunction by reducing transepithelial resistance, impairing the function of cellular tight-
junctions, and increasing epithelial tight-junction permeability (Al-Sadi et al., 2009, Brune 
et al., 2015, Capaldo and Nusrat, 2009, Coyne et al., 2002, Georas and Rezaee, 2014). 
Therefore, the inflammatory response generated by mTECs to NTHi may disrupt 
epithelial barrier function. I did not determine whether tracheal epithelial permeability and 
transepithelial electric resistance were affected by exposure to NTHi, but these two 
measurements could be defined in the future studies. For example, the change in the 
permeability of epithelium could be determined by measuring epithelial permeability to 
both a small solute (e.g. 10-kDa dextran) and a larger solute (e.g. 2000-kDa dextran), or 
to sodium and chloride ions. Localisation of other epithelial junctional proteins such as 
claudin, occludin, and junctional adhesion molecule could also be investigated to obtain 
more detailed results. 
 
5.4.7 WT and Bpifa1-/- mTECs generated a similar inflammatory 
response after exposure to NTHi 
 
Inflammatory response generated at 72 hours post-challenge by Bpifa1-/- mTECs was 
similar to inflammatory response induced by WT mTECs. However, I observed that 
Bpifa1-/- mTECs potentially released slightly greater amounts of major pro-inflammatory 
cytokines such as IL-6, TNF-α, CXCL1, and CXCL2. I suggest that WT mTECs may be 
better in controlling inflammatory response to NTHi than Bpifa1-/- mTECs. However, this 
requires further investigation using more quantitative methods. The release of 
inflammatory mediators by mTECs challenged with NTHi could be examined at the 
shorter bacterial exposure times. Further analysis of inflammatory response generated 
by mTECs to NTHi in the presence and absence of BPIFA1 would be of great interest as 
there is a possibility that release of inflammatory mediators would differ more at 24 and 
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48 hours post-exposure. This suggestion is supported by the study showing that the 
levels of pro-inflammatory cytokines (e.g. CXCL1, IL-6, IL-1β, CXCL2) were greater in 
the response to P. aeruginosa challenge in the absence of BPIFA1 at 6 and 24 hours 
post-inoculation (Liu et al., 2013b). Suggestion that BPIFA1 plays a role in regulating 
inflammatory response to NTHi is also supported by other studies demonstrating 
immunodulatory properties of BPIFA1 in M. pneumoniae and P. aeruginosa infections 
(Chu et al., 2007, Lukinskiene et al., 2011). 
In this study, I showed that NTHi exposure activated mTECs and induced the 
inflammatory response. I observed an up-regulation in the release of inflammatory 
mediators such as CXCL1, CXCL2, IL-6, TNF-α, M-CSF, G-CSF, and GM-CSF by NTHi-
exposed mTECs compared to MOCK-exposed mTECs. My observation of CXCL1, 
CXCL2, IL-6, and TNF-α production in response to NTHi is in accordance with other 
studies (Bresser et al., 1997, Clemans et al., 2000, Khair et al., 1994). Chemokines 
CXCL1 and CXCL2 are known as the murine homologues of human IL-8 and are 
mediators of neutrophil activation and chemotaxis (Hol et al., 2010, Khair et al., 1996, 
Turner et al., 2014). Based on this evidence, I suggest that mTECs released these 
chemokines to recruit neutrophils to the site of infection to aid in the fight against the 
spread of NTHi and eliminate bacterial cells from airway epithelium. Secretion of IL-6 
and TNF-α in response to NTHi is mediated through TLR2. Previous studies showed that 
NTHi binds to TLR2 and this leads to activation of NF-κB signalling cascade which, in 
turn, mediates induction of IL-6 and TNF-α (King and Sharma, 2015, Liu et al., 2017, 
Lugade et al., 2011). TNF-α is an early response pro-inflammatory cytokine and plays an 
important role in the clearance of bacterial pathogens from the respiratory tract as it 
mediates recruitment of polymorphonuclear cells through regulation of CXC chemokines 
which stimulate migration of inflammatory cells to the site of inflammation (Strieter et al., 
2002). Production of IL-6 by NTHi-exposed mTECs could also be induced by release of 
TNF-α. This suggestion is supported by the study showing that levels of IL-6 mRNA in 
HBECs increased after stimulation with TNF-α (Cromwell et al., 1992). Furthermore, it 
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also explains the observation of slightly higher IL-6 production by Bpifa1-/- mTECs 
compared to WT mTECs, because Bpifa1-/- mTECs released slightly more TNF-α than 
WT mTECs. IL-6 may play a multifunctional role in response to NTHi as it can function 
as pro-inflammatory or anti-inflammatory cytokine. IL-6 as pro-inflammatory cytokine is 
involved in the transition from innate immunity response to adaptive immunity response 
as it induces a differentiation of B-cells and T-cells and activates Natural Killer cells 
(Keller et al., 1996). However, IL-6 can also function as anti-inflammatory cytokine by 
down-regulating production of pro-inflammatory cytokines such as IFN-γ, TNF-α, CXCL2, 
and GM-CSF and in such manner contributes towards resolution of inflammation (Opal 
and DePalo, 2000). 
Exposure of mTECs to NTHi led to up-regulation of GM-CSF and G-CSF pro-
inflammatory cytokines which are involved in activation of polymorphonuclear cells, 
dendritic cells and monocytes and promote survival of these immune cells by inhibiting 
apoptosis (Saba et al., 2002). In addition, study by LeVine et al. demonstrated that GM-
CSF plays an important role in bacterial infection as mice deficient for GM-CSF were 
shown to be significantly more susceptible to group B streptococcal infection compared 
to WT mice (LeVine et al., 1999). NTHi-challenged mTECs also up-regulated production 
of M-CSF compared to basal levels produced by their respective MOCK controls and this 
suggested that M-CSF may have an essential role in fighting against NTHi infection. My 
suggestion is supported by the evidence showing the importance of M-CSF in Gram-
negative bacterial pneumonia as immunoneutralisation of M-CSF in mice caused 
increased bacterial burden, greater lung injury, and reduced survival (Bettina et al., 
2016). 
It is also worth to mention the up-regulation in CD54/ICAM-1 by NTHi-exposed mTECs 
compared to basal levels produced by MOCK-exposed mTECs. Production of CD54 
increased slightly more from basal levels in NTHi-exposed Bpifa1-/- mTECs compared to 
WT mTECs. This may be a result of a slightly greater production of CXCL1, CXCL2, and 
TNF-α by NTHi-exposed Bpifa1-/- mTECs compared to NTHi-exposed WT mTECs. CD54 
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is an intercellular adhesion molecule produced by airway epithelial cells and plays an 
important role in inflammatory response as it allows adhesion of neutrophils to epithelial 
cells (Gómez and Prince, 2008). Importance of CD54 in NTHi infection was 
demonstrated in the study by Pang et al., showing that reduced levels of CD54 in mice 
model of COPD resulted in significantly decreased pulmonary clearance of NTHi (Pang 
et al., 2008). 
Taking all results into consideration, I suggest that the mTEC model responds to NTHi 
stimulation in the manner of native respiratory tract, as secretion of TNF-α, IL-6, and IL-8 
(human homologue for murine CXCL1 and CXCL2) in response to NTHi challenge 
correlates with previously published in vivo studies (Moghaddam et al., 2008, Singh et 
al., 2014). This makes the mTEC model valuable for studying the mechanisms of NTHi 
infection. Additionally, I suggest that earlier inflammatory responses generated by 
mTECs in response to NTHi stimulus should be studied to obtain a better insight of the 
effect of BPIFA1 absence on immune response to bacterial challenge. 
 
5.4.8 Variation in the batches of mTECs 
 
In this study, my results were influenced by mTEC batch-to-batch variation. I observed 
differences in the expression of epithelium-specific genes, production and secretion of 
proteins, and intensity of NTHi infection among the batches of mTECs. Primary cell 
cultures are well known to exhibit variability among different batches of cells and 
sometimes to provide inconsistent results. Variation in the batches of primary cell 
cultures can be caused by the multiple factors. One of the major factors influencing a 
variation in batches of cells in my study was adherence of certain type of cells after 
seeding. I detected that only a small portion of seeded cells was able to attach to the 
transwell membrane and later to proliferate and differentiate in the upper airway-like 
epithelium. Consequently, the composition of day-14 ALI tracheal epithelium was highly 
dependent on the cells which adhered to the membrane after seeding. This means that 
proportion of various types of cells such as goblet cells, ciliated cells and secretory cells 
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could be different in each batch and even well of mTECs, leading to the differences in 
the levels of airway epithelial markers expressed and proteins produced. Based on this, I 
speculate that variation in the composition of mTEC epithelium could also cause 
differences in the intensity of NTHi infection among the batches and wells of mTECs. A 
second major factor causing a variability among the batches of cells is the growth media. 
The media used was optimised to promote the growth and differentiation of tracheal 
epithelial cells (You et al., 2002) and carefully prepared every time. However, certain 
factors such as a lot-to-lot variation of media components (e.g. growth supporting 
factors) could not be controlled. Another factor which might influence variation in the 
batches of differentiated tracheal epithelium was caused by the sex and age of mice 
used in this study. However, the usage of same age and same numbers of female and 
male mice for preparation of mTECs was not always possible in this study.  
In the future these issues can be addressed by using same age of mice, same numbers 
of female and male mice for each batch and increasing the number of batches and wells 
used for each NTHi challenge experiment. Unfortunately, I was not able to increase the 
number of batches used in this study due to the time required to grow and differentiate 
each batch of mTECs and usage of multiple wells of cells was not possible due to limited 
numbers of mice and wells of cells required for validation of cell differentiation.  
 
Taking into consideration my results and existing research data, demonstrating the 
importance of BPIFA1 in the innate host defence, I suggest that BPIFA1 plays a role in 
the innate protection of tracheal epithelial cells against NTHi and the loss of this 
multifunctional protein increases susceptibility of mTECs to bacterial infection.  
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5.5 Key experimental conclusions 
 
• WT and Bpifa1-/- mTECs differentiated into an upper airway-like epithelium. 
• Bpifa1-/- mTECs showed a trend towards an increased susceptibility to NTHi 
colonisation compared to WT mTECs, suggesting that BPIFA1 provides an initial 
protection for WT mTECs against NTHi. 
• mTECs exhibited resistance to NTHi infection and only patchy NTHi infection of 
mTECs was observed. 
• NTHi was observed to associate with the multiple cell types of mouse tracheal 
epithelium, but not with BPIFA1-positive cells.  
• NTHi infection caused a disruption of cellular tight-junctions and impairment of 
epithelial barrier function. This, in turn, allowed the crossing of NTHi through the 
layers of mTECs. 
• NTHi exposure affected Bpifa1 expression and reduced BPIFA1 secretion. 
• No obvious difference was observed in the inflammatory response generated by 
WT and Bpifa1-/- mTECs in response to NTHi challenge at 72hpi. 
• Variation in the batches of mTECs was detected. 
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CHAPTER 6: GENERAL DISCUSSION 
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BPIFA1 (SPLUNC1), the prototypic member of the wider BPI-fold containing family of 
putative innate defence proteins, is structurally similar to proteins with demonstrated 
innate immune roles (Bingle and Craven, 2002, Elsbach and Weiss, 1998, Hailman et 
al., 1996, Levy, 2000, Masucci-Magoulas et al., 1995). Produced mainly in the upper 
respiratory tract and nasopharynx, it is one of the most abundant proteins in mucosal 
lining fluids (Campos et al., 2004, Bingle and Bingle, 2000, Bingle et al., 2005, Britto and 
Cohn, 2015, Musa et al., 2012, Weston et al., 1999). Although it was originally 
hypothesised that the protein would be an innate immune regulator (Bingle and Craven, 
2002, Chu et al., 2007, Liu et al., 2013a, Liu et al., 2013b, Lukinskiene et al., 2011, 
Thaikoottathil et al., 2012), the true role of the protein in protecting the mucosal surface 
remains to be elucidated. The mechanisms by which BPIFA1 performs its biological 
functions are also not fully understood and few studies have aimed to identify regions 
important for its activity (Ahmad et al., 2016, Walton et al., 2016, Wu et al., 2017, Zhou et 
al., 2006). 
 
Data in my thesis adds support to the view that BPIFA1 plays a role in airway host 
defence. I showed this in a number of ways. Human and mouse BPIFA1 proteins are 
able to bind not only to Gram-negative bacteria (NTHi), but also to Gram-positive 
bacteria (S. aureus and S. pneumoniae). This suggests that BPIFA1 exhibits activity 
against both types of bacteria. Existing data on BPIFA1’s antimicrobial activity against 
Gram-positive pathogens is inconclusive. Some studies suggested that human BPIFA1 
does not exhibit antimicrobial activity against Gram-positive pathogens, such as S. 
aureus (Ahmad et al., 2016, Walton et al., 2016), whereas others reported that BPIFA1 
shows antimicrobial properties against S. aureus (Yu et al., 2018). Therefore, I suggest 
that the biological activity of BPIFA1 against Gram-positive pathogens should be further 
investigated. 
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The ability of hBPIFA1 to bind to bacterial pathogens appeared to be influenced by the 
S18 region of protein, but not by the disulphide bond. In contrast to my findings, currently 
available data suggests that the S18 region of protein does not influence the ability of 
protein to bind to LPS from bacterial pathogens nor does it possess antimicrobial 
properties (Ahmad et al., 2016, Walton et al., 2016). It may also be possible that the S18 
region of hBPIFA1 binds to a different target on the surface of bacterial cells. I suggest 
that further research is required to fully determine the importance of the S18 region for 
the biological properties of hBPIFA1.  
 
Throughout this project, I analysed the differences of the bacterial binding between 
human and mouse BPIFA1 proteins. Binding of hBPIFA1 and mBPIFA1 to bacteria 
seemed to be generally similar and no apparent differences were observed. Both types 
of proteins bound to Gram-positive and Gram-negative bacteria. Ability of mBPIFA1 to 
bind to bacteria may be explained by the certain features of protein sequence (i.e. N-
glycosylation sites and proline-rich region) as outlined in Chapter 4 (Section 4.4). The 
mechanisms by which mBPIFA1 binds to bacteria were not investigated in my thesis and 
remain to be determined.  A better understanding of the mechanisms by which mBPIFA1 
performs its biological functions may also provide extra clues for the understanding 
biological functions of hBPIFA1. 
 
On the basis of my findings, showing the ability of mBPIFA1 to bind to NTHi, I 
hypothesised that mTECs lacking BPIFA1 would exhibit an enhanced susceptibility to 
NTHi infection. Although statistical significance was not detected, my data showed the 
trend towards an increased NTHi colonisation in Bpifa1-/- compared to WT mTECs. A 
great variation in the bacterial colonisation between individual batches of cells was also 
detected. In addition, I observed that mTECs challenged with NTHi were not readily 
infected and infection exhibited a patchy pattern. Overall, I can say that BPIFA1 
deficiency did not to lead to significantly enhanced NTHi infection in mTEC cultures. 
Currently, antimicrobial properties of BPIFA1 against NTHi have been analysed in two 
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studies (Jiang et al., 2013b, McGillivary and Bakaletz, 2010). Bpifa1-/- mice were 
demonstrated to have increased bacterial burden and inflammation in the lungs after 
NTHi exposure compared to control mice (Jiang et al., 2013b). It was also shown that 
chinchilla BPIFA1 exerted bactericidal activity against NTHi in vitro and was able to kill 
more than 50% of bacterial cells when used at concentration of 1.3µg/ml (McGillivary 
and Bakaletz, 2010). It may be possible that mBPIFA1 exhibits bactericidal activity 
against NTHi and this may be a reason for the lower NTHi colonisation in WT mTECs 
compared to Bpifa1-/- mTECs. Bacteriostatic and bactericidal properties of mBPIFA1 
against NTHi were not examined in this study and remain to be determined in the future 
research. The true role of BPIFA1 in NTHi infection should also be determined in the 
future studies using a fully established NTHi infection model of mTECs. 
 
My findings also suggested that NTHi exposure affected expression and secretion of 
mBPIFA1. Reduced levels of mBPIFA1 may act as a signal to initiate the activation of 
other immune mechanisms which are more effective for the clearance of NTHi. These 
findings are consistent with previous data from our laboratory showing a decrease in 
BPIFA1 secretion from middle ear epithelial cells challenged with NTHi (Mulay, 2016). 
They are also in agreement with studies which showed that exposure of WT mice to P. 
aeruginosa and S. pneumoniae caused a reduction in the levels of secreted BPIFA1 in 
the BAL fluid (Britto et al., 2013, Jiang et al., 2013). Based on these results, it could be 
suggested that bacterial stimulus regulates expression and secretion of BPIFA1. 
Fluctuations in the levels of mBPIFA1 observed after bacterial exposure may be caused 
not by direct effect of pathogen onto the protein but by bacterial effect on the epithelium 
and its microenvironment. Another reason for reduction in levels of BPIFA1 could be 
associated with the release of inflammatory mediators in response to the bacterium. 
NTHi challenge caused a considerable induction and release of inflammatory molecules 
in the mTEC cultures and the presence of these inflammatory molecules in the 
microenvironment could also have modulated levels of BPIFA1. Previous studies have 
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shown that expression and secretion of BPIFA1 are reduced by other immune mediators 
(Chu et al., 2007, Britto et al., 2013, Wei et al., 2014). Therefore, I suggest that 
regulation of expression and secretion of BPIFA1 may not be directly affected by the 
environmental insult (pathogen) but by a more general response of the airway epithelium 
to the organism.  
 
Results from my study appeared to show that NTHi associates with multiple epithelial 
cell types but did not appear to be associated with mBPIFA1-positive cells. Perhaps 
mBPIFA1-positive cells are resistant to initial NTHi infection because of BPIFA1’s 
antimicrobial properties. BPIFA1-positive cells have also been shown to exhibit 
resistance to IAV invasion and IAV was mainly seen to be associated with other types of 
epithelial cells (Akram et al., 2018). In addition, studies in our laboratory demonstrated 
that mouse middle ear epithelial cells positive for BPIFA1 exhibited resistance to initial 
NTHi infection and NTHi was observed to invade other types of epithelial cells (Mulay, 
2016). All of this data suggests that BPIFA1-positive cells exhibit resistance to invading 
microorganism during the initial stages of infection, but that pathogens would infect 
BPIFA1-positive cells after mucosal homeostasis of epithelium has been impaired. I 
suggest that alterations in the epithelium and impaired mucosal homeostasis causes a 
reduction of mBPIFA1 expression and production, and that this would predispose 
mBPIFA1-positive cells to NTHi invasion. It is important to more fully determine the types 
of cells affected by NTHi as it could provide additional insights into the mechanisms used 
by bacterium to initiate an infection. Better understanding of the mechanisms used by 
NTHi to initiate infection could assist in the future development of the therapy against 
NTHi infections.  
 
I was able to show that NTHi infection caused a disruption of cellular tight-junctions, 
suggesting that inflammatory response generated by the cells to NTHi impaired the 
epithelial barrier function. This, in turn, allowed the crossing of bacteria through the 
layers of mTECs. These activities of NTHi were not influenced by BPIFA1. These 
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findings are in the agreement with other studies (Marrazzo et al., 2016, van Schilfgaarde 
et al., 1995). Perhaps, mBPIFA1 may influence the time required by NTHi to cross 
through the layers of cells? It would be of great interest to determine this effect of 
BPIFA1 as the possibility of BPIFA1 slowing down the passage of NTHi through layers of 
epithelial cells would suggest that BPIFA1 may be able to delay the passage of NTHi into 
the circulatory system and reduce systemic infection.   
 
My data also suggested that the presence of mBPIFA1 did not have a great impact on 
inflammatory response generated by NTHi-exposed mTECs, as the absence of BPIFA1 
did not lead to significantly enhanced release of inflammatory molecules. Low NTHi 
infectivity of mTEC cultures may be a factor which influenced this. Both WT and Bpifa1-/- 
mTECs exhibited resistance to NTHi infection and only patchy infection was caused. 
This may be overcome by the usage of different NTHi strains or longer bacterial 
exposure times. It is also possible that NTHi growth was suboptimal, and therefore 
infection limited, due to the growth of the mTECs in a defined media. Variability of 
infection levels was also observed in mTEC cultures and may be a second factor 
masking the differences in the inflammatory response by WT and Bpifa1-/- mTECs. 
Variation in the batches of the cells may be a third factor masking differences of the 
inflammatory responses. I suggest that in the future studies efforts should be made to try 
to reduce batch-to-batch variation in culture preparations by using cell cultures grown 
from clonally expanded basal cells. The usage of clonally expanded basal cells may 
reduce variability as clonally expanded basal cells would be obtained from single batch 
of cells. Techniques for clonal expansion of epithelial basal cells by dual SMAD 
signalling inhibition has recently been achieved by using Rho Kinase inhibitor, bone 
morphogenetic protein (BMP), and transforming growth factor beta (TGFβ) inhibitors 
(Mou et al., 2016). The effect of mBPIFA1 on inflammatory response generated by the 
mTECs in response to pathogen may be more accurately determined if cell batch-to-
batch variation could be reduced. 
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Summary 
 
Data from this thesis contribute to the view that BPIFA1 plays a role in the airway 
defence. Here, I showed that human and mouse BPIFA1 proteins are able to bind to 
Gram-positive and Gram-negative bacteria. This bacterial binding of BPIFA1 may be one 
of the protein’s functions contributing to protection of the airways against microbial 
invaders. The ability of human BPIFA1 to bind to bacteria appeared to be influenced by 
the S18 region (G22-L42) of the protein, but not the conserved disulphide bond. Further 
studies are required to investigate the biological importance of the S18 region for the 
functions of human BPIFA1. BPIFA1 may play an important role in the host defence 
against NTHi infection. The ability of BPIFA1 to provide initial protection for BPIFA1-
positive cells against NTHi infection may imply that BPIFA1 is a mucosal defence 
molecule. Further research is required to directly investigate functional regions of 
BPIFA1 and to allow the development of systems that will permit reproducible 
establishment of NTHi infection of mTEC cultures.  
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APPENDIX I 
 
Table I: Materials used in the sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE). 
 
 
 
 
Solution Components Amount 
Running buffer (10x) 
Tris 30.3g 
Glycine 2.9g 
20% SDS solution 50ml 
Water Up to volume of 1000ml 
Transfer buffer 
Tris 2.9g 
Glycine 1.45g 
20% SDS solution 925µl 
Methanol 100ml 
Water Up to volume of 500ml 
TBS (10x) 
Tris-HCl 1M pH8.0 solution 100ml 
Sodium chloride 97.3g 
Water Up to volume of 1000ml 
TBS-Tween (10x) 
Tris-HCl 1M pH 8.0 solution 100ml 
Sodium chloride 97.3g 
Tween-20 5ml 
Water Up to volume of 1000ml 
2x SDS Lysis buffer 
1M DTT solution 1ml 
20% SDS solution 1ml 
Glycerol 2ml 
Tris-HCl 0.5M pH6.8 1.25ml 
0.2% bromophenol blue 200 µl 
Protease Inhibitor tablet 1 tablet 
Water 4.55ml 
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Figure I: Map of pMA-T plasmid containing FLAG-tagged S18 deletion BPIFA1 DNA. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure II: DNA sequence of human BPIFA1-FLAG gene missing amino acids 22-42.  
Start codon (ATG) and Stop codon (TAA) are highlighted in yellow. DNA sequence of FLAG tag is 
highlighted in orange with black underline. 
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Figure III: Sequencing of FLAG-tagged human S18 deletion BPIFA1-pMA-T construct. 
Sequencing was performed by Invitrogen GeneArtTM Gene Synthesis service. Data was analysed 
using FinchTV program (Version: 1.5.0). Gene sequence of interest was translated into the 
protein using ExPASy Translate Tool. No mutations were detected in the sequence and it was 
read through into FLAG tag. 
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Table II: Materials used in calcium phosphate transfections of HEK293T cells 
 
 
 
 
 
 
 
 
 
 
  
Solution Components Amount 
2x HEPES-buffered saline 
pH7.0 (Filter sterilised) 
NaCl 8g 
HEPES 6.5g 
Na2HPO4-7H2O 0.2g 
Distilled water Up to volume of 500ml 
2.5M CaCl2 (Filter 
sterilised) 
CaCl2(2H2O) 36.76g 
Distilled water 100ml 
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APPENDIX II 
 
 
Figure S1: Sequencing of GFP-tagged FL-BPIFA1-pcDNA3.1 construct. 
Sequencing was performed using T7 forward primer (A) and GFP reverse primer (B). Data was 
visualised and analysed using FinchTV program (Version: 1.5.0). Gene sequence of interest was 
translated into the protein sequence using ExPASy Translate Tool (C). No mutations were 
detected in the sequence and it was read through into GFP tag (black arrow indicates a beginning 
of GFP tag sequence). 
 
 
 
A. 
B. 
C. 
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Figure S2: Sequencing of GFP-tagged F/R1-BPIFA1-pcDNA3.1 construct. 
Sequencing was performed using T7 forward primer (A). Data was visualised and analysed using 
FinchTV program (Version: 1.5.0). Gene sequence of interest was translated into the protein 
sequence using ExPASy Translate Tool (B). No mutations were detected in the sequence and it 
was read through into GFP tag (black arrow indicates a beginning of GFP tag sequence). 
 
  
A. 
B. 
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Figure S3: Sequencing of GFP-tagged F/R2-BPIFA1-pcDNA3.1 construct. 
Sequencing was performed using T7 forward primer (A). Data was visualised and analysed using 
FinchTV program (Version: 1.5.0). Gene sequence of interest was translated into the protein 
sequence using ExPASy Translate Tool (B). No mutations were detected in the sequence and it 
was read through into GFP tag (black arrow indicates a beginning of GFP tag sequence). 
 
  
A. 
B. 
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Figure S4: Sequencing of GFP-tagged FL-BPIFA-pcDNA5/FRT construct. 
Sequencing was performed using T7 forward primer (A) and BGH reverse primer (C). Data was 
visualised and analysed using FinchTV program (Version: 1.5.0). Gene sequences of interest (B 
– forward sequencing data; and D – reverse sequencing data) were translated into the protein 
sequences using ExPASy Translate Tool. No mutations were detected in the sequence and it was 
read through into GFP tag (black arrow indicates a beginning of GFP tag sequence). 
 
A. 
B. 
C. 
D
. 
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Figure S5: Sequencing of GFP-tagged F/R1-BPIFA-pcDNA5/FRT construct. 
Sequencing was performed using T7 forward primer (A) and BGH reverse primer (C). Data was 
visualised and analysed using FinchTV program (Version: 1.5.0). Gene sequences of interest (B 
– forward sequencing data; and D – reverse sequencing data) were translated into the protein 
sequences using ExPASy Translate Tool. No mutations were detected in the sequence and it was 
read through into GFP tag (black arrow indicates a beginning of GFP tag sequence). 
 
A. 
B. 
C. 
D. 
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Figure S6: Sequencing of GFP-tagged F/R2-BPIFA-pcDNA5/FRT construct. 
Sequencing was performed using T7 forward primer (A) and BGH reverse primer (C). Data was 
visualised and analysed using FinchTV program (Version: 1.5.0). Gene sequences of interest (B 
– forward sequencing data; and D – reverse sequencing data) were translated into the protein 
sequences using ExPASy Translate Tool. No mutations were detected in the sequence and it was 
read through into GFP tag (black arrow indicates a beginning of GFP tag sequence). 
 
 
 
A. 
B. 
C. 
D. 
 232 | P a g e  
 
 
 
 
 
 
 
 
 
Figure S7: Verification of pOG44 expression plasmid. 
E. coli cells transformed with pOG44 expression plasmid were regrown in the LB-ampicillin broth 
overnight to generate plasmid DNA for transfection reactions. Maxiprep samples were digested 
with EcoRI to verify the quality of extracted pOG44 plasmid DNA. Restriction digest on maxiprep 
samples was expected to produce two fragments of 1051bp and 4734bp size, indicating that 
maxiprep product was pOG44 plasmid DNA. Fragments of correct size were observed. 
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Figure S8: Detection of human and mouse FLAG-tagged proteins in NCI-H292 cells. 
Images were taken at 100x magnification with immunofluorescence microscope (Zeiss Axioplan 
2) (scale bar: 10µm). Nuclei of transfected NCI-H292 cells were stained by DAPI in blue and 
BPIFA1-FLAG proteins of interest were stained in green using Alexa Flour 488. Images were 
processed using ImageJ-win32 program. 
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Figure S9: Staining for MUC5B is increased in Bpifa1-/- mTECs compared to WT mTECs. 
IFC images showing a staining for cytosolic MUC5B in MOCK-exposed WT mTECs (A) and 
MOCK-exposed Bpifa1-/- mTECs (B) after 72hrs post-challenge. Each panel represents 2 central 
fields at 10x magnification. Data are representative of 3 independent batches of WT and Bpifa1-/- 
mTECs. Scale bar: 100µm. Analysis of IFC images suggested an increased staining for MUC5B 
in MOCK-exposed Bpifa1-/- mTECs compared to MOCK-exposed WT mTECs (C). This increase 
was not statistically significant and appeared to be caused by variation in the batches of mTECs. 
Data was analysed using unpaired non-parametric two-tailed student’s t-test and represented as 
mean ± SEM, n=3 individual batches of mTEC cultures. 
 
 
  
MUC5B staining in Bpifa1-/- mTECs 
MUC5B staining in WT mTECs 
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Figure S10: MUC5B staining is increased in NTHi-exposed Bpifa1-/- mTECs compared to 
MOCK-exposed mTECs. 
IFC images showing a staining for MUC5B in MOCK-exposed Bpifa1-/- mTECs (A) and Bpifa1-/- 
mTECs exposed to NTHi at MOI-200 (B) after 72hrs post-challenge. Each panel represents 2 
central fields at 10x magnification. Data are representative of 3 independent batches of Bpifa1-/- 
mTECs. Scale bar: 100µm. Analysis of IFC images suggested a slight increase in MUC5B 
staining in NTHi-exposed Bpifa1-/- mTECs compared to MOCK-exposed Bpifa1-/- mTECs (C). This 
increase was not statistically significant and seemed to be caused by variation in the batches of 
mTECs. Data was analysed using unpaired non-parametric two-tailed student’s t-test and 
represented as mean ± SEM, n=3 individual batches of mTEC cultures. 
 
  
MUC5B staining in MOI-200 Bpifa1-/- mTECs 
MUC5B staining in MOCK-exposed Bpifa1-/- mTECs 
MUC5B Mean Integrated Fluorescence 
in Bpifa1-/- MOCK vs MOI-200 
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WT batches 
Incubation time points 
 
Figure S11: Secretion of BPIFA1 by NTHi- and MOCK-exposed WT mTECs.  
Results of dot blotting, showing the secretion of BPIFA1 by MOCK- and NTHi-challenged (MOI-
200, MOI-500, and MOI-1000) WT mTECs at 24, 48, and 72 hpi. Apical secretion washes from 
four independent batches of WT mTECs were analysed. Experiment was performed in the 
triplicates. 
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